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Abstract 
The risk of hip fracture in people with type one diabetes mellitus (T1DM) is reported to be 
7 to 12 times greater than in those without T1DM, and this increased risk is evident in both 
children and young adults. This fracture risk is higher than expected bone mineral density 
(BMD) measurements, which indicates the likelihood that other skeletal factors, not 
captured by DXA, may contribute toward increased fracture risk. There is increasing 
evidence that alteration in trabecular bone microarchitecture and increased bone marrow 
adiposity (BMA) are causes for excess skeletal fragility, yet these data are lacking in 
people with T1DM. Recent technological advances in magnetic resonance imaging (MRI) 
have allowed the quantification of trabecular bone architecture.  In addition, MRI can 
quantify the amount of intra-abdominal fat, and magnetic resonance spectroscopy (MRS) 
can also be used to assess BMA. These advances may enhance our understanding of the 
underlying causes of diabetic osteopathy which may lead to improved fracture risk 
predictors and preventive measures in patients with T1DM beyond that provided by dual 
energy x-ray absorptiometry (DXA). 
The overall objective of this thesis was to improve the understanding of the bone pathology 
of young adult women with childhood-onset T1DM by using high resolution MRI. 
A cross-sectional study was first carried out to assess trabecular bone microarchitecture of 
the tibia, vertebral BMA and abdominal adiposity in patients with childhood onset T1DM 
(n=30) compared with healthy controls (n=28). Additionally, the biochemical markers of 
bone turnover, adiposity and GH/IGF-1 axis (IGF-1, IGFBP3, and ALS) were examined to 
evaluate the underlying mechanism that might result in bone deficit in this group of people. 
We found that young women with childhood onset T1DM had reduced apparent trabecular 
bone volume (appBV/TV) and apparent trabecular number (appTbN) and greater apparent 
trabecular separation (appTbSp) than women without T1DM. Interestingly, these 
differences remained significant after adjustment for multiple confounders. Furthermore, 
these abnormalities were markedly obvious in those with microvascular complication 
compared with those without microvascular complication. Although women with T1DM 
had greater abdominal adiposity compared with healthy controls, there was no significant 
difference in BMA between the groups. However, BMA showed positive significant 
association with current glycaemic control (r= 0.45, p=0.02). Women with T1DM had 
lower bone turnover and decreased GH/IGF axis compared with healthy controls. 
Osteocalcin and ALS were negatively correlated with trabecular separation in women with 
T1DM.  
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Next, a one-year prospective study was conducted in a subset (n=28) of the participants 
involved in the cross-sectional study. The aim of this study was to compare one year 
changes in trabecular bone microarchitecture and BMA in women with and without 
T1DM. Additionally, the study aimed to evaluate the effect of glycaemic control on these 
changes over this period. After adjustment for relevant confounders, the cases (n=17) had a 
lower median appTbN and a higher median appTbSp at baseline and 12 months compared 
with healthy controls (n=11). Although the sample size was small at follow-up, the 
trabecular bone deficits were clearly noticeable in those with retinopathy compared with 
those without retinopathy. Similarly, there was no difference in median BMA which was 
26.2% (12.1, 62.1) and 22.4% (9.6, 41.9) in cases and controls, respectively (p=0.57). 
Additionally, over the 12 month period, there was no significant change in MRI-measured 
parameters in cases or in controls, and no differences in the change of these variables 
between the two groups. Mixed model effect analysis showed that age was a negative 
predictor of percent changes of appBV/TV, appTbN and appTbSp in both cases and 
controls (p=0.02, p=0.02, p=0.002, respectively). Interestingly, there was a strong 
correlation between change in HbA1c and change in BMA (r=0.8; p=0.002).  
In the third study, we aimed to assess adiposity-based determinants of bone mineral density 
and bone microarchitecture in healthy young women and women with T1DM. 
Additionally, we aimed to compare the feasibility of using DXA and MRI-measured bone 
parameters to differentiate women with and without T1DM. In addition to high resolution 
MRI we used DXA scans to measure BMD and body composition from the same 
participants (n=26) involved in the longitudinal study.  Vertebral BMA was positively 
correlated with VAT. Additionally, we demonstrated evidence of an inverse association of 
vertebral BMA and DXA-measured bone parameters of femoral neck, lumbar spine and 
total body independent of demographics and body composition in healthy young women 
and women with T1DM. These finding support the hypothesis that BMA is linked with 
low bone density, and may contribute to excess bone fragility. Moreover, this study 
suggested that MRI-measured trabecular bone measurements were able to differentiate 
between T1DM with and without microvascular complication compared with DXA-
measured BMD.  
In summary, differences in MRI-measured trabecular microarchitecture parameters 
identified in this body of work provide preliminary explanations for elevated fracture risk 
in young women with childhood onset T1DM. Additionally, these findings provide 
potential insight into a number of possible underlying mechanisms of diabetic osteopathy. 
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1.1 Bone development and its Components  
1.1.1 Bone architecture  
Bone is a multifunctional organ organized in a hierarchical way that enables it to perform 
its functions. Structurally, the bone is formed of two tissues: cortical and trabecular bone 
(Figure 1.1). Cortical bone is found in the diaphysis of long bones and outer surfaces of flat 
bones, and trabecular bone is found mainly at the end of long bones and in the inner parts 
of flat bones. Different skeletal sites have different proportions of cortical to trabecular 
bone (1). Both types of bone will be discussed in detail below. 
 
1.1.1.1 Trabecular bone  
Trabecular bone is a porous type of bone tissue found inside the bone, and known as 
cancellous or spongy bone. Trabecular bone constitutes 20% of total bone mass in the 
skeleton. The greatest volumes of trabecular bone are at the skeletal sites where the 
majority of osteoporotic or fragility fractures occur (2). Trabecular bone is identifiable by 
the sponge-like appearance of calcified tissue, with spaces filled with bone marrow, giving 
them the alternative name of spongy bones. The bone marrow spaces of trabecular bone 
provide vascular and neural access and create the large surface area through which bone 
remodelling occurs (3).  Trabecular bone is unlike cortical bone in that the osteon does not 
contain a central harversian canal, but has lacunae filled with bone cells, and canaliculi 
which connect these lacunae and the trabecular surface, through which the nutrition of 
bone cells is facilitated  (4). The trabecular structure resembles a honeycomb of 
mineralized trabeculae in the shape of rod-like structures connected by plate-like 
structures. Each individual trabecula is approximately 100-300 μm thick and trabeculae are 
separated by spaces of 300–1500 μm (5). The trabecular tissue properties are determined 
by the orientation and the connectivity of the trabeculae (6). Furthermore, the trabecular 
tissue properties are determined by the total amount of mineralized trabecular tissue and 
the morphological characterization of these trabeculae. The most important morphological 
parameters are Bone Volume (BV/TV), Trabecular Number (Tb.N), Trabecular Thickness 
(Tb.Th), and Trabecular Separation (Tb.Sp). These parameters are typically determined 
using histomorphometry (7), or by 3D imaging techniques(8, 9).  
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1.1.1.2 Cortical bone  
Cortical bone is the solid thick outer shell of bones often referred to as “compact” bone. It 
constitutes about 80% of the total bone mass in the skeleton, but it accounts for a 
considerably smaller surface area than trabecular bone because of its high cellularity that in 
turn give rise to its higher mass to volume ratio (1, 10). The basic structure in the cortical 
bone is the osteons, which are cylindrical structures oriented with the long axis of the bone, 
forming the Haversian system (1). The spaces between the harversian systems are filled 
with the interstitial bone. Each osteon consists of a central canal (Haversian canal) through 
which vascular access is facilitated. The Haversian canals are oriented with the long axis of 
the bone, surrounded by layers of calcified bone matrix called concentric lamellae. The 
concentric lamellae contain collagen fibres oriented in a specific direction to provide 
strength to the tissue. Between these concentric circles there are specific interconnected 
canals (lacunae and canaliculi) through which bone cells communicate. In fact, cortical 
bone is not solid; it typically contains about 5% cavities to its total volume, including 
cellular lacunae and canaliculi (1). The cortical volumetric bone mineral density (vBMD) 
is determined by the number and average size of the cavities (osteonal canals) (porosity) 
and the mineralization density of the cortical tissue (11). 
 
Figure  1.1: Schematic diagram illustrates the hierarchical structures of cortical and trabecular bone 
(12). 
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1.1.3 Bone cells and matrix  
Within both trabecular and cortical bone there are three main types of bone cells: 
osteoclasts, osteoblasts, and osteocytes. Osteoclasts are terminally differentiated 
multinucleated cells derived from hematopoietic stem cells and are responsible for bone 
resorption (13). Once osteoclasts are differentiated they are capable of secreting enzymes 
that dissolve the bone matrix. Additionally, they secrete factors to promote osteoblast 
precursor recruitment and differentiation and thereby promote bone formation (14, 15). 
Osteoblasts are derived from mesenchymal stem cells (MSCs) and are responsible for 
building the organic bone matrix and regulating mineral deposition on the matrix (16). The 
commitment of MSCs towards the osteoprogenitor lineage requires expression of specific 
genes (17-22). Runx2 is a master gene of osteoblast differentiation, as demonstrated by the 
fact that Runx2-null mice are devoid of osteoblasts (23). Osteocytes are the most abundant 
and long-lived cells derived from MSC lineage through osteoblast differentiation. 
Osteocytes act as Master Orchestrator of skeletal activity, regulating both bone formation 
and resorption to govern the skeletal response to mechanical forces (24-26).   
These cells are embedded within the bone matrix which is composed of organic materials 
(20%), inorganic materials (70%) and water (10%) (27, 28). The organic portion is mainly 
composed of type 1 collagen (90%), which forms an extracellular matrix where the 
inorganic materials can be deposited to strengthen the collagen structure. The most 
abundant inorganic material in bone is calcium and phosphate ions, which nucleate to form 
hydroxyapatite crystals (27, 29). The water content of the matrix binds to the collagen and 
minerals. Collagen-bound water influences its three-dimensional structure, which can be 
visualised by magnetic resonance imaging (MRI) (30). Each of these bone matrix 
components plays a critical role in the biomechanical properties and functional integrity of 
bone (29, 31-38). 
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1.1.5 Bone turnover and remodelling  
Bone remodelling is a life-long process that involves cyclical removal of discrete packets 
of old bone (bone resorption) and replacement of these packets with newly synthesized 
bone (bone formation) (39-41). To maintain the structural integrity of the skeleton, it is of 
crucial importance that the amount of bone resorbed matches the amount of newly formed 
bone in each remodelling site. This requires that the processes of bone resorption and bone 
formation are linked in a temporally and spatially coordinated manner within the 
remodelling cycle and form a coupling mechanism (42-44). To maintain the balance, bone 
cells communicate directly, and indirectly through signalling pathways (45). However, the 
specific signals that maintain the coupling process are still not well understood. It is clear, 
however, that the osteocyte acts as an orchestrator in regulating bone remodelling (46, 47).  
Additionally, there are several systemic factors  (genetic, mechanical, vascular, nutritional, 
and hormonal) and locally produced growth factors suggested to  modulate the balance 
between bone resorption and formation (3, 48). Any defect in the coupling process results 
in bone loss (13, 49-51). The bone remodelling cycle is precisely coupled in the third 
decade at the time of the peak bone mass attainment, and this is maintained with small 
variations until the age of 50. After that, resorption dominates, resulting in bone loss in 
both sexes, with dramatic bone loss in women around the time of the menopausal transition 
making them more susceptible to osteoporosis (52, 53). With aging, men as well as 
postmenopausal women demonstrate gradual increase in bone loss (54, 55).  
Remodelling takes place within bone area that need to be remodelled.  In this bone area, all 
bone cells are organized with their precursors cells, nerve cells and blood vessels in 
temporary specialized unite called basic multicellular unite (BMUs). The BMU is a 
mediator mechanism for bone remodelling via connecting individual cellular activity to 
whole bone morphology (56-58). Bone remodelling occurs both in trabecular and cortical 
bone, but the metabolic rate is ten times higher in trabecular bone compared to cortical 
bone due to the greater surface area to volume ratio of trabecular bone.  Bone remodelling 
occurs on trabecular surfaces in the form of shallow irregular Howship’s lacunae, whereas 
in cortical bone it occurs as a cylinder to form the Haversian canal, which is then replaced 
to form an osteon.  The cortical remodelling cycle lasts approximately four months, 
compared with almost seven months in trabecular bone (3, 56).  
The remodelling cycle is composed of three consecutive phases (Figure 1.2): an initiation 
phase, which consists of bone resorption by osteoclasts, followed by a transition (or 
reversal) phase, and finally a phase of bone formation by osteoblasts. In the initiation 
phase, hematopoietic stem cells are recruited to specific bone surface areas and 
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differentiate into mature osteoclasts that initiate bone resorption. This is achieved under the 
action of osteoclastogenic cytokine factors including RANKL and M-CSF. They are one of 
the key signalling molecules that facilitate crosstalk between the osteoblasts and 
osteoclasts and help coordinate bone remodelling. This system is held in balance by the 
production of a decoy receptor, osteoprotegerin (OPG), which is a key factor inhibiting the 
differentiation and activation of osteoclasts (59, 60). Osteoprotegerin inhibits the binding 
of RANK to RANKL and thus inhibits the recruitment, proliferation, and activation of 
osteoclasts. Abnormalities in the balance of the RANK/OPG system lead to the increased 
bone resorption that underlies the bone damage of postmenopausal osteoporosis (60, 61). 
This resorption takes approximately one month.  During the reversal phase, osteoblast 
precursors appear at the same resorption site. Finally, during the formation phase, which 
lasts for a period of approximately five months, the preosteoblast grouping phenomenon 
occurs and starts bone formation (3). The preosteoblasts synthesize a cementing substance 
upon which the new tissue is attached and express bone morphogenic proteins (BMPs) 
responsible for differentiation. A few days later, the already differentiated osteoblasts 
synthesize the osteoid matrix which fills the resorption cavity. Subsequently, 
mineralisation of this matrix occurs and a basic structural unit (BSU) of new bone is 
formed. The remaining osteoblasts continue to synthesize bone until they eventually stop 
and transform to quiescent lining cells that completely cover the newly formed bone 
surface and connect with the osteocytes in the bone matrix through a network of canaliculi 
(62-65).   
25 
 
 
 
Figure  1.2:  Illustrating Remodelling pathway and how the bone cells communicate through signalling 
pathways.  
The osteocyte acts as an orchestrator in regulating bone remodelling, by its lacunocanalicular 
system the osteocytes act as mechanosensors can detect mechanical pressures and microcrack 
which cause osteocyte apoptosis and thus signals osteoclast to resorb the bone matrix. Lining cells 
and osteocytes release local factors that attract cells from blood and marrow into the remodeling 
compartment (BMU) in which osteoclastogenesis occurs. Consequently, groups of osteoblasts 
deposit new bone. Osteoblasts that are trapped in the matrix become new osteocytes; others die or 
form new, flattened osteoblast lining cells (65).   
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1.1.6 Bone turnover markers (BTMs) 
Bone turnover markers (BTMs) represent different processes in bone turnover from 
collagen synthesis (procollagen type 1 amino terminal propeptide (P1NP)) and degradation 
(C-terminal cross-linked telopeptide of type-I collagen (CTX)) to markers released by bone 
cells (osteocalcin (OC) and bone specific alkaline phosphatase (BAP)). These markers can 
be broadly classified as reflecting either bone formation (OC, BAP, P1NP) or bone 
resorption (CTX and N-terminal cross-linked telopeptide of type-I collagen (NTX)) (66). 
In addition, non-classical bone biochemical markers are more specific regulators of bone 
turnover, including specific cell signalling markers (RANKL, OPG, PTH, VIT-D and 
Sclerostin), and one could also include markers of other metabolic pathways (Insulin, IGF-
1, adiponectin and pentosidine) (67). Bone strength is highly dependent on its structural 
and material properties. The balance between bone formation and resorption greatly 
influences the structural and material properties of bone (bone strength parameters). 
Consequently, it has been suggested that bone strength may be reflected in part, 
independent of BMD levels, by measuring bone turnover using specific serum and urinary 
markers of bone formation and resorption. Recently, CTX and P1NP have been proposed 
as standardised reference markers of bone resorption and bone formation, respectively 
(68). Irrespective of BMD, an increase in fracture risk is approximately 20% per standard 
deviation increase in s-PINP or s-CTX (69).  Although technical advances have greatly 
enhanced assay performance, resulting in reliable, rapid, non-invasive cost-effective assays 
with improved sensitivity and specificity, BTMs still have limited clinical utility. Lack of 
adopted international reference standards is the main reason for uncertainties over their 
clinical use. In addition, several biological and external factors cause measurement 
variability, and poor quality control of measurement techniques is also a problem (68). Not 
all components of bone markers are bone-specific markers.  For example, BAP is one of 
several isoenzymes in the alkaline phosphatase family and is present in the liver, kidney, 
and bone tissue. Additionally, biochemical markers of bone resorption are based 
principally on type I collagen, which is not bone-specific and is widely distributed in 
several tissues of the body.  Furthermore, the systemic levels of BTMs reflect overall bone 
metabolism and do not provide particular information on the remodelling process of each 
bone tissue individually, although their relative contribution may vary with aging, disease 
and treatment. Moreover, BTMs reflect quantitative changes of bone turnover and do not 
offer any information on the structural abnormalities of bone matrix materials, which are 
an important determinant of bone fragility. The existing evidence indicates that the 
diagnostic value of BTMs in predicting osteoporosis is low,  and their use in osteoporosis 
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treatment decisions and monitoring of individual therapy is not well established (70). 
However, their utility in providing insight into the pathophysiology of osteoporosis and the 
presence of secondary bone pathology, and their changes following various osteoporosis 
treatments are well defined (71). It has been shown that u-NTX and s-CTX are the most 
responsive BTMs following antiresorptive treatment (72). The following are descriptions 
of bone turnover markers which will be examined in this study.   
1.1.6.1 Bone Formation Biomarkers 
1.1.6.1.1 Osteocalcin and uncarboxylated osteocalcin  
 
Osteocalcin, also known as bone δ-carboxyglutamic acid-containing protein (BGLAP), is 
the most abundant non-collagenous protein in bone, compromising about 20% of non-
collagenous matrix protein, and is produced exclusively by differentiated osteoblasts in the 
later period of bone formation and stored in the extracellular matrix (57, 73). Therefore, 
osteocalcin is considered one of specific markers of bone formation. To generate the 
mature form of osteocalcin, the OC gene is regulated at transcriptional level by Vitamins D 
and K as essential cofactors for γ-carboxylation of OC, resulting in an increase  in the 
affinity for Ca and hydroxyapatite, allowing mature carboxylated osteocalcin deposition in 
mineralized bone matrix (74-77). In contrast, noncarboxylated osteocalcin (ucOC) has a 
low affinity for hydroxyapatite and is more easily released into the circulation. 
Carboxylated, as well as total osteocalcin forms, can be also detectable in the peripheral 
blood, and measured as markers of bone formation.  Approximately 10–40% of 
carboxylated osteocalcin is released into the circulation and is considered a reliable marker 
of bone formation (78). In normal individuals, an immunoassay analysis can identify up to 
50% of osteocalcin as the undercarboxylated form. The levels of undercarboxylated 
osteocalcin are influenced by vitamin K status. However, total circulating concentrations 
of osteocalcin are influenced by bone cell activity independent of vitamin K (78). 
Osteocalcin has some disadvantages: it is an unstable molecule and therefore might causes 
some problems in the specificity and sensitivity of the osteocalcin assay, and it has 
circadian variability and a short half-life of a few minutes, is influenced by Vitamin K 
status, and is released during formation and resorption. While osteocalcin is secreted by 
osteoblasts and deposited within the mineralized bone matrix [2], its physiological role in 
bone mineralization has not been fully explained (79-81). Recently, it was shown that in 
addition to acting as a marker of bone formation, several experimental studies in rodent 
models showed that circulating undercarboxylated osteocalcin (ucOC) acts as a hormone 
which regulates the whole body’s metabolism and reproduction (82, 83). It stimulates 
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insulin production and secretion by pancreatic β-cells and adiponectin by adipocytes (84-
90). Additionally, osteocalcin has the ability to induce testosterone production by 
stimulating the Leydig cells of the testes (91). 
1.1.6.1.2 Bone Alkaline Phosphatase (BAP)  
 
BAP is a member of the alkaline phosphatase (AP) family which are common enzymes 
distributed among different tissues throughout the body. In humans, four genes encode AP 
enzyme isoforms: tissue nonspecific AP (TNAP), intestinal AP (IAP), placental AP, and 
germ cell AP (92). TNAP is mainly expressed in liver, bone, and kidney but is also found 
in circulating leukocytes and the colon and its expression within the intestine is increased 
during inflammation (93, 94). Most of the total ALP isoenzymes are derived from the 
bones and liver, and each represent approximately 50% of the total effect of all isoenzymes 
in each organ.  Although total ALP is not a specific bone marker, ALP level increases in 
patients with bone disorders such as Paget’s disease or osteomalacia (95-97). Bone-specific 
ALP (BSAP) levels provide more selective bone formation data than that provided by 
measurements of total enzyme activity. BAP is present in the osteoblast plasma membrane, 
and it is probably cleaved off from the membrane and released into circulation. It is 
expressed in the early period of osteoblastic differentiation and is produced in high 
amounts during the cycle of bone formation.  Therefore, BAP represents the most  
frequently used marker of bone formation (98). It is specific for bone, but with some cross-
reactivity with the liver isoform (up to 20%). Cheap assays are available that detect more 
specifically the bone-derived isoform, bone-specific ALP. The main advantages of bone-
specific alkaline phosphatase is that it has a very small circadian rhythm, low intra-
individual variability of less than 10%, long circulatory half-life of 1–2 days, and sample 
stability (99, 100). 
1.1.6.2 Bone Resorption Biomarkers 
1.1.6.2.1 C-terminal cross-linking telopeptide of type 1 collagen (CTX) 
 
Carboxy terminal cross-linked telopeptide of type 1 collagen (CTX) is currently considered 
the marker of choice for measuring bone resorption. It is generated from type 1 collagen by 
cathepsin-K during bone resorption (101). The CTX exists in an isomerised beta-CTX 
form and a non-isomerised alpha-CTX form. The α-form converts to the β-form as the 
bone ages. CTX can be measured in urine and blood, and because serum CTX  is one of 
the most responsive BTMs following antiresorptive treatment it is therefore widely used in 
clinical practice (102). However, it has some disadvantages: it has intra individual 
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variability with a large circadian variation with the highest level between 01:30 – 04:30, 
which is approximately twice the level of the nadir between 11:00–15:00. This 
inconsistency necessitates a morning fasting sample for accurate interpretation (103). 
Physical activity (104) and the menstrual status are also significant factors affecting the 
CTX level (105). Additionally, CTX level has inter individual variability as it may be 
attenuated by several factors such as age, gender, ethnicity, menopausal status and 
osteoporotic stage (106). However, currently there are some studies being carried out to 
establish reference intervals classified by age, gender and, in women, menopausal state 
(107). 
1.1.7 Bone marrow and its composition  
Bone marrow is soft, sponge-like tissue that occupies approximately 85% of the bone 
cavity scattered within a mesh of trabecular bone (108). It is a complex environment, in 
which a variety of cell types share a common space. The main cellular components within 
the bone marrow include two types of stem cells: haematopoietic stem cells which develop 
into blood cells, and marrow stromal cells (MSCs) which develop into bone mass-
regulating cells, and marrow adipocytes (108, 109).  Bone marrow provides an 
environment for controlling both haematopoiesis and bone remodelling through a variety 
of autocrine, paracrine and endocrine activities of its different cellular components (109).  
Based on the composition, two types of bone marrow exist: red (hematopoietic, active) and 
yellow (fatty, inactive) marrow. Hematopoietic marrow is red because of the presence of 
haemoglobin within erythrocytes and their precursor cells, and is actively involved in 
haematopoiesis. It is found primarily in flat bones and at the rounded ends of long bones. 
In contrast, fatty yellow marrow is yellow due to its high lipid content, consisting mainly 
of adipocytes (95%), and it is found in the medullary cavity of long bones. Red and yellow 
bone marrows contain multiple chemical components, but predominantly water, 
lipids/triglycerides (TG) and proteins. The concentration of these chemical components 
varies according to the type of marrow present.  Red marrow is 40–60% lipid, 30–40% 
water, and 10–20% proteins. In contrast, yellow marrow is 80% lipid, 15% water, and 5% 
protein (108, 110-112). The MRI signal of bone marrow reflects its chemical composition: 
the major determinants of the MRI appearance of bone marrow are the fat and water 
content (113). Therefore, the bone marrow fat can be visualized and quantified by MRI; 
this is discussed in greater detail below (Section 1.5.2.3).  
The cellular proportion of bone marrow in term of red and fatty marrow varies 
significantly over time depending on age, gender, location, homeostatic requirements and 
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concomitant disease (114, 115). Although both hematopoietic and stromal cells are present 
during the embryonic and early stages of life, at birth the bone marrow is entirely red and 
the fatty marrow only reaches significant levels during the second decade of life at the 
peak bone mass acquisition  (116). The conversion in the direction of fatty bone marrow 
follows an anticipated pattern, which starting in the appendicular skeleton, followed by the 
axial skeleton (117). By age 10 to 20 years, the shafts of long bones are predominantly 
filled with yellow marrow. By the age of 25 years, red marrow is limited to the axial 
skeleton. The process of progressive fatty infiltration of the bone marrow space increases 
with aging until finally it occupies a major proportion of the bone marrow in the axial 
skeleton (118, 119). Detailed knowledge of the speed and anatomical pattern of bone 
marrow conversion allows MRI to detect the expected bone marrow changes throughout 
the skeleton (111, 113, 120, 121).   
Predisposition of bone marrow MSCs to the adipocyte versus osteoblast lineage is the main 
contributing factor for progressive fatty infiltration of bone marrow. However, the master 
controls over MSCs lineage allocation are still not well defined (119). This process will be 
discussed in more details in section 1.2.5. In contrast to the other body fat depots (BAT, 
WAT), the metabolic function of yellow marrow fat is largely unknown (122).  Marrow fat 
may participate in lipid metabolism; it acts as localized reservoir for triglycerides which 
can then be released during demand, for example during bone fracture healing (123). It has 
been suggested that bone marrow fat is acting as energy source activating the bone 
remodelling process (82, 122). On the other hand, a large number of studies documented 
the detrimental effect of marrow fat on bone mass in different metabolic disease as they 
enhance bone marrow adipogenesis. This will be discussed in sections 1.2.4 and 1.4.1.4. 
1.2 Osteoporosis  
1.1.1 Epidemiology of osteoporosis 
Osteoporosis is a weakening of bone microarchitecture which results in low bone density, 
reduced bone strength, increased fragility and consequently increased risk of fracture 
(124). The osteoporotic deficit of bone microarchitecture is illustrated in Figure 1.3. It is 
usually asymptomatic unless osteoporotic fracture and secondary changes of bone structure 
occur. It is estimated that approximately 30% of all postmenopausal women are affected 
and up to 40% will develop a fragility fracture within their lifetime (125). It is estimated 
that one in four men over the age of 50 years will develop at least one osteoporosis-related 
fracture in their lifetime (126). A recent report from 27 countries of the European Union 
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(EU27) estimated that nearly 22 million women and 5.5 million men in these 27 countries 
were expected to have osteoporosis, and 3.5 million new fragility fractures were sustained, 
comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures 
and 1,800,000 other fractures (127). Given the aging population, the annual occurrence of 
hip fracture worldwide has been predicted to reach 8.2 million by 2050 (128). 
 
Figure  1.3:  Microarchitecture of normal and osteoporotic bone. 
(A) Healthy vertebral bone (B) Compressed osteoporotic vertebra with reduced trabecular 
number, connectivity and density and more trabecular spaces (129). 
 
1.2.1 Risk factors for osteoporosis  
Osteoporosis can occur in both men and women and at any age but it is most common in 
elderly people and postmenopausal women (primary osteoporosis/senile) (61), due to an 
increased rate of bone resorption compared with the rate of bone formation (130). 
Osteoporosis may arise from secondary causes (secondary osteoporosis), such as endocrine 
(Type 1 diabetes mellitus (T1DM)), drug use, malignancy, chronic disease, or medication 
(129). Other risk factors for osteoporosis include lifestyle and dietary factors, late onset of 
sexual development, early menopause, family history of osteoporosis and low body weight, 
race (Caucasian or Asian postmenopausal women), and immobilisation (20).   
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1.2.3 Diagnosis of osteoporosis 
Currently, the clinical diagnosis of osteoporosis is made on the basis of the widely 
accepted Bone Mineral Density (BMD) T-score criteria established by the World Health 
Organization (WHO) as shown in (Table 1.1) (131). The T-score is based on the studies 
that evaluated postmenopausal women. .  More details about DXA measured BMD will be 
explained in (Section 2.4.1). 
Table  1.1: Showing WHO BMD T-Score criteria 
 T-score  
Normal  > −1.0 SD 
Osteopenia  Between −1.0 and −2.5 SD 
Osteoporosis  ≤ −2.5 SD  
Severe osteoporosis ≤ −2.5 SD with one or two fragility fracture  
SD;standard deviation. T-score is the number of SD’s away from the young adult mean. 
 
 
Although dual-energy X-ray absorptiometry (DXA)-measured BMD remains the important 
determinant of fracture risk and osteoporosis in the clinical setting, BMD alone does not 
fully explain and predict fracture risk of bone (132-135). There exists considerable overlap 
in T-scores in adults with and without fragility fractures (136, 137). Some studies reported 
that over half of trauma fractures occur in people with non-osteoporotic BMD (BMD T-
score > –2.5) (134, 138-141). Furthermore, BMD does not adequately explain the effect of 
therapeutic interventions on fracture risk (142). A new paradigm fracture risk assessment 
tool (FRAX) which includes clinical risk factors for fracture risk prediction has been 
implemented for the assessment of osteoporosis (129). FRAX is a diagnostic tool that is 
used to evaluate the 10- year probability of fracture. Along with femoral neck T-score, age, 
gender, prior fracture, and use of systemic glucocorticoids, additional risk factors that 
influence the risk of fracture are implemented into this tool. In FRAX, T1DM has been 
recognized as a secondary cause of osteoporosis and increases the probability of fracture 
independent of BMD (143, 144). Kanis et al. (145) stated that the prediction of fractures 
with the use of clinical risk factors alone in FRAX is comparable to the use of BMD alone 
to predict fracture. However, in spite of methods for the refinement of DXA indication and 
interpretation via FRAX scoring (146),  the 1994 WHO criteria are still used as a 
diagnostic gold standard (131). 
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1.2.4 Determinants of bone strength and their clinical implications for 
osteoporosis diagnosis  
The definition of osteoporosis emphasizes bone strength as the predictor of fracture risk 
(147-149). In addition to BMD, which accounts for approximately  60–70% of the 
variation in bone strength (150), there are other skeletal factors that influence bone strength 
(Bone quality parameters) (Figure 1.4). They encompass the spatial distribution of bone 
mass (structural properties) and the intrinsic properties of the materials that comprise the 
bone. Some of the important structural characteristics are bone size and shape, trabecular 
bone microarchitecture and cortical bone thickness and porosity. The intrinsic material 
properties of bone include the accumulation or removal of microdamage, matrix 
mineralization and crystallinity, collagen denaturation and covalent cross-links between 
collagen microfibrils (151). Additionally, changes in the amount of bone remodelling 
resulting in alterations in tissue degree of mineralization and trabecular microarchitecture. 
Therefore, any factors impact bone remodelling will influences the bone strength An 
impairment of trabecular microarchitecture with loss of connectivity between trabeculae 
and cortical thinning is the characteristic feature of osteoporosis (148, 149). Therefore, 
assessment of the extent of compromised bone strength is of particular importance to 
predict the magnitude of fracture risk which cannot be assessed by BMD alone. However, 
there is currently no accurate measure of overall bone strength. There is an increasing body 
of evidence suggesting that indices of trabecular structure and cortical measures are better 
than DXA-derived bone measures in separating men and women with and without 
fractures (152, 153), and the apparent  trabecular bone volume (BV/TV) has been found to 
be the best morphometric strength predictor (154). In a research context, new imaging 
techniques such as High Resolution Peripheral Quantitative Computed Tomography (HR-
pQCT) and  micro-MRI have provided greater dimensions to assessment of fracture risk 
and skeletal health in a variety of diseases related to bone abnormalities irrespective of 
DXA-measured BMD (155-159). T1DM was one of disorders for which newer approaches 
to evaluating skeletal health has been introduced. The existing data showed that DXA-
measured BMD did not explain the higher fracture risk in this group of the population 
(160-162). QCT and HR-pQCT (163, 164) showed that deficits in cortical and trabecular 
bone vBMD and microarchitecture are greater in patients with T1DM compared with 
healthy controls. These promising results achieved by applying 3-dimensional imaging 
techniques will give insights into bone strength determinants of fracture risk that cannot be 
fully studied by DXA alone.   
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Figure 1.4: Determinants of bone strength including bone mineral density (BMD), structural properties 
and material properties. The bone remodelling has influences on the bone strength parameters  (165).  
 
1.2.5 The relationship between adiposity and osteoporosis 
More recently, evidence has accumulated to suggest another mechanism for osteoporosis 
involving the relationship between osteoporosis and excess adiposity (166-172). A number 
of potential mechanisms have been proposed to explain the complex relationship between 
adipose tissue and bone (Figure 1.5), yet precise mechanisms underlying this relationship 
remain unclear (169).  The existing literature suggests that the fat bone connection can be 
either due to the effect of peripheral adipose tissue (e.g., abdominal fat) or the fat present 
within the bone marrow (bone marrow adipogenesis). However, the role of BMF is distinct 
from that of other fat depots as demonstrated in the patients with anorexia nervosa who 
display extreme low body fat mass with high vertebral BMA (173). The adverse effect of 
peripheral adipose tissues on bone metabolism is elucidated partially through the influence 
of the biochemical factors that are secreted by adipocytes. These factors include 
inflammatory cytokines such as resistin (174), tumour necrosis factor-a (TNF-a), 
interleukin (IL-1, IL-6) (175, 176), and endocrine hormones such as leptin (177-179) and 
adiponectin (180, 181), which modulate bone remodelling by enhancing bone resorption or 
suppressing bone formation. On the other hand, adipose tissue is the source of other 
hormones such as oestrogen which play a key role in the maintenance of skeletal 
homeostasis (182, 183). Indeed, there is increasing evidence that the developmental origins 
of various fat depots are different (184, 185), which explains why various adipose tissues 
themselves have individual characteristics in terms of production of biochemical factors, 
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which are thought to have different effects on bone metabolism (186-189). There is some 
discrepancy regarding the effect of peripheral adipose tissue on bone metabolism, and both 
positive and negative effects have been reported (190-193).  Although a growing number 
of in vivo and in vitro studies examine the effect of peripheral adipose tissue on bone 
metabolism, the mechanism of this effect is not yet understood. The local activity of fat 
within the bone marrow milieu and its interaction with other bone cells is better 
understood. An extensive body of literature suggests that the first local connection between 
bone and fat is demonstrated by the finding that the differentiation programmes of 
osteoblasts and adipocytes share a common progenitor, the mesenchymal stem cells 
(MSCs). This balanced differentiation programme is under the tight control of multiple 
transcription factors including the peroxisome proliferator-activated receptor (PPAR)-γ and 
RUNX2, with many regulating pathways and additional factors being directly or indirectly 
involved (119, 194-199). The commitment of MSCs towards adipocyte lineages 
(adipogenesis) depends on PPAR- γ (i.e., PPAR-y2) (200), whereas RUNX2 promotes 
osteoblast differentiation and inhibiting adipogenic differentiation (201). In addition to 
bone marrow adipogenesis, adipocytes secrete lipotoxic substances (paracrine factors) 
which affect the bone cells in the vicinity of the bone marrow (202). The existing data 
indicate that there are certain conditions such as ageing (203), and other osteoporosis-
induced diseases, e.g., diabetes mellitus (204), that can be considered adipocytic risk 
factors and induce the alteration of MSC commitment. This will be explained in more 
detail in sections 1.4.1.4 and 1.5.2.4.2. 
In conclusion, the ultimate effect of adiposity on bone mass is emphasized through these 
opposing pathways. However, the relationship of marrow adipose tissue to other fat depots 
is complex and might play a very distinct role in bone metabolism and thus remains to be 
explored. Understanding the relationship between bone and fat at the marrow level 
provides us not only with the pathophysiology of disease-related osteoporosis, but also 
with a novel approach to the diagnosis and treatment of osteoporosis (205). 
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Figure  1.5: Illustrating the relationship between adipose tissue and bone. The connection can be via 
peripheral fat and fat within bone marrow milieu. 
The Peripheral fat can affect the bone mass either through Leptin or other secretory factors (Inflammatory 
cytokines, fatty acids, adiponectin and oestrogen). Osteoblasts, osteoclasts and MSCs express the leptin 
receptor. The direct peripheral action of leptin on bone occurs via binding to the Ob-R on bone cells (MSCs, 
osteoblasts, and osteoclast). Leptin suppresses adipogenic differentiation of MSCs and promotes osteoblastic 
differentiation. In addition, leptin increases OPG production in association with reducing that of RANKL, 
thereby inhibiting osteoclastic differentiation. Leptin also exhibits a central indirect effect on bone by binding 
to its receptor in the hypothalamus and activating the SNS, enabling binding of noradrenalin to β2-AR on 
osteoblasts and thus inhibiting bone formation. It also increases RANKL expression and promotes the 
differentiation of osteoclasts. However, to date the precise mechanisms of leptin action on skeletal 
homoeostasis remain unknown. Other secretory factors produced by adipocytes can positively or negatively 
regulate skeletal mass. In the bone marrow setting, activation of PPAR-γ causes bone loss in part through 
altering the fate of MSCs towards adipogenesis and away from osteogenesis.  Activation of PPARγ also 
results in recruitment of hematpoietic cells that can differentiate into osteoclasts under the influence of m-
CSF and RANKL, which are produced by preosteoblasts, thereby ensuring a coupled process. Furthermore, 
secretory factors released by marrow adipocytes are toxic and block osteoblast differentiation and enhancing 
adipogenesis, whereas secretion of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) can stimulate osteoclast 
activity thereby enhancing bone resorption processes. HBSC, haematopoietic stem cells; MSC, mesenchymal 
stem cell; RANKL, receptor activator for nuclear factor κB ligand; OPG, osteoprotegerin; PPARγ, 
peroxisome proliferator-activated receptor γ; Runx2, runt-related protein;OSX,osterix;IL, interleukin;TNF-α, 
tumour necrosis factor; M-CSF, macrophage clonally stimulating factor; SNS, sympathetic nervous system; 
β2-AR, β2-adrenergic receptor; Ob-R, leptin receptor. Red line indicate inhibitory action; black arrow 
indicate stimulatory action (206). 
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1.4 T1DM  
1.4.1 Background  
T1DM is a chronic metabolic disorder characterized by hypoinsulinemia and chronic 
hyperglycaemia due to the autoimmune destruction of insulin-producing pancreatic β cells 
(207, 208). T1DM account for 10% of all diabetes, and the overall incidence of T1DM 
seems to be increasing in recent decades up to 4.8% per year, an increase which is 
attributed to a number of possible immune-modulatory factors which include social 
changes in hygiene, infectious exposures and nutritional factors (209, 210). If these trends 
continue, the incidence of people with type 1 diabetes will increase in coming years (211, 
212).  It is one of the most common chronic diseases of childhood. The peak age of 
presentation is school entry (5 -7 years), and at puberty (10-14 years), but the disease can 
also be diagnosed at any age. In adults, it constitutes approximately 5% of all diagnosed 
cases of diabetes (213, 214).  Diagnosis of diabetes is generally given when fasting blood 
glucose is equal or higher than 7 mmol/L (126 mg/dL), any blood glucose of 11.1 mmol/L 
(200 mg/dL) or higher with symptoms of hyperglycaemia, or an abnormal 2h oral glucose-
tolerance test. In addition, recently HBA1C has been set as a standard of diagnosing 
diabetes.  If an individual has an HA1C of  6.5%  (47.5 mmol/mol) or higher, they meet the 
criteria for the diagnosis of diabetes (215). Some cases of T1DM are misdiagnosed as 
T2DM. Therefore,  pancreatic autoantibodies are considered characteristic of type 1 
diabetes, and more than 90% of individuals with newly diagnosed T1DM have 
autoantibodies at disease onset (216). The management of T1DM is by exogenous insulin 
replacement which is usually delivered by multiple daily injections or by using an insulin 
pump. An adjustment of the insulin dose is made according to the number of carbohydrates 
in each meal, which is what is known as carb counting (217). Regular monitoring of 
average blood glucose over a period of 6-10 weeks by using glycated haemoglobin 
HBA1C is essential to tightly regulate the glycaemic control and in turn decrease the risk 
of developing complications. Additionally, a regular screening programme for people with 
diabetes is imperative to prevent the long term complications that develop as a result of 
chronic hyperglycaemia. 
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1.4.2 Complications of diabetes  
Long term complications of diabetes include microvascular disease, nephropathy, 
neuropathy, retinopathy, and macrovascular disease, cardiovascular and peripheral 
vascular complications (218). Recently, fragility fracture is another common complication 
of diabetes (161, 219). The interaction of advanced glycation end-products (AGEs) with 
their receptors on different body tissues are thought to play a significant role in the 
pathogenesis of diabetic complications via activation of pro-inflammatory pathways (220). 
AGEs are generated by the non-enzymatic addition of reduced sugar moieties to amine 
groups on both tissue-specific and circulating proteins. In the presence of hyperglycaemia, 
AGEs accumulate within various organs including the kidney, retina, and the 
cardiovascular system. These AGEs may also accumulate in bone and contribute to 
diabetic bone disease; this will be discussed in more details in the following section 
(Section 1.4.1.1). 
1.5 T1DM and abnormalities of bone health  
In addition to the many target organs that are typically associated with dysfunction, the 
skeleton has been recognized as another organ that is adversely affected in diabetes 
mellitus with fragility fractures being increasingly recognized in people with diabetes 
mellitus (161, 162, 221). An extensive volume of clinical data supports altered bone 
structure and biochemical markers of bone turnover in people with both Type 1 and Type 2 
diabetes (T1D and T2D)(222-224). In addition, a series of experimental studies have 
reported several possible mechanisms that could explain the link between diabetes and 
adverse bone health. In the following section, we review the pathophysiological 
mechanisms of diabetic bone loss and the evidence that exists for abnormalities of bone 
health in people with T1DM. 
1.5.1 Pathogenesis of altered bone metabolism in T1DM 
1.5.1.1 Hyperglycemia 
Several in vivo and in vitro studies indicate that hyperglycemia contributes to bone loss 
through a variety of mechanisms: direct glucose toxicity to osteoblast through 
polyolpathway activity affecting osteoblast numbers and function (225, 226); osmotic and 
nonosmotic pathways which independently suppress osteoblast maturation and 
mineralization (227, 228); down regulation of vitamin D receptor thus indirectly impairing 
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osteoblast maturation in response to 1,25(OH)D3 (226); oxidative stress(229); and 
formation of glycation products (230). Hyperglycemia leads to increased nonenzymatic 
protein glycation and excessive formation of these modified proteins called advanced 
glycosylation end-products (AGEs). AGEs appear to be the common biochemical entity 
accumulating in individuals with long term diabetic complications. They are seen in 
various sites such as vascular tissues, kidneys and bones(231, 232). The accumulation of 
AGEs increases formation of collagen cross-links which results in increased stiffness of the 
collagen network in the cortical bone, but this has no overall effect on the stiffness of the 
mineralized bone(233). Accumulation of pentosidine, a well-characterized AGE, is 
negatively correlated to trabecular bone volume and the structural strength of the trabecular 
bone, which may explain how AGEs contribute to bone fragility (234-236). In support of 
this hypothesis, in vivo studies in both T1D and T2D rats have confirmed that an increase 
in AGE production is negatively correlated with bone mineral density (BMD) and bone 
strength (237, 238). Moreover, AGE was found at higher concentration in cortical and 
cancellous bones of people with femoral neck fracture compared to post-mortem controls 
(235, 237). Higher pentosidine levels and AGE products have been found to reduce bone 
strength and elevated vertebral fracture risks in T2D (235, 239).  In addition to affecting 
bone physical properties, AGEs also have direct effects on bone cells. There is a growing 
body of evidence suggested that linking of AGEs with their receptor (RAGE) causes 
oxidative stress generation and induces inflammatory reactions in a variety of bone 
forming cells, including osteoblasts, osteoclasts, and mesenchymal stem cells (MSCs). In 
vitro and ex vivo findings suggest that elevated AGE can inhibit proliferation and 
differentiation of osteoblast (240, 241) in mouse and human mesenchymal stem cells 
(MSCs). It is also associated with reduced osteocalcin mRNA expression as seen in rodents 
with diabetes (238, 242). Furthermore, Okazaki et al. demonstrated that the inhibition of 
osteoblastic differentiation by AGEs can occur independently of hyperglycemia (243). 
AGEs can also cause osteoblast death by provoking inflammation and generation of 
reactive oxygen species (ROS) which in turn lead  to cell apoptosis as a result of oxidative 
stress (229, 242, 244, 245). However, reports regarding the influence of AGEs on 
osteoclasts and bone resorption show inconsistent effects with some evidence of 
increased(246), decreased (247) as well as no effect of AGE on bone resorption (240). 
MSCs are pluripotent stem cells capable of differentiating into bone, muscle, cartilage and 
adipose tissues. Emerging evidence suggests that hyperglycemia may also alter the 
differentiation of the MSCs promoting adipogenesis instead of osteogenesis via AGE-
RAGE oxidative stress system (241, 248). Mice with spontaneously and pharmacologically 
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induced diabetes with bone loss have shown increased marrow adiposity, determined by 
histology and by mRNA markers of adipogenesis (PPARg and aP2)(249). Hyperglycemia 
diverts the MSC differentiation signaling pathways toward adipogenesis at the expense of 
osteogenesis. This effect is achieved via ERK-1/-2-activated P13K/Akt-regulated pathway 
in mouse MSCs (250), and via suppression of HO-1 expression (251)and Wnt/protein 
kinase C noncanonical pathway in human MSCs (252), evidenced by increased PPARg 
expression in high glucose stimuli and reduction of osteocalcin levels. Wang et al. 
demonstrated that hyperglycemia can also promote adipogenesis through synthesis of 
hyaluronan matrix which promotes an inflammatory response culminating in 
demineralization of trabecular bones (253). 
1.5.1.2 Insulin, IGF-1 & other growth factors 
Insulin is increasingly recognized to have an anabolic effect on bone that is distinct from 
the effect of its analogue IGF-1. This effect is mediated either indirectly through its control 
of blood glucose concentration while maintaining the levels of parathyroid hormone 
(PTH), IGF-1, vitamin D (254, 255), or directly on bone cells through specific insulin 
receptors (IRs) and IGF-1 receptors in osteoblast. IRs are present on osteoblasts and its 
expression varies with differentiation status of the osteoblast both in vivo and in vitro (256, 
257). In vitro studies on primary osteoblasts and clonal osteoblast cell lines show insulin 
promotes glucose uptake (258), alkaline phosphatase activity, collagen synthesis (259, 
260) and osteoblast proliferation (261) of these cells. Maor et al. demonstrated reduced IRs 
in the skeletal growth centers of mice with streptozocin (STZ)-induced diabetes and these 
were reversed with insulin therapy (262). Evidence for a direct link between insulin action 
and bone formation in vivo can be observed in IR knock out mice which show altered bone 
formation (86), abnormal trabecular microarchitecture (263) and reduced bone strength 
(264). Insulin positively regulates bone formation by stimulating osteocalcin production. 
Observational studies in people with T1D and T2D, with insulin deficiency and resistance 
respectively, demonstrate reduced osteocalcin levels compared with controls (265, 266). 
Furthermore, there is a positive correlation between insulin dose and BMD (267, 268). The 
dichotomy of lower BMD in T1D with insulinopenia and higher BMD in T2D with clinical 
hyperinsulinemia further implicates a causal anabolic effect of insulin on bone. The direct 
effect on bone may also be mediated by the IGF-1 pathway. IGF-binding protein (IGFBP) 
serves as a carrier protein for IGF1. Insulin inhibits IGFBP-1, 4 expression in osteoblasts 
and therefore lack of insulin leads to an increase in IGFBP-1 and 4 levels, accordingly 
decreasing the availability of unbound IGF-1 for anabolic effects on bone (269). In 
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addition to insulin deficiency, T1D individuals and animal models demonstrate 
dysregulation of a variety of endocrine factors including reduced amylin (162) and IGF-1 
(270). Amylin is another osteotropic factor that is cosecreted by pancreatic beta-cells and 
absent in T1D (271). Amylin-deficient mice displayed low bone mass with increased 
number of osteoclast (272) and that treatment with amylin in diabetic rat result in increased 
BMD and bone strength (271). Similarly, diabetic animals with low blood IGF-1 and 
knock-out mice for its receptor displayed diminished bone formation (273, 274). Also, 
serum IGF-I level was another predictor of prevalent VFs in postmenopausal women with 
T2D (275). 
1.5.1.3 Calcium, vitamin D & calciotropic hormones 
It is well known that calcium homeostasis plays a major role in regulating bone 
metabolism, Therefore, imbalance in systemic factors which are capable of regulating 
calcium balance have been found to influence diabetic bone loss (276). Similar to diabetic 
patients, several but not all studies demonstrate that diabetic animal models have reduced 
levels of PTH, vitamin D, calcium, magnesium and phosphate (277). The effect of DM on 
calcium metabolism is complex, but essentially it is associated with a negative calcium 
balance hallmark by both bone and renal loss (278). There is a growing body of evidence 
which demonstrate exacerbation of osteopenia and osteoporosis in animals and humans 
with vitamin D deficiency and T1D or T2D (279-281). Verhaegae et al. found that diabetic 
rats have higher urinary calcium excretion and significantly lower serum concentrations of 
both 1,25-dihydroxyvitamin D3 and vitamin D-binding protein (280). Frazer et al. 
demonstrated that alteration in vitamin D metabolism in young insulin-dependent diabetics 
aged 7–18 years old, who have markedly reduced 1,25-dihydroxyvitamin–D but normal 
serum calcium, phosphate and PTH concentrations, could be related to their observed 
decrease in cortical bone mass (281). More recently, Zhang et al. aimed to explain the 
mechanism involved by demonstrating that male STZ-induced diabetic mice have high 
urinary calcium excretion and decreased BMD (276). Quantified PCR results showed 
alteration of vitamin D metabolic enzyme expression and down regulation of mRNA 
expression levels for renal calcium transporter receptors, plasma membrane Ca-ATPase, 
and vitamin D receptor. In support of this, treatment with calcitriol in STZ-induced rats 
demonstrated recovery of BMD (282). In terms of PTH, several in vivo and in vitro studies 
indicate that an imbalance in PTH was associated with bone loss and increase fracture risk 
(283, 284). PTH encourages bone formation and turnover by increasing the expression of 
osteocalcin, IGF-1, IGFBP-3, bFGF, MMP-1 and MMP-13 in rat osteoblasts in vitro (285), 
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as well as MMP-13 in mice in vivo (286). Moreover, treatment with PTH to T1D and T2D 
mice demonstrated reversal of trabecular bone parameters through its anabolic effects on 
osteoblasts differentiation and maturation (284, 287). PTH-treatment was also associated 
with reduced TUNEL-staining of osteoblast suggesting its antiapoptotic effect on 
osteoblasts. It has been suggested that PTH promotes repair of DNA damage by increasing 
PCNA and Foxo3a (288), hence prolonging osteoblast survival. Intermittent PTHtreatment 
reversed bone loss to baseline in mice compared to only partial reversal in continuous 
PTH-treatment, although this effect may be due to underlying differences between the T1D 
and T2D mouse models (284, 287). Similarly, treatment with PTH-related protein, which is 
produced at high levels by differentiating osteoblasts, also reverses trabecular bone loss in 
STZ-induced diabetic mice suggesting its modulatory effect on osteoblast function and role 
in diabetic osteopenia (289). 
1.5.1.4 Marrow adiposity & adipokines 
There is a growing body of evidence that suggests that the fat one connection plays an 
important role in the pathophysiology of bone loss. Osteoblasts and adipocytes share a 
common precursor, both derived from the pluripotent MSCs located in the bone marrow 
suggesting a mutually exclusive and reciprocal lineage selection of one or the other. The 
main lineage-specific transcription factors that direct the differentiation of MSC are the 
runt-related transcription factor 2 (Runx2) for osteoblastogenesis and the PPARg for 
adipogenesis (199). It has been suggested that lineage selection could regulate bone density 
and result in bone loss when MSCs commit to the adipocytes at the expense of osteoblasts 
(251, 290, 291). Botolin et al., 2005 were the first to report an increase in the expression of 
PPARg and an increase in visible adipocytes in tibia of T1D mouse models compared with 
control (292). Subsequently, several experimental animal studies have demonstrated an 
increase in bone marrow adiposity in both spontaneously and STZ-induced T1D mice 
compared to controls (249, 289, 293). As described earlier, hyperglycemia is capable of 
promoting adipogenesis by altering the lineage commitment of MSCs to adipocytes 
through various signaling pathways contributing to the diabetic osteopenia (250, 253, 294). 
Rzonca et al. demonstrated in vivo that rosiglitazone (PPARg agonist) administration 
results in significant bone loss whilst Cock et al. 2004 demonstrated that congenitally 
PPARg deficient mice had increased BMD and bone trabecular microarchitecture 
parameter including BV/TV and trabecular thickness (295). However, Botolin and McCabe 
found that inhibition of PPARg by administration of an antagonist to insulin deficient T1D 
mice prevented bone marrow adiposity but not bone loss (249). This inability in preventing 
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bone loss in T1D mice suggested that bone marrow adiposity may only be partially 
responsible for diabetic bone loss. Bone marrow adiposity can also have direct effect on 
osteoblasts as demonstrated by several coculture studies in mouse and human cells (296-
298). The presence of adipocytes inhibit osteoblast proliferation (296) through the 
lipotoxic effect of free fatty acid in the bone marrow microenvironment (297). Coe et al. 
demonstrated that the diabetic bone marrow itself is a mediator for osteoblast death with an 
increase in caspase-3 activity, a marker for extrinsic apoptotic pathway which are activated 
by extracellular ligands such as TNFa, in bone marrows of both spontaneous and 
pharmacologically-induced diabetic mice. By treating the cocultures with TNFa antibodies, 
they prevented osteoblast death further supporting the negative correlation of diabetic bone 
marrow adiposity and bone mass. In addition to releasing large amounts of free fatty acid, 
adipocytes in the bone marrow also secrete cytokines including leptin, resistin and TNFa, 
the last of which will be discussed in the next section. Leptin is an adipokine which has a 
complex regulatory role on bone metabolism, with an indirect inhibitory effect on 
osteoclastogenesis and a direct stimulatory effect on osteoblastogenesis through a central 
(hypothalamic) and peripheral pathway (299-301). Despite being an adipokine, in vitro 
studies indicate that leptin promotes an osteoblast rather than adipocyte lineage (300, 301). 
In contrast to T1D patients who demonstrate increased (302) or slightly decreased leptin 
level (303), leptin levels were found to be significantly suppressed in T1D mice, its 
absence results in reducing bone mass with increasing marrow adiposity (299)[83]. T2D is 
typically associated with obesity, which has been associated with higher leptin level and 
higher BMD. Vasilkova et al., however, demonstrated that leptin has an independent 
positive correlation to BMD, irrespective of BMI (304). In addition, interventional studies 
in mice have demonstrated that leptin administration reduces bone marrow adiposity and 
increase bone mass (305, 306). However, similar to their work on PPARg antagonist, 
Motyl and McCabe concluded that leptin administration to T1D mice modify and prevent 
marrow adiposity but did not prevent diabetic bone loss (307). Adiponectin (APN), the 
most abundant adipocyte-secreted adipokine, regulates energy homeostasis and exerts 
well-characterized insulin sensitizing properties. The peripheral and central effects of APN 
on bone metabolism are beginning to be explored but are still not clearly understood. APN-
knockout (APN-KO) mice fed a normal diet exhibit decreased trabecular structure and 
mineralization and increased bone marrow adiposity and central administration of APN 
decreased osteoclast numbers, whereas osteoblast osteogenic marker expression and 
trabecular bone mass increased both, in APN-KO and WT mice (308). The insulin-
sensitising effect of OC is known be due to the upregulation of the expression of the 
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insulin-sensitizing APN gene in adipocytes (89) but there is some suggestion that in 
humans the link between OC and APN may be gender specific (309). 
1.5.1.5 Chronic inflammation 
The pathogenesis of both T1D and T2D are associated with activation of the immune 
system, especially so in T1D which involves an autoimmune destruction of pancreatic b-
cells whilst T2D involves a more chronic low-grade inflammatory process (310, 311). 
Several experimental studies using T1D mice model indicate that systemic and local 
inflammatory cytokines are increased at the onset of diabetes with rapid suppression of 
osteoblast markers and increase in adipocyte markers, indicating that bone inflammation 
may be another contributing factor to the diabetic bone pathology (298, 312, 313). Serum 
cytokine levels (TNFa, IFN-g, IL-1Ra and LT-b) and corresponding bone cytokine mRNA 
expression were increased from as early as 5 days after induction of diabetes in mouse 
models (249, 312) with decrease in osteocalcin mRNA expression in bone RNA extracts, 
and it remains suppressed at 40 days post induction. mTNFa can either directly suppress 
osteoblast maturation as well as promote osteoblast death in vitro (313) or act indirectly by 
contributing to elevation of ROS causing osteoblast apoptosis from oxidative stress (229, 
245). Coe et al. also found that TNFa in the bone marrow microenvironment directly 
mediate osteoblast death with increase in increased expression of proapoptotic factors and 
osteoblast TUNEL staining, further contributing to T1D bone loss (298). Inhibition of the 
cytokines with TNFa neutralizing antibodies prevented osteoblast apoptosis (298) but 
transgenic mice with IFN-g KO proceeded to have diabetic bone pathology (312), 
supporting the idea that diabetic inflammatory bone loss involves an interplay of more than 
one cytokine and/or a combinations of other factors. Apart from proinflammatory 
cytokines, abnormal hyaluronan production in bones of diabetic rodents also induced 
monocyte and macrophage infiltration into the bone collagen matrix, promoting 
adipogenesis at the expense of osteogenesis (253). The concept of T2D as an inflammatory 
disease is relatively new with increased fat depots in T2D implicated as the source for 
more proinflammatory cytokines and adipokines (310). However, a large prospective 
population study (EPIC) in Germany found that systemic inflammatory markers are 
independent predictors for the development of T2D, independent of degree of insulin 
resistance and obesity (314).  
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1.5.1.6 Vasculopathy 
Similar to other diabetic microvascular complications of retinopathy, nephropathy and 
neuropathy, bone microangiopathy has been insinuated as another possible mechanism for 
diabetic bone loss. In hypoxic condition (2% oxygen), the bone marrow shifts toward 
adipogenic lineage by enhancing expression of genes associated with adipogenic/lipogenic 
phenotype (C/EBPb, PPARg2, and aP2) and by suppressing expression of genes associated 
with osteoblast differentiation (alkaline phosphatase, AP) (315). Oikawa et al. found that 
the cumulative vascular density was reduced by three fold in bone marrow of STZ-induced 
diabetic mice compared to control, along with reduction in blood flow (316). In addition, 
there is also evidence of reduction in bone marrow volume and bone marrow remodeling 
with cell depletion mainly affecting the osteoblastic niche secondary to hypoperfusion and 
oxidative stress (316). Correspondingly, boosting the antioxidative pentose phosphate 
pathway with benfotiamine supplementation prevented microangiopathy and 
hypoperfusion in the bone marrow with reduction in cell apoptosis, providing further 
compelling evidence for vasculopathy in diabetic bone pathology. Regenerating mouse 
tibia has reduction in blood vessels with lower expression of VEGF, a signaling protein 
which regulate angiogenesis, and its receptor (289). Clinically, histomorphometric 
evaluation of iliac crest bone biopsy in 118 diabetic patients revealed evidence of diabetic 
bone microangiopathy in 82% with significant osteopenia and reduction in the sinusoidal 
capillaries (317). 
1.5.1.7 Anti-diabetic medications 
Although insulin has a clear anabolic role on bone as reported earlier, the skeletal effects of 
insulin treatment remain controversial with increased risk of falls from hypoglycemic 
attacks resulting in fractures (318). Total daily insulin requirement has a positive predictive 
value for low BMD, although the need for higher insulin dose may reflect the presence of 
more severe disease (319). Different classes of anti-diabetic medication, such as 
thiazolidinediones (TZDs), metformin and glycogen-like peptide 1 inhibitors have been 
reported to have both varying effects on bone. TZDs such as pioglitazone and rosiglitazone 
have been shown to increase adipocyte differentiation and decreased osteoblast 
differentiation through activation of PPARg activity (295, 320, 321). Consistent with these 
preclinical observations, a meta-analysis clearly indicate that TZD use is associated with a 
higher risk of fracture, particularly in women (321). In contrast, metformin and 
sulfonylurea have been reported to be bone protective with a reduction in risk of fractures 
in patients treated with these agents (322, 323). Both compounds exert a direct osteogenic 
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effect in vitro by stimulating proliferation and differentiation of osteoblast (324-328) 
through preventing AGE-induced deleterious effects in osteoblastic cells (329) and various 
signaling pathways including the PI3K/Akt pathway (327), ERK-1/2 (324) and AMPK 
activation (326, 328). Zhen et al. also demonstrated an indirect effect of metformin on 
osteoblast survival through reduction of intracellular ROS (330). In addition to its 
osteoblastogenic potency in vitro, metformin can further prevent bone loss by inhibiting 
osteoclastic differentiation (331). However, ovariectomized rodents treated with metformin 
demonstrated inconsistent radiological findings of no change in bone microarchitecture 
(332) to increased BMD (331). A newer class of oral antidiabetic agent, the dipeptidyl 
peptidase-4 (DPP-4) inhibitors, such as sitagliptin, has been observed to have anabolic 
effects on the bone (333) but the long-term skeletal consequences of these drugs are yet 
unclear. Lastly, dapagliflozin, a highly selective inhibitor of sodium-glucose cotransporter 
2 which reduces hyperglycemia and weight in patients with T2D by increasing urinary 
glucose excretion has also been studied for its effects on bone metabolism but no clear 
effects have been described (334, 335). 
1.5.2 Clinical evidence of fracture 
Although fracture data for T1D is scarce, the existing evidence indicates that people with 
T1D have a higher fracture risk compared to the general population and these fractures 
occur more frequently in the lower limbs (161, 336-338). More recently, vertebral fractures 
have been also reported (160, 339). The risk of hip fractures in those with T1D is reported 
to be 7–12 times greater (336, 340) and this increased risk is also evident in young adults 
(221). Recent population-based cohort study used data from The Health Improvement 
Network (THIN) in the U.K. in which 30,394 participants aged 0-89 years with type 1 
diabetes were compared with 303,872 randomly selected age-, sex-, and practice-matched 
participants without diabetes. They found that T1DM was associated with increased risk of 
incident fracture that began in childhood and extended across the life span. HR were 
lowest in males and females age <20 years, with HR 1.14 (95% CI 1.01-1.29) and 1.35 
(95% CI 1.12-1.63), respectively. Risk was highest in men 60-69 years (HR 2.18 [95% CI 
1.79-2.65]), and in women 40-49 years (HR 2.03 [95% CI 1.73-2.39]). The majority of 
these fractures were lower extremity fracture(219). The increased fracture risk was much 
higher than expected based on BMD assessed by dual energy x-ray absorptiometry (DXA), 
which was only 10% lower than normal (162). In a meta-analysis that highlighted the 
fracture rates and the discrepant relationship with BMD, the relative risk for hip fracture 
amongst T1D studies was almost 7 (161). Poor glycemic control and disease duration have 
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also been reported to play a contributory role in this raised fracture risk irrespective of 
BMD (322, 340, 341). The fracture risk could also be attributed to the microvascular 
complications of diabetes such as neuropathy, retinopathy and nephropathy (336, 342). 
Recently, elevated AGEs and pentosidine levels has been found to impair bone strength 
and cause fragility fractures in T1D (339). Studies that have evaluated fracture risk in 
patients with T1DM are summarized in (Table 1.2). 
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Table  1.2:  Studies that evaluated fracture risk in people with Type 1 Diabetes Mellitus (T1DM).   
BMD; bone mineral density: CI; confidence interval: RR, relative risk: VF; vertebral fractures.
Author and 
year  
Study design  Sex  Study 
population  
Age 
(mean±SD) or 
range     
Fracture  site and  
assessed outcome 
Comments  
Nicodemus, 
2001 (336) 
Prospective cohort  F 30377 55-69 Hip  
 
Women were 12.25 times more likely to report an incident hip 
fracture than women without diabetes. 
Miao,  
2005 (342) 
Prospective cohort  F/M  24,605 20.7± 10.9 Hip  Elevated risks were observed in both sexes (standardized 
hospitalization ratios =7.6 [95% CI 5.9 –9.6] and 9.8 [7.3–12.9], 
respectively), increasing with follow-up time. Ophthalmic, 
nephropathic, neurological, and cardiovascular complications 
were indicators of particularly high risks. 
Ahmed, 
2006 (338) 
Prospective cohort  F/M 12,639 25-98  All non-vertebral and hip   Men had an increased risk of all non-vertebral [RR, 3.1(95% CI 
1.3–7.4)] and hip fractures [RR 17.8 (95% CI 5.6–56.8)]. Men 
and women using insulin had increased hip fracture risk. 
Duration of disease did not alter hip fracture risk 
Janghorbani, 
2007 (222) 
Prospective cohort  F 101343 
 
54.7 ± 9.3  Hip  
  
RR of hip fracture was 7.1 (95% CI 4.4 –11.4), after adjustment 
for BMI, smoking, physical activity, menopausal status, intake 
of calcium, vitamin D and protein, and postmenopausal 
hormone use, RR for T1D was 6.4 (3.9 –10.3).  
Zhukouskaya
,2013 (160) 
Cross-sectional  F/M 82/82   31.1 6 8.6  VFs  No association between VF and lumbar spine BMD in the T1D 
group. No effect of age of diagnosis, disease duration, HBA1c 
and related complication on the prevalence of VF. 
Neumann , 
2014 (339) 
Cross-sectional  F/M 128/77    43.4±8.8  Fractures of ribs, fingers 
and toes were excluded  
Those with prevalent fractures had higher HbA1c, pentosidene 
level and more diabetes-related complications. BMD was lower 
in those with prevalent fractures. 
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1.5.3 Bone turnover studies 
In people with T1D, an assessment of markers of bone turnover often shows a state of 
reduced bone formation which may be associated to factors such as deficiency of insulin 
and chronic hyperglycemia but this needs further investigation (224). Abnormalities in the 
growth hormone–IGF-1 axis may also play a contributory role but this needs further 
investigation. Among the markers of bone turnover, serum osteocalcin level has often been 
reported to be low whereas bone alkaline phosphatase has been found to be increased in 
some studies (343, 344). This imbalance of bone formation markers (Increased ALP, 
decreased osteocalcin) may reflect an impairment of osteoblast differentiation and 
maturation as bone ALP is expressed early in development of osteoblast and osteocalcin is 
released from the mature osteoblast. Reports on markers of bone resorption are scarce and 
conflicting, with studies reporting either normal or reduced circulating levels bone 
resorption markers (341, 345, 346). Serum PTH has been found to be increased or normal 
(341). Though levels of the Wnt signaling antagonist, sclerostin, are reported to be higher, 
its link to other markers of bone metabolism has not been confirmed yet (339). Only one 
longitudinal study showed that bone turnover returned to normal after improved glycemic 
control (347). 
1.5.4 Bone imaging studies in DM 
The association between DM and bone changes has become a subject of extensive 
research, but the results so far are inconclusive. There is still an open question of whether 
the effect of diabetes on bone health is primarily due to changes in bone density or changes 
in the inherent material properties of bone tissue. The majority of BMD studies in children 
with T1DM have reported either a slightly low BMD or a normal BMD (Table 1.3) (348-
351). In adults with T1D, the most consistent observation is that BMD is reported to be 
significantly decreased at lumbar spine and femoral neck (Table 1.4) (319, 346, 348, 349, 
352-359). In one meta-analysis, a significantly lower BMD Z-score at the hip (-0.37 ± 
0.16) and spine (-0.22 ± 0.01) [1] was observed. These findings have been confirmed by 
several subsequent studies (356, 357) but there are also a small number of studies that have 
reported no abnormalities in BMD (352, 355, 360). The effect of T1D on cortical and 
trabecular bone structure in humans has not been as well characterized as it has in rodent 
models (234, 276). Studies that have evaluated bone mass and structure by using pQCT 
show reduced total and cortical cross sectional area and lower muscle mass in children and 
adolescence with T1D compared to healthy control (361-365). Another pQCT study by 
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(366) indicated that as T1D adolescents reached 14 and 15 years of age, their cortical CSA 
normalized, becoming equivalent to the cortical CSA of nondiabetics at the same age. 
However, T1D was associated with a decreased bone CSA at the radius at the end of 
pubertal growth comparing to controls (367). Recently, few studies have analysed cortical 
and trabecular bone structure measured with high-resolution quantitative computed 
tomography (HR-pQCT) (163) and QCT(164), and measured trabecular bone score derived 
from DXA (368). QCT has shown that young and middle aged people with T1DM have 
lower cortical thickness and lower vBMD compared to healthy controls (164). A single 
study recently evaluated HR-pQCT in patients with T1D compared to controls concluded 
that the presence of MVD was associated with deficits in cortical and trabecular bone 
microarchitecture that could partly explain the increased bone frailty in those group of 
people (163).  TBS which is a measure of bone texture has been found to be  lower in T1D 
patients with prevalent fractures, suggesting an alteration of bone microarchitecture in this 
subgroup of patients(368) .In light of the emerging importance of the interactions between 
marrow fat and bone and the evidence for the negative effects of marrow fat on bone 
density, marrow fat as an independent surrogate for bone quality has also been recently 
assessed by MRI (369).The factors that may be associated with BMD in T1D are not well-
known yet. Some studies have documented a decreased BMD in those with a recent onset 
of T1D (354, 362, 370) indicating the existence of mechanisms before the appearance of 
clinical symptoms such as autoimmune and inflammatory mechanism (350). However, 
others studies have not detected an abnormality of BMD in recently diagnosed children 
indicating that the metabolic consequence of the disease over time may play an important 
role than a predisposing covariant. Some studies have suggested that metabolic control, 
including its effect on the growth hormone/ IGF-1 axis, plays a strong role in the genesis of 
osteopenia (164, 319, 358, 362, 370-373). These findings are supported by a study of 
intensive insulin therapy that stabilized BMD (345). However, others have failed to show 
this association (161, 353, 374-378). Vikram V Shanbhogue,et al  suggested that the 
presence of MVD was associated with deficits in cortical and trabecular bone 
micreoarchitecture comparing to patient without MVD (163). In summary, the available 
data on the structural quality of bone in T1D are still scarce and controversial. There are 
limitations such as small sample sizes, different techniques to measure and interpret data 
and inadequate adjustment of confounders such as age, disease duration and metabolic 
status.
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Table  1.3: Bone densitometry studies in children with T1DM. 
BMD: Bone mineral density; BMC: bone mineral content; BMI: body mass index; CSA:cross sectional area; DR: distal radius; DXA: dual X-ray absorptiometry; FA: forearm; 
FN:femoral neck; GH/IGF-1:growth hormone/ Insulin-like growth factor-I; LS:lumbar spine ;pQCT- peripheral quantitative computed tomography ; ICAM-1:intercellular adhesion 
molecule-1 (ICAM-1).
Author, year  N(f/m) Age (yrs) 
(range or 
means ± SD) 
Dis duration 
(yrs) (range, 
means± SD) 
Modality Site Major finding in                               
cases vs controls 
Comments 
Gunczler 
1998 (375) 
26(11/15) 12.1±3.1 4 yrs DXA LS, FN ↓LS BMD Adjusted for age, sex and pubertal status. No association with 
disease duration, glycaemic control, 24 h urinary calcium 
excretion or bone turnover markers. 
Pascual 
1998 (374) 
55(29/26) 5-15 1-13.8 
 
DXA LS, FA No abnormalities No effect of glycaemic control or disease duration. Adjusted for 
age and sex. 
Heap 
2004 (361) 
55(25/35) 12–17 6.7± 3.6 pQCT 
DXA 
Tibia           
LS,FN 
↓↓Tibia and FN BMD Inverse association to HbA1c.Adjusted for sex, maturation, and 
body size 
Léger 
2006 (377) 
127(54/73) 6-20 4.1-8.6 DXA LS, TB ↓↓ Total BMC and BMD  Only present in girls. Adjusted for age, sex, pubertal stage, and 
BMI SDS. 
Brandao 
2007 (351) 
44 (22/22) 8.8±4.4 6.6±3.9 DXA LS No abnormalities After adjustment for weight, height and pubertal development, the 
BMD was ≤2.0 S.D. in only two diabetic patients (4.5%).Longer 
duration and poor metabolic control may have a negative impact 
on bone mass, 
Moyer-Mileur 
2008 (363) 
11(11/0) 
 
12.9±1.0 5.9±3.7 PQCT 
   DXA 
Tibia              
LS, FN 
↓Tibial and FN BMD Altered markers of GH/IGF-1 axis associated with low BMD. 
The results were adjusted for height and puberty. 
Heilman 
2009 (371) 
30 (11/19) 4.7-18.6 5.4±3.4 DXA LS, TB ↓↓Total BMC and LS BMD  Only present in boys. Inverse association to urinary markers of 
oxidative stress, plasma ICAM-1 levels and HbA1c. The result 
was adjusted for age, sex and BMI. 
Saha 
2009 (364) 
48 (26/22) 12-17.8 1-13.5 pQCT 
DXA 
Tibia               
LS, FN 
↓BMC                                          
↓CSA 
Only present in girls. Adjusted for height, weight, age and sex. 
Roggen 
2013 (367) 
56 (23/33) 17.2–24.8 10.6±3.9 pQCT DR Similar Trabecular BMD,  
↓  CSA 
Adjusted for age, gender, height score and BMI.Ingirls, the CSA 
SDS correlated negatively with the BMI SDS and positively with 
the height SDS. 
Molina 
2014 (350) 
75((39/36) 6-20 - DXA LS (L1-
L4) 
↓↓ LS BMD Children and adolescents with early onset T1D presented with 
low BMD associated withpoorer glycaemic control. BMD was 
not adjusted for any variables. 
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Table  1.4: Bone densitometry studies in adults with Type 1 diabetes.  
Reference Subject 
N(f/m) 
Age, Yrs 
(range or 
means± SD) 
Disease 
Duration,Yrs 
(mean±SD) 
Modalities Site Major findings in cases Comments 
Kayath 
1994 [152] 
90 18-54 2–20 DXA LS, FN ↓ BMD in 34%of IDDM patients. Positive correlation with glucose levels 
duration of disease and insulin dosage. 
 Lunt  
1998 [156] 
99  
(99/0) 
42median 27median DXA LS 
FN 
No difference in BMD from control Positive correlation with BMI and height. 
Kemink  
2000 [157] 
 
35 
(14/21) 
37.6±9.9 
 
8.5±3.5 DXA 
 
LS, FN ↓FN BMD, ↓LS BMD,                         
Osteopenia in 67% of men 
57% of women 
 
Lopez-Iberra 
2001 [158] 
32  
(10/22) 
20–39 At diagnosis DXA LS, FN ↓LS BMD, ↓FN BMD.  
Liu 
2003 [153] 
33 
 (33/0) 
20–37 14..5±5.7 DXA FN, LS,  wrist, 
TB. 
↓LS BMD, ↓FN BMD 
 
. 
Bridges 
2005 [159] 
35 
(0/35) 
49.3 20 DXA DR No difference in BMD from control  
Strotmeyer  
2006 [160] 
67  
(67/0) 
35-55 32.2 ±5.3 DXA 
QUS 
Total hip 
FN,TB, LS 
↓ total hip BMD p<0.001 
↓ FN BMD P<0.001 
↓ TB BMD  P<0.01 
↓ Calceneal BUA P<0.001 
 
Hamilton  
2009 [161] 
102 
(52/50) 
20–71 5.5-23.6 DXA FA, FN, LS ↓BMD at LS, FN and FA Only present in women, Lower BMD was 
associated with impaired bone formation. 
Danielson 
2009 [162] 
75 
(75/0) 
28 16 DXA Calcaneus 
FA, FN,LS 
↓ BMD at FA and FN Inverse correlation with HbA1c and markers 
of bone formation in patients with ↓BMD. 
Eller-
Vainicher2011 
[104] 
175 
(104/71) 
32±8.4 13 8.4 DXA LS 
FN 
↓ BMD at LS and  FN Low BMD is associated with low BMI; 
chronic complications have a 
negativeassociation with BMD. 
Botushanov 
2014 [163] 
162 
(97/ 65) 
29.17 / DXA LS 
FN 
↓BMD at FN and LS LS BMD negatively correlated with marker of 
bone formation. 
Shanbhogue et 
al. 2015 (163) 
55 
(27/28) 
45.6± 11.7 17 median HR-pQCT 
DXA 
Distal radius 
and tibia.  
Total hip, LS 
↓Trabecular vBMD and cortical 
vBMD at the radius and tibia. 
The presence of MVD was associated with 
deficits in cortical and trabecular bone 
micreoarchitecture comparing to patient 
without MVD. 
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↓: Decrease in BMD; ↑: Increase in BMD; BMD: Bone mineral density; BMI: Body mass index; BUA: Broadband ultrasound attenuation; CSA: Cross sectional area; DR: Distal radius; 
DXA: Dual X-ray absorptiometry; FA: Forearm; FN: Femoral neck; LS: Lumbar spine; QUS: Quantitative ultrasound; T1D: Type 1 diabetes; TB: Total body
2 year prospective  
(Mastrandrea et al 
2008) [139] 
63(63/0) 15-39  DXA LS, FN, FA, 
TB 
↓ BMD at  FN and TB Statistically significant in women ≥20 yearts 
of age. 
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1.5.5 Conclusion 
Figure 1.6 showing the factors that might play significant role in pathogenesis of bone 
disease in T1DM. In summary, the evidence from experimental studies, with supporting 
evidence from bone marker and bone density data, suggest that adults with diabetes are at 
increased risk for fractures. Patients with T1D are at a higher risk for osteoporotic fractures 
compared to T2D patients or general population. This may be explained by the initial 
period of insulin deficiency which results in impaired bone formation and prevents accrual 
of an adequate peak bone mass. This maybe complicated further by subsequent poor 
glycaemic control. T1D is typically associated with reduced BMD, whereas those with 
T2D usually have normal or elevated BMD. This inconsistency indicates that impaired 
bone quality may further explain the higher fracture risk in addition to frequent falls and 
associated comorbidities. There are several mechanisms by which diabetes could affect 
bone mass and strength, including insulin level, hyperglycemia, AGE accumulation which 
influences collagen characteristics, increased marrow adiposity and increased bone 
inflammation. In addition, associated diabetic complications and treatment with TZDs may 
increase fracture risk. Future studies are needed to clarify the impact of different aspects of 
diabetes metabolism, glycemic control and specific treatments for diabetes on bone. Given 
that DXA related BMD is a poor predictor of bone morbidity in this group of patients, 
there is a need to explore novel approaches to assessing bone quality. A better 
understanding of how diabetes affects bone will improve our ability to protect bone health 
and prevent fractures in the growing population of adults with diabetes. 
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Figure  1.6: Pathophysiological mechanisms of diabetes bone disease.  
T1DM leads to hyperglycaemia, increased inflammation, formation of AGEs, generation of ROS, activation of PPAR-γ, alteration of Vitamin D, PTH and other mineral metabolites. 
This dysregulation as well as reduced insulin signalling and IGF-1 deficit may adversely affect bone cells (MSC, osteoblast, and osteoclast), and induce adipogenesis, low bone 
turnover and consequently resulting in reduced BMD and bone quality. These abnormalities in addition to associated complications and the use of antidiabetic medications lead 
altogether to osteoporosis and increasing fracture risk. T1DM; Type 1 diabetes mellitus: IGF-1; insulin growth factor-1: PTH; parathyroid hormone: AGEs; advanced glycation end 
products: ROS; reactive oxygen species: PPAR-γ; peroxisome proliferator-activated receptor-gamma: TNF-α; tumour necrosis factor-alpha: IL(6,8,1B); interleukin-(6,8,beta).
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1.6 Imaging Modalities for assessment of bone health 
1.6.1 Overview  
Dual-energy X-ray absorptiometry (DXA) is by far the most widely used densitometry 
technique for quantifying bone mass. It is a quick and non-invasive procedure with a low 
radiation dose of around 0.5-35 μSv.  However, it has several major limitations because it 
provides two-dimensional projected area of a three-dimensional structure, it cannot 
measure true volumetric BMD and cannot reliably differentiate between cortical and 
trabecular bone. Furthermore, DXA provides minimal information on bone shape and 
cannot provide any information on microarchitecture, supporting views that DXA by itself 
is not reliable in predicting risk of osteoporotic fractures (379) 
Quantitative ultrasound (QUS)) represents an alternative method for studying bone tissue 
and managing patients presenting with osteoporosis or other metabolic bone diseases 
(380). Although QUS does not directly measure bone mass, it measures bone quality which 
depends on bone density, bone size, and trabecular architecture (381). It is a method 
developed on the basis of physical changes that ultrasonic waves undergo while they pass 
through bone mass. Bone elasticity and hardness could be demonstrated by QUS. Two 
measures are important in QUS; speed of sound (SOS) and broadband attenuation (BUA). 
The major advantages of QUS are low cost, accessibility, ease of application, and no 
radiation exposure allowing it to be used in a large number of disorders such as relatively 
immobile patient as preterm babies or children (382, 383). The most important limitation 
of QUS is that it can be used to measure bone quality only on single superficial bones such 
as the patella, tibia, and calcaneus. Also, clinical interpretation of bone measurements is 
challenging (384).  
More recently, advanced radiological modalities have facilitated assessment of trabecular 
bone microarchitecture. Micro-computed tomography (μCT), synchrotron radiation 
computed tomography (SRCT), peripheral quantitative computed tomography (pQCT) and 
magnetic resonance imaging (MRI) can be used to image and measure trabecular bone 
microarchitecture (5, 8, 157, 385, 386). Due to high levels of radiation exposure with μCT 
and SRCT, these methods are currently reserved for ex vivo studies only.  
Quantitative computed tomography (QCT) allows for three-dimensional imaging and 
results in accurate quantification of bone density, but it is more costly and delivers more 
radiation dose of around 100 μSv (387).  
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pQCT and HR-pQCT  are suitable tools for investigating trabecular bone microarchitecture 
because they produce images of bone at appendicular sites. However, there are limitations 
with using pQCT and HR-pQCT for clinical research. There is radiation exposure 
associated with the scan. The scans are also susceptible to motion artifact causing 
measurement error. Additionally, because trabeculae size is similar to image resolution, 
pQCT is limited by partial volume effects which decrease measurement accuracy. To 
increase image resolution, there are many factors should be taken in amount, higher 
radiation exposure, more operating costs, longer scan time and processing time for image 
analysis. Despite these limitations, several research groups have shown the feasibility of 
pQCT and HR-pQCT to explore changes in cortical and trabecular bone microarchitecture 
during growth and to differentiate patients with and without established fragility fractures 
irrespective of their BMD (388-390). 
Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) have 
shown great potential in studying bone parameters without any radiation burden to the 
patient as would be encountered in pQCT, and are currently used in research settings. In 
the following section detailed description about the basics of MRI and use of MRI in 
quantification of bone parameters. 
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1.6.3 The Use of MRI and MRS for the Assessment of Bone Health 
1.6.3.1 Overview 
Imaging of bones is an important topic of research in identifying abnormalities based on its 
structure and composition. Different imaging methods are available for measurement of 
bone properties, but very few modalities are capable of quantifying both structure and 
composition. Quantitative computed tomography (QCT), peripheral quantitative computed 
tomography (pQCT) and MRI are suitable imaging techniques that are commonly 
employed for the non-destructive measurement of trabecular bone microarchitecture and 
cortical bone. However, QCT and pQCT both require radiation exposure. Magnetic 
resonance (MR) is a technique that is capable of providing bone information related to both 
bone quantity and quality from the whole-body without the burden of ionizing radiation to 
the patient. Additionally, magnetic resonance is emerging as a comprehensive tool for fat 
quantification, bone marrow adiposity and abdominal adiposity can be measured with 
MRI, which may contribute to a more complete assessment of bone health. With no 
ionizing radiation, MRI allows for multislice volume imaging and indefinite repeatability 
in longitudinal studies and in children. In addition, the signal intensity of fat from CT scans 
is very low and is similar to that of air and bowel gas. Conversely, the strong bright signal 
intensity of fat on MR images and the absence of signals from bowel gases permit accurate 
distinction among fat, other tissues, and gas. 
 
1.6.3.2 Introduction to Magnetic Resonance Imaging (MRI) 
The fundamentals of magnetic resonance imaging (MRI) are based on the intrinsic 
magnetic properties of atomic nuclei. Atomic nuclei with an odd number of protons and 
neutrons such as 
1
H, 
13
C, 
19
F, 
23
Na, 
31P have a property known as “spin” and possess a 
nuclear magnetic moment, which means that they produce a small magnetic field. 
Hydrogen is present within water (H2O) and fat (CH3 etc.) and is the most abundant 
element within the body, and hence hydrogen nuclei (
1
H) generate the strongest MR signal 
(391, 392). MRI uses a strong external magnetic field (B0) to align the nuclear magnetic 
moments of hydrogen atoms in the tissues of the body. Due to the spin characteristics of 
protons (hydrogen nuclei), when no external magnetic field is present the spins are 
randomly aligned, and the net magnetic field (M) generated is zero.  When an external 
magnetic field is applied, the spins are aligned either parallel or anti-parallel to the external 
magnetic field, and the magnetic fields from each pair of parallel and anti-parallel spins 
cancel out, except for a tiny excess of spins that exist in the low energy state which 
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generates a small equilibrium magnetisation in the direction of the static field This is 
illustrated in (Figure 1.7) (393).   
 
 
Figure  1.7: Illustration of spin alignment a) with no external magnetic field and b) in the presence of 
an external magnetic field (393). 
 
Similarly, at body temperature, there is a slightly higher likelihood of spins being aligned 
parallel to B0, which results in a small net magnetic field (M) in the same direction as B0.  
In order to distinguish between M and B0, it is necessary to rotate M from being aligned 
with B0 (longitudinal plane) to being perpendicular to B0 (transverse plane). The individual 
spins rotate, or “precess”, around the axis of the magnetic field at a special frequency 
called the Larmor frequency, which depends on the strength of the external magnetic field.  
Typical clinical MRI scanners have a magnetic field strength of 1.5 or 3 Tesla (T), which 
have corresponding Larmor frequencies of 64 MHz and 128 MHz respectively(394). By 
applying radiofrequency (RF) pulses of the same resonant frequency as the Larmor 
frequency and orthogonal to both the Bo field and the direction of motion of the 
magnetisation into the x-y plane, energy is transferred to the spins and the net 
magnetisation deviates from the longitudinal plane into the transverse plane. This is 
illustrated in (Figure 1.8). 
(a) (b) 
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Figure  1.8: Illustration of transfer of net magnetisation (M) from the longitudinal plane to the 
transverse plane 
 
When the RF pulse is turned off, the spins re-emit the RF energy that they absorbed and 
the net magnetisation moves, or “relax”, back into the longitudinal plane.  The RF energy 
emitted by the spins can be measured in the transverse plane using an RF receiver known 
as a “coil”. RF energy is not directly measured by the RF coil.  The coil actually measures 
an induced sinusoidal electric current as a result of the oscillating magnetic field associated 
with the proton spins. This is Faraday’s law of induction.  
The relaxation process can be divided into two parts, called T1 and T2 relaxation.  T1 
relaxation, which is also known as spin-lattice relaxation, describes the recovery of 
longitudinal magnetisation, and occurs due to the transfer of energy between the spins and 
the surrounding environment (lattice).  T2 relaxation, which is also known as spin-spin 
relaxation, describes the decay of transverse magnetisation, and occurs due to interactions 
between adjacent spins.  T1 and T2 relaxation curves are illustrated in (Figure 1.9)(395).  In 
Figure 1.9, longitudinal magnetisation is denoted as Mz and transverse magnetisation is 
denoted as Mxy.  The time taken for T1 and T2 relaxation to occur varies between tissues, 
and so at a given time t, the signal intensity available to create the MRI image will be 
different for each tissue. 
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Figure  1.9: Illustration of a) T1 and b) T2 relaxation curves for fat, muscle and fluid(395). 
 
Before an MRI image can be created, it is necessary to know where in the body the 
measured signals originated from.  This is achieved by applying linear magnetic field 
gradients in three orthogonal directions (head-foot, left-right and anterior-posterior),  
Selection of an imaging slice is performed by applying an RF pulse which contains a small 
range of frequencies, and only spins which are precessing at those frequencies will 
contribute to the net magnetisation in the transverse plane.  Localisation in the other two 
planes (denoted as frequency and phase) is determined according to the frequencies of 
individual signals – since the magnetic field gradient is linear, the difference in frequency 
between two spins is directly related to their spatial separation.  The area of the body over 
which data is acquired to form an image is called the field of view (FOV).  This is 
illustrated in (Figure 1.10) (395).   
 
 
Figure  1.10: Illustration of a) slice selection and b) localisation in the frequency and phase directions 
using linear magnetic field gradients(395). 
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The FOV is separated into an array of three-dimensional elements known as voxels.  The 
signal intensity in a given voxel depends on the abundance of hydrogen within the region 
of the body which contributes to the signal in that voxel.  A large voxel will contain more 
spins and therefore a higher signal, while a small voxel will contain fewer spins and a 
lower signal. However, a large voxel is not suitable for obtaining images of small 
structures, and so a balance must be achieved between the required image resolution and 
an acceptable level of signal intensity.  Examples of axial images of the tibia acquired with 
different voxel sizes are shown in (Figure 1.11).   
 
 
Figure  1.11:  Images of the tibia acquired with voxel sizes of a) 2.2x2.2x3.0, b) 1.1x1.1x3.0 and c) 
0.4x0.4x3.0 mm
 
The sequence of RF pulses and magnetic field gradients used to generate an MR image is 
called a pulse sequence.  A pulse sequence will be applied many times in order to build up 
a single MR image.  An example of a typical MRI pulse sequence is shown in (Figure 
1.12) (396). 
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Figure  1.12: Example of an MRI pulse sequence diagram. The RF pulses are shown on the top line, 
and the magnetic field gradients are shown on the lines marked Gs, Gp, and Gf, where the subscripts 
refer to the slice, frequency and phase directions.   
The important timing parameters shown in the pulse sequence diagram are the repetition time (TR) and the 
echo time (TE).  TR is the time between subsequent applications of the pulse sequence, and TE is the time 
between the application of the first RF pulse and the measurement of the signal in the transverse plane (396). 
 
The intensity values of the acquired image are generally influenced by the underlying 
properties of the tissues from which the RF signal is generated. One of the main 
advantages of MRI compared with other imaging modalities is that the contrast between 
different biological tissues may be tuned by varying the acquisition parameters. These 
parameters are either intrinsic or extrinsic parameters. Intrinsic parameters cannot be 
changed because they are inherent to the body tissues (e.g. T1 and T2 values), while 
extrinsic parameters are those that can be changed and which depend on the pulse 
sequences parameters used (e.g. TR, TE)(397).  An example MRI image of the tibia is 
shown in (Figure 1.13), which illustrates the differences in signal intensities between bone, 
bone marrow, muscle and subcutaneous fat.   The signal intensities of bone and fatty 
marrow are very different, which makes MRI ideal for imaging trabecular structure.  This 
will be discussed in more detail in (Section 1.6.3.4.1). 
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Figure  1.13: Sagittal MR image of the tibia 
 
 
1.6.3.3 Introduction to Magnetic Resonance Spectroscopy (MRS) 
Magnetic Resonance Spectroscopy (MRS) is similar to MRI, , but instead of using 
hydrogen nuclei (
1
H) mainly within water and fat to produce anatomical images, MRS 
measures the abundance of 
1
H within a range of molecules (including water and fat). 
As mentioned previously, the resonant frequency of a 
1
H nucleus is determined by the 
strength of the magnetic field it is exposed to.  
1
H nuclei within molecules are surrounded 
by orbiting electrons whose motion induces small magnetic fields.  This alters the strength 
of the magnetic field experienced by the 
1
H nuclei, and causes a shift in the resonant 
frequency.  The magnitude of the frequency shift varies between different molecules, and 
plotting a spectrum of signal amplitude against frequency shift allows the relative 
abundance of molecules to be assessed(393).  The frequency shift is expressed in “parts per 
million” (ppm) rather than Hz to allow comparison between MRS acquisitions obtained at 
different main magnetic field strengths, and is typically calculated relative to a reference 
metabolite (tetramethylsilane (TMS) at 0 ppm)(398).  MRS data is acquired in a similar 
way to MRI data i.e. by using a suitable pulse sequence, typically with a single voxel.  In a 
clinical setting, MRS is most commonly performed in the brain, and an example of a 
typical brain spectrum is shown in (Figure 1.14). 
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Figure  1.14: Typical MRS spectrum within the brain 
 
The total area under a particular metabolite peak is directly proportional to the 
concentration of the metabolite.  Absolute quantification in biochemical units, e.g. mm/kg, 
requires calibration using an external solution containing a known concentration of a 
metabolite, which can be impractical in a clinical setting.  Relative quantification is often 
used instead, which involves defining one metabolite to be the reference metabolite and 
then calculating the ratio of all other metabolites relative to this (399). 
 
1.6.3.4 Quantification of Bone Structure and Adiposity using MRI and MRS 
1.6.3.4.1 Trabecular Bone Microarchitecture 
 
In recent years, MRI has evolved into a powerful tool for non-invasive in vivo 
visualisation of trabecular bone microarchitecture, using a high resolution technique which 
is often referred to as micro-MRI.  As discussed previously (Section 1.5.2.2), the variations 
in signal intensity of the imaged tissues depend upon the density of hydrogen nuclei and 
their T1 and T2 relaxation times.  Bone has an extremely short T2 which causes the signal to 
decay before it can be measured, and consequently bone yields a low MR signal.  The MR 
signal of bone marrow on the contrary is relatively high, and hence bone structures can be 
indirectly visualised against the fatty background marrow signal, and information on the 
microarchitecture of the bone can be extracted from the acquired data(400, 401). An 
example axial image of the tibia which illustrates the high signal intensity from marrow 
and the low signal intensity from bone is shown in (Figure 1.15). 
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Figure  1.15: Axial MRI image of the tibia 
 
The most relevant morphological values in the characterization of trabecular bone are the 
bone volume to total volume ratio (BV/TV), trabecular thickness (Tb.Th), trabecular 
separation (Tb.Sp) and trabecular number (Tb.N) (394, 402). The methods developed to 
obtain such morphological parameters are presented in methodology (Section 2.2.1.2).  
However, quantification of trabecular bone parameters is limited by partial volume effects 
(PVE), which overestimate trabecular bone microarchitecture measures in particular Tb.Th 
(403, 404). The susceptibility of the image to PVEs depends on the alignment of the image 
plane with respect to trabecular alignment, the size of the trabeculae, spatial resolution, and 
voxel size (405). Anisotropic bones (vertebrae) are more vulnerable to PVEs than isotropic 
bone (tibia), due to more random trabecular alignments.  
Fundamentally, when the trabecular thickness is greater than image resolution, absolute 
values of trabecular scale can be reported, while if the trabecular thickness is comparable 
to or smaller than image resolution, the reported parameters are typically denoted as 
‘apparent’ rather than absolute scalar values. Each individual trabeculae are approximately 
100-300 μm thickness separated by spaces of 300–1500 μm. In order to accurately resolve 
small features like trabeculae and reduce PVEs, we need to increase MR image resolution 
and the slice thickness (voxel size) should be similar to the thickness of the trabeculae. 
High field strengths and improved coil technology have made it possible to achieve an in-
plane resolution of 150 μm (406). However, because of current signal-to-noise constraints, 
minimal slice thickness is usually about 300 μm. Although this resolution is larger than 
trabecular thickness, trabecular spacing (800–1000 μm) is still much larger than the size of 
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a single MR voxel, so that trabecular parameters can be reasonably measured or estimated 
with MRI.  
There are obstacles associated with improving MR image resolution. For example, in order 
to avoid partial volume effects, voxel sizes less than the size of the trabeculae are 
desirable. This is not feasible, as voxel sizes are associated with lower SNR (a measure 
of signal strength relative to background noise).  Conversely, thicker slices are associated 
with an increase in partial volume effects. Consequently, the poorer SNR of small voxel 
size can be compensated to some extent by increasing the number of acquisitions or by a 
longer TR to get adequate signals. However, this is accomplished only at the expense of 
the overall image acquisition time. Consequently, with longer imaging time patients are 
more likely to move during a longer scan and increasing the susceptibility to motion 
artefacts. To avoid that we need to reduce the patient movement, this is often done by 
patient immobilization; for example, padding can be applied around the limb of the 
participant being scanned to prevent motion, or by using alternative methods (e.g. 
sedation). 
Higher magnetic field strengths are preferred for bone imaging since with a stronger 
magnetic field, image resolution can be increased with the same scan acquisition time, or 
acquisition time can be decreased with the same resolution.  Various magnetic field 
strengths e.g. 7 T, 9.4 T, 11.74 T, 14.1 T, and 17.6 T have been used in vitro (405), 
however in vivo imaging is usually performed at magnetic field strengths ranging from 1 T 
to 7 T (152, 153, 407-411).  The majority of these studies have been performed at 1.5 T, 
but recent studies (412) have shown practical utility of 3T and 7 T scanners for in vivo 
imaging of trabecular bone. 
Several different pulse sequences have been used to image trabecular microarchitecture, 
such as spoiled gradient-echo (394) and Fast Large-Angle Spin-Echo (FLASE) (413).  
FLASE has been shown to provide detailed and reproducible visual delineation of 
trabecular networks in three dimensions at both anisotropic (137×137×410 µm
3
 ) and 
isotropic (160×160×160 µm
3
 ) resolutions in the human distal tibia in vivo (413).  
However, this pulse sequence was developed by a research group in the US and is not 
available on standard clinical MRI scanners.  Recently, balanced steady-state free 
precession (b-SSFP) has been used as an alternative technique.  It uses RF excitation 
pulses with small flip angles, which consequently shortens the repetition time (TR) and the 
total scan time (414, 415).  Because of improved SNR, the majority of the studies which 
have used MRI to investigate trabecular microarchitecture have been done at the peripheral 
sites e.g. distal radius, distal tibia and calcaneus (402, 416-419).  More recently, in vivo 
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MRI of individual trabeculae within the deeper regions e.g. proximal femur has become 
possible (411, 420-422).  
With the recent advances in high-resolution MRI methods, a large number of studies have 
documented the feasibility of MRI in quantification of trabecular bone microarchitecture to 
highlight normal and pathological conditions in a variety of clinical applications. Table 1.5 
summarizes some studies using MRI to study trabecular bone microarchitecture in 
different populations. Variety in MRI protocols was reported, including different magnetic 
field strength, image resolution; scan time, anatomical location, pulse sequence and 
immobilisation technique. The early publications by (402, 419, 423, 424) have documented 
the feasibility and potential of MRI-derived measures of trabecular bone microarchitecture 
in studying osteoporosis. Furthermore, MRI has been used to explore age and gender-
related differences in trabecular bone microarchitecture (425-432). MR-derived structural 
parameters of trabecular bone microarchitecture are better than DXA at differentiating men 
and women with and without vertebral fracture (152, 403, 419, 433). Additionally, Change 
et al., (153) demonstrated the feasibility of 3 Tesla MRI to detect deterioration in proximal 
femur microarchitecture in long-term glucocorticoid users compared with controls who do 
not differ by BMD  (153). 
A study using 1.5 Tesla MRI in children with quadriplegic cerebral palsy (CP) revealed 
that appBV/TV, appTb.N, and appTb.Th were lower (30, 21, and 12%, respectively) and 
appTb.Sp was higher (52%) ( p≤0.001) in children with CP than in controls. Distance from 
the growth plate was inversely related to appBV/TV and appTb.N and was positively 
related to appTb.Sp at the same distance in children with CP and controls (all p<0.01) 
(429).  
The MRI Department in Glasgow and the Developmental Endocrinology Research Group 
(DERG) have successfully performed some pilot studies exploring the utility of 1.5T and 
3.0T MRI in assessing the microarchitecture of bone in healthy volunteers and some young 
adults with concerns about bone health (434). They found that people with OI or GHD had 
a significantly lower appBV/TV and appTb.N and a significantly higher appTb.Sp than the 
control group.  
Moreover, numerous longitudinal studies have demonstrated that MRI–measured 
trabecular bone  parameters found to be more sensitive than BMD in monitoring the 
response to; different therapeutic effects (435-437), physical activity (438) and diseases 
progression (439). In a prospective study over 24 months, hypogonadal men who received 
testosterone replacement therapy, showed the largest changes in surface to curve ratio 
(+11.2%) and erosion index (- 7.5%), compared to BV/TV (5%) or Tb.Th (1.5%) despite 
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good reproducibility of BV/TV and Tb.Th (437). Additionally, a 2-year longitudinal study 
of 91 post-menopausal women receiving either calcitonin nasal spray or placebo studied 
MRI of trabecular micro-architecture at the distal radius and calcaneus revealed 
preservation of apparent BV/TV, apparent TbN and app TbSp for the calcitonin group, 
compared to significant loss in the placebo group. Over the same time, no significant 
change in DXA BMD was observed among either group (436). Folkesson and Goldenstein, 
(435) evaluated 2 years longitudinal effects of alendronate on MRI-based trabecular bone 
structure parameters at distal tibia, distal radius, and proximal femur. They reported 
significant changes in trabecular bone microarchitecture at the distal tibia but not the radius 
after 2 years treatment when compared to BMD. These studies suggest that changes are 
detectable in some, but not all, trabecular bone microarchitecture measures and more 
apparent at some but not all the skeletal sites. Therefore, the site of assessment may also 
influence whether changes are apparent. 
Concerning diabetes, a small number of recent studies used MR based techniques to 
investigate bone architecture in patients with diabetes. Pritchard et al., (159) were the first 
to use high-resolution MRI of the distal radius to compare trabecular bone 
microarchitecture of postmenopausal women with and without T2DM. They concluded 
that in women with T2DM, the average pore size within the trabecular bone network at the 
distal radius is greater compared to controls and hypothesized that this may explain the 
elevated fracture risk in women with T2DM. A recent study in T2DM aimed to compare 2-
year changes in trabecular bone microarchitecture in women with and without T2DM. By 
using 1 T MRI, they did not find significant differences in the change of trabecular bone 
microarchitecture variables at the distal radius between the two groups (439).  
In summary, trabecular bone microarchitecture may be an important structural bone quality 
to consider in bone fragility. BMD measurements may not be sensitive enough to detect 
changes in microarchitectural integrity that impact bone strength. There is abundant 
evidence now from clinical studies suggested the feasibility of MRI-measured trabecular 
bone microarchitecture to differentiate between individuals with different bone 
abnormalities. Additionally, the existing evidence shows a good correlation of MRI 
measured parameters with the standard quantitative techniques like pQCT and HR-pQCT. 
While these tools are not yet used in clinical practice for assessing trabecular bone 
microarchitecture and osteoporosis, recent researches provide evidences of the validity, 
reproducibility and feasibility of use in clinical settings in the future. 
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 Table  1.5: Summary of MRI studies which report assessment of trabecular bone microarchitecture in different population. 
GHD; growth hormone deficiency: OI; osteogenesis imperfecta: T2DM; type 2 diabetes mellitus: MRI, magnetic resonance imaging: DXA; Dual X-ray absorptiometry: pQCT; 
peripheral quantitative computed tomography: (HR)-pQCT; high resolution peripheral quantitative computed tomography: QUS; quantitative ultrasonography: DR; distal radius: 
bSSFP; balanced steady-state free precession: bSSSE; balanced steady-state spin-echo sequence: 3D FLASH; 3 Dimension Fast Large-Angle Spin-Echo. 
Author, year. Population 
(cases/controls) 
Techniques Field 
strength 
Resolution (mm) Anatomical 
location, 
Scan time (M/S) Pulse sequence Immobilisation technique 
McComb, C., et 
al.2014 (434) 
 
GHD, OI (17/22) MRI 3 T 0·3 ×0·3 × 0·3 Proximal tibia 10 min. bSSFP Achieved by placing additional 
padding within the extremity coil. 
Chang, G., et 
al.2015(153) 
long-term 
glucocorticoid use 
(6/6) 
MRI, DXA 3T 0.234×0.234×1.5 Proximal femur 15:18 3D FLASH The hip was immobilized by a 
sandbag laterally secured by a large 
Velcro strap. 
Issever, A.S., et 
al. 2010 (440) 
postmenopausal 
women (51/0) 
MRI, QCT 3T / DR, tibia, and 
calcaneus 
 
20 min. for each bSSFP Custom-built immobilization 
devices were used. 
Pritchard, J.M., 
et al.2012 (159) 
 
T2DM ( 30/30) MRI, DXA 1 T 0.195×0.195×0.1 DR 12:9 A spoiled 3-D gradient-
echo sequenc 
Bracing and padding were applied. 
Modlesky, C., 
et al. 2015(429) 
CP (12/12) MRI 1.5 T / Distal femur / 3D fast gradient echo 
sequence 
 
The Body FIX (was used to limit 
motion of the children from the 
waist down during the scan. 
Krug, R., et al. 
2008 (408) 
10 healthy 
controls 
MRI, HR-pQCT 7T, 3T / Distal tibia 9:10(7T), 9:25 
(3T). 
 
bSSFP and bSSSE / 
Kazakia, G.J., 
et al. 2008(441) 
Postmenopausal 
women (53/0) 
MRI,  (HR)-
pQCT, DXA 
3 T 0.156 × 0.156  ×0.2 DR and tibia 10 min (Radius) 
and 15 min (Tibia) 
 
bSSFP Custom-built immobilization 
devices were used. 
Ladinsky, G.A., 
et al. 2008(442) 
Postmenopausal 
women (98/0) 
MRI, DXA, 
pQCT, heel QUS 
1.5 T 0.137 × 0.137 × 0.410 Distal tibia, DR 16:23 for tibia and 
12:18 for DR. 
 
3D FLASE / 
Pritchard, J.M., 
et al. 2013(439) 
T2DM 
(15/22) 
MRI,DXA 1 T 0.195× 0.195× 0.1 DR. 12:9 A spoiled 3-D gradient-
echo sequence 
Bracing and padding were applied. 
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1.6.3.4.2 Bone Marrow Adiposity 
 
As discussed in (Section 1.5.2.3), MRS can be used to quantify the relative abundance of 
hydrogen nuclei within different molecules. MRS is typically used to investigate 
metabolites within organs such as the brain and heart; however it can also be used to assess 
bone marrow adiposity. The majority of clinical studies on BMA have used MRS to 
analyse separate water and fat signals of BMA at the vertebrae or hip (443-446). The 
resulting spectrum shows peaks corresponding to water and fat (444) as shown in (Figure 
1.16).  In MRS measurements, BMA is expressed as a percentage fat fraction FF%.   
 
 
 
Figure  1.16: The resulting spectrum shows peaks corresponding to water and lipid peaks 
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Li et al. (445) examined the reproducibility of 1H-MRS for assessing vertebral bone 
marrow fat content at 3T. They found that the average CoV of fat content measured was 
1.7% (fat content ranged from 45.5% to 66.1%). This lower CoV indicate that 1H-MRS is 
a highly reproducible method for quantitatively and noninvasively evaluating fat contents 
in vertebral bone marrow. Such assessment is critical during interpretation of 1HMRS 
results for both cross-sectional and longitudinal studies. Additionally, they showed 
variation of marrow adiposity at different vertebral levels and feasibility for identifying 
patients with low bone density. In addition to quantifying overall bone marrow fat at 3 T, 
they were also able to selectively quantify the unsaturation level of the bone marrow fat.  
Examining and understanding the connection between BMA and bone loss has emerged as 
an exciting area of research. The study of bone marrow composition for diagnosis of bone 
abnormalities has been proposed by many groups (443, 447-453). Table 1.6 reviews some 
of the literature which has used bone marrow composition for diagnosis of bone 
abnormalities.  Variety in MRI protocols was reported; including used technique, magnetic 
field strength and anatomical location. 
Several studies of healthy populations have shown the feasibility of MRS to detect age and 
gender related differences in marrow adiposity (454-461). Additionally, higher BMA with 
lower BMD has been reported in patients with osteoporosis (443-445), as well as in 
individuals with metabolic diseases such as obesity (462) and anorexia nervosa (173). 
Moreover, studies have reported a relationship between higher BMA and prevalent 
vertebral fracture (463-465).  
It is well known that diabetes is an independent risk factor for fragility fractures, BMA 
may be altered by diabetes as observed in mouse models of diabetes (Section 1.4.1.4), 
however, the role of BMA, including the underlying mechanisms of its relationship to bone 
strength, remains poorly understood. Specifically by using MRS in patients with diabetes 
mellitus, it was shown that vertebral bone marrow fat content correlated significantly with 
HbA1c and visceral adipose tissue in patients with T2DM (466) and that decreased 
unsaturated bone marrow lipids were found to be associated with T2DM and fragility 
fractures (158). In summary, these results demonstrate that altered bone marrow fat 
composition (lower unsaturation level) is linked with fragility fractures and diabetes. The 
authors suggested that MRS of spinal bone marrow fat may therefore serve as a novel tool 
for BMD-independent fracture risk assessment.  
In T1DM, there is only one clinical study which examined the relationship between BMA 
and diabetes. A study of 16 adult men and women with T1DM and 12 healthy controls, 
vertebral BMA did not differ by diabetes status but there was a striking positive correlation 
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between vertebral, femur, and tibia marrow adiposity and serum lipid levels. Also BMA 
increased with age and was reciprocally related to bone density. Taken together, these data 
suggest that marrow adiposity may be an indicator of elevated serum lipid levels and 
decreased bone density (369).  
To summarize, there is an accumulating amount of evidence that supports a relationship 
between higher BMA, lower bone density, and increased prevalence of vertebral fracture in 
variety of populations. These cross-sectional studies focus on the relationship between 
bone marrow adiposity and DXA measured BMD, but a limited number of studies also 
show an association between BMA and bone microstructure (467). Additionally, 
longitudinal data on these relationships are limited, therefore, prospective data are needed 
to determine the relationship between changes in BMA and bone, particularly in context of 
populations of individuals with metabolic diseases (eg, diabetes) in which BMA 
abnormalities have been demonstrated. A better understanding of the role of BMA in 
humans may lead to new avenues to promote bone formation and hence prevent and treat 
osteoporosis. 
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Table  1.6:  Summary of MRI studies which report assessment of bone marrow composition in different populations. Variety in MRI protocols was reported; including 
adiposity used technique, magnetic field strength and anatomical location.  
Author, year Population type , age Adiposity measure, anatomical site Technique, field strength  Bone measures Adjustment  
Kugel, H., et al. 
2001(454) 
154 healthy men and women 
(11- 95 yrs.) 
 
FF% of L3 MRS, 1.5 T None None  
Tang, G.Y., et al. 
2010(444) 
78postmenopausal women 
 (55-81 yrs.) 
 
FF% and ADC of L3.  MRS and DWI, 1.5 T BMD of LS by DXA None  
 
Griffith, J.F., et al. 
2012(455) 
259 healthy men and women 
(62-90 yrs.) 
 
FF%  of L3 MRS, 1.5 T BMD of  LS by DXA None  
 
Baum, T., et al. 
2012(466) 
13 postmenopausal women 
with T2DM and 13 age- and 
body mass index-matched 
healthy controls 
 
FF%  and unsaturated lipid fraction 
of l2-l3 
 
MRS, 3T VBMD of L1–L3 (QCT). None  
Slade, J.M., et al. 
2012 (369) 
16 adult men and women with 
T1DM compared to 12 adult 
men and women without 
T1DM. 
 
FF% of femur, tibia and L4.  Ideal MRI, 3 T BMD by DXA None  
Patsch, J.M., et al. 
2013(464) 
33 postmenopausal women 
with T2DM, with and without 
fragility fracture compared to 
36 postmenopausal women 
with and without fragility 
fracture. 
 
FF% and  composition of L3 MRS, 3 T  BMD of the hip and LS  by 
DXA  and QCT  
Age, race, and spine BMD 
Shen, W., et al. 
2014(461) 
 181 healthy children (5-17yr.) 
and 495 healthy adults (≥18yr.)  
Pelvic BMA (ilium, sacrum, 
ischium, pubis, coccyx and femoral 
heads) 
Whole-body MRI, 1.5T Pelvic BMD by DXA, pelvic 
vBMD calculated by dividing 
BMC by the pelvic bone volume 
(BV) determined by MRI. 
 
Age, weight, TBF, SAT, 
VAT, skeletal muscle, 
sex, ethnicity and 
menopausal status 
Bredella, M.A., et 
al.2014 (173), 
14 women with AN 
(29.5±1.9yrs) and 12 age-
matched normal-weight 
Total marrow fat content 
and marrow fat composition of the 
femoral diaphysis and soleus 
MRS, 3 T  BMD of LS and hip by DXA %IBW 
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T1DM; Type 1 diabetes mellitus: T2DM; type 2 diabetes mellitus: AN; anorexia nervosa:  alloHSCT; Allogeneic  hematopoietic stem-cell transplantation (alloHSCT): BMI; body mass 
index: FF%; fat fraction: ADC; apparent diffusion coefficient: PDFF; Proton density fat fraction: BMA; bone marrow adiposity:L3, L4, L5; lumbar vertebrae:C3; third cervical 
vertebrae: LS; lumbar spine: MRS; magnetic resonance spectroscopy: MRI; magnetic resonance imaging: DWI; Diffusion-weighted magnetic resonance imaging: DXA; Dual-energy x-
ray absorptiometry: QCT; quantitative computed tomography: CBA; cortical bone area: %IBW; ideal body weight: BMD; bone mineral density:VBMD; volumetric bone mineral 
density: TBF; total body fat: WB-FM; whole body fat mass: SAT; subcutaneous adipose tissue: VAT; visceral adipose tissue. 
 
 
 
 
controls 
 
intramyocellular lipids  
and unsaturated muscle lipid 
 
Gao, Y., et al. 2015 
(453) 
185 healthy children (76 
females and 109 males, aged 5-
18 yrs.)  
 
BMA (cm2) of femur  Whole body MRI, 1.5 T Femoral-CBA by whole body 
MRI  
Weight, TBF,SCAT,VAT, 
and skeletal muscle 
Baum, T., et al. 
2015(468) 
28 healthy young subjects 
(26 ± 4 yrs.) 
PDFF of C3-L5. Chemical shift encoding 
 based water-fat MRI, 3T 
 
None  None  
 
Agrawal, K., et al. 
2015(449) 
50 postmenopausal women 
(40-73 yrs.) 
 
FF% and ADC  of  L3  
 
MRS and DWI, 1.5T BMD of L3 by DXA 
 
None  
Mostoufi-Moab, S., 
et al. 2015 (469) 
25 alloHSCT survivors (12-25 
yrs.) compared to 25 age-, 
race-, and sex-matched healthy 
controls. 
 
FF% for the five lumbar vertebrae MRSI, 1.5 T Digital topological parameters 
were acquired at distal tibia by 
using 1.5-T whole-body scanner   
Sex, VAT, SAT, and 
muscle density, WB-FM  
Huovinen, V., et al. 
2015(462),  
18 normal-weight (BMI 
<25kg/m
2
; 2 males, 16 
females) and 17 overweight 
(BMI ≥25kg/m2; 9 males, 8 
females) (15-27 yrs.). 
BMA unsaturation index (UI) of 
the tibia  
MRS, 3 T  None Age, gender, physical 
activity and blood glucose 
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1.6.3.4.3 Abdominal Adiposity 
 
Compared to other methods (470), MRI is currently the gold standard for non-invasive 
direct accurate quantitative measurement of intra-abdominal adipose tissue (470-
475).There are several MRI methods for abdominal fat quantification, T1-weighted 
imaging, magnetic resonance spectroscopy (MRS), and chemical-shift imaging (CSI).  In 
this thesis T1-weighted imaging has been used. 
T1-weighted sequences are very common in clinical MRI. They are available as standard 
software on all commercial MRI scanners (GE, Philips, Siemens, Hitachi, and Toshiba) 
and can be easily applied. It is based on relaxation rates of fat and water proton signals as 
they recover after radio-frequency excitation. T1-weighted MRI is mainly used for white 
adipose tissue (WAT) quantification because fat is characteristically bright in contrast to 
other lean tissues and organs owing to its rapid T1 recovery rate (Figure 1.17)(476, 477). 
Thus bright fat can be easily identified and delineated by simple signal thresholding from 
darker structures. by using partially automated software, the sharp contrast between the 
bright adipose and dark water-containing lean tissues creates the visual basis that enable 
the segmentation of each image, consequently, the distribution of adipose tissue in terms 
of total(TAT),visceral (VAT) and subcutaneous (SAT) were semi-automatically calculated.   
 
Another method for quantifying abdominal fat adiposity is by the use of the Dixon 
technique.  The technique acquires two separate images with two TE settings such that one 
image has the water and fat signals in-phase and the other has the water and fat signals 
180° out-of-phase. Dixon showed that from these two images, a water-only image and a 
fat-only image can be generated. The availability of both the water-only and fat-only 
images allows direct image based water and fat quantitation  (478).   
 
A consistent body of literature suggests that the arrangement of regional fat deposition into 
the subcutaneous and visceral compartments to be a stronger predictor of disease risk than 
overall fat mass (479-482). Therefore, a frequent approach is to only scan the trunk region. 
Methods range from a single slice at a predefined abdominal level to the whole trunk that 
includes intrathoracic, intra-abdominal, and intra-pelvic cavities and associated adipose 
tissues (483). The multislice imaging is generally considered a gold standard reference for 
measuring total and regional adipose tissue volumes (484). However, with the cost 
involved with multislice imaging for volumetric analysis, single-slice images can be used 
as representative measures of VAT (483). One major concern in using single-slice analysis 
for MRI is that soft-tissue structures are continuously moving and may adversely affect the 
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reliability of the visceral fat measurement, as movement of these tissues will change the 
location of VAT in a particular single slice. The commonly used technique to overcome 
this limitation is by using breath holding technique which has been applied in the presented 
thesis. 
 
 
 
 
Figure  1.17: Example of T1-weighted axial magnetic resonance images acquired in abdomen at the 
level of the L3 vertebrae demonstrating the typical high signal intensities of fatty tissues (arrows) in 
contrast to other darker muscles and organs. Data were acquired on a 3 Tesla MRI scanner using T1 
weighted turbo-spin-echo sequence. 
 
The feasibility of MRI in accurate quantification of abdominal adiposity has been shown 
by several studies (473, 485). The differential effect of abdominal adiposity measures 
(VAT, SCAT) on metabolic risk factors is well described, yet it is uncertain whether 
abdominal adiposity measures protects against osteoporosis or adiposity is harmful to bone 
as different adipose tissues express different biochemical factors and in varying 
concentrations (482, 486, 487).  Studies using direct measures of VAT appear to provide 
more consistent finding on the association between VAT and BMD (486, 488-493) than 
those using surrogate measure (360, 494-496). These studies were limited by the use of 
crude measures (e,g. DXA) of abdominal adiposity that are unable to separate VAT from 
other soft tissues; therefore, the contribution of VAT on bone is difficult to define in these 
studies. 
In summary, direct accurate quantitative assessment of abdominal adiposity measures are 
essential to evaluate their influence on bone health. In particular, there is a need to use this 
technique in diabetic patient and this may contribute to a more complete assessment of 
bone health. 
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1.7 The rationale for the present work  
Based on the current fracture risk predictors the explanation for the higher fracture risk in 
patients with T1DM is yet unclear. Although, numerous studies have assessed the bone 
structure and turnover markers in patients with T1DM, these studies have not provided a 
consensus. Detailed trabecular bone microarchitectural assessments are lacking, and it is 
not known whether patients with T1DM have altered bone microarchitecture compared to 
healthy controls without T1DM. Further, considering the possibility that bone deficit  may 
related to adiposity measures (BMA, abdominal adiposity), which may contribute to the 
increased bone fragilty, studies in rodent models of T1DM have suggested that diabetic 
bone  loss is associated with increasing bone marrow adiposity. However, whether bone 
marrow adiposity is different and associated with bone deficit in people with T1DM is not 
known. In addition, how trabecular bone microarchitecture and bone marrow adiposity 
changes over time in patients with T1DM is not known.  Further, as noted earlier in the 
introduction, numerous studies have investigated the possible underlying mechanisms that 
might affecting  the bone health in those group of people, however, these studies have not 
provided a consensus and the results are inconclusive yet.  
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1.9 Key Aims and hypothesis 
Primary hypothesis: 
1. There are differences in the measurements of key bone parameters and bone 
adiposity parameters obtained using micro-MRI images and MRS and biochemical 
markers of bone metabolism and adiposity in patients with T1DM compared to 
healthy women without T1DM. 
2. The expected deficit in bone parameters in patients with T1DM is associated with 
increasing bone marrow adiposity and abnormal levels of biochemical markers of 
bone metabolism and adiposity. 
3. There would be changes in the measures of bone microarchitecture and adiposity in 
women with T1DM compared to women without T1DM.  
Secondary hypothesis:  
1. Different body adiposity measures have different effects on DXA and MRI -
measured bone parameters. 
2. Abdominal adipose tissue is positively correlated with vertebral bone marrow 
adiposity, and negatively with DXA and MRI -measured bone parameters. 
3. The MRI- measured bone parameters demonstrate good correlation with DEXA 
data and are able to differentiate between people with and without T1DM. 
4.  Markers of diabetic control are inversely associated with the bone and adiposity 
measured parameters.  
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Thesis Aims: 
To study the measurements of trabecular bone microarchitecture, bone marrow 
adiposity and abdominal adiposity obtained by MRI, and the biochemical markers of 
bone metabolism and adiposity in group of young women with childhood onset T1DM 
compared to healthy women without T1DM (chapter 3).  
1. To explore the differences in trabecular bone microarchitecture and bone marrow 
adiposity parameters between a group of young adult women with childhood-onset 
T1DM and controls without T1DM.  
2. To examine differences in the biochemical markers of bone metabolism and 
adiposity between women with T1DM and women without T1DM.  
3.  To evaluate whether the bone marrow adiposity, abdominal adiposity and the 
biochemical parameters of bone metabolism and adiposity are associated with bone 
deficit in patients with T1DM.  
4. To evaluate the relationship between the all these measured parameters with 
markers of diabetes control and disease parameters. 
To examine the longitudinal changes in the measurements of bone microarchitecture 
and adiposity parameters in young adult women with childhood onset T1DM 
compared to healthy controls (chapter 4).  
 
1. To compare the prospective changes in trabecular bone microarchitecture and 
adiposity parameters over one year period in the same groups of women who were 
enrolled in the first study.  
2. To evaluate whether there is any association between the changes in trabecular 
bone microarchitecture with vertebral bone marrow adiposity and abdominal 
adiposity in the studied group. 
3. To evaluate whether the expected changes in these measurements are associated 
with the changes of markers of diabetic control. 
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To study the adiposity based determinants of bone density and microarchitecture in 
healthy young women and women with T1DM (chapter 5). 
1. To compare adiposity and bone parameters measured by DXA and MRI in healthy 
young women and women with T1DM, 
2.  To determine the associations between the markers of diabetic controls and disease 
related parameters and these measured outcomes.  
3. To ascertain which adiposity measure (s) is most strongly associated with bone 
measured parameters in healthy young women and women with T1DM.  
4. To compare the feasibility of DXA and MRI measured parameters to differentiate 
between women with and without T1DM.
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Chapter 2 
 
 Methodology 
84 
 
2.1 Introduction 
This chapter provides details of the image acquisition and analysis protocols for the study 
procedures that are presented in this thesis. Further analysis was performed for specific 
investigations, and the details will be provided in the relevant chapters. The procedures 
involved in this study are MRI of the right knee and abdominal adiposity, MRS of L3, a 
DXA scan of the lumbar spine, hip and total body, venous blood sampling and biochemical 
assays.   
2.2 MRI scanning 
All imaging was performed using a 3 Tesla (T) Siemens VerioMRI scanner (Siemens, 
Erlangen, Germany) using a transmit/receive (Tx/Rx) extremity coil for the knee, an 8-
element spine coil for MRS of L3 and surface body coils for the abdominal scanning.  All 
MR imaging was performed during a single scanning session, more details are shown in 
appendix A. 
2.2.1 Proximal Tibia Imaging   
2.2.1.1 Acquisition 
MRI images of the proximal tibia were acquired using an extremity coil positioned over 
the knee. During scanning, the participants were positioned supine with legs extended; 
immobilisation of the leg was achieved by placing additional padding within the extremity 
coil. Following immobilisation, three localiser scans were performed in the sagittal, axial 
and coronal planes to identify the region of interest using a T1-weighted spin-echo 
sequence. Scan locations are shown in (Figure 2.1). The pulse sequence parameters used to 
provide 3D volume of isotropic resolution using a fully balanced steady state free 
precession (bSSFP) pulse sequence is shown in (Table 2.1). Thirty axial Micro-MRI 
images (0.3mm thick) of the metaphysis were collected immediately below the growth 
plate. Analysis was performed using the slice that was located at the insertion point of the 
patellar ligament.  
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Figure  2.1: Representative MR image of the knee. Scan locations are shown, (A) showing the 
placement of the reference line and the region of interest captured in the coronal image, (B) The region 
of interest captured in the saggital image. 
 
Table  2.1: Pulse sequence parameters for tibia imaging 
Parameter Used value  
Resolution  0.3 mm x 0.3 mm 
Slice thickness  0.3 mm 
Repetition time (TR) 10.19 ms 
Echo time  (TE) 4.39 ms 
Flip angle  60° 
Bandwidth 180 Hz/pixel 
Matrix size 384x384 
Field of view  100 mm x 100 mm 
Scan time 10 minutes 
 
2.2.1.2 Image processing and Analysis  
Following scanning, images were coded and analysed using IDL software that was 
developed in-house (Research Systems Inc, Boulder, CO, USA), based on a method that 
was described  by Majumdar et al(402), which give measures for apparent bone volume to 
total volume ratio (appBV/TV), apparent trabecular number (appTbN), apparent trabecular 
thickness (appTbTh) and apparent trabec#ular spacing (appTbSp). The proportion and 
location of magnetic resonance images that need to be processed to yield representative 
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estimates of trabecular bone microarchitecture have been assessed by our group (509), and 
also by Modlesky et al (497). The image processing steps required for quantifying 
trabecular bone microarchitecture parameters are shown in (Figure 2.4). 
2.2.1.2.1 Image processing  
 
A median filter is applied to the MR image to reduce the effects of noise.  A 3x3 filter was 
used as shown in Figure 2.2, which means that the intensity of each pixel from the original 
image is replaced with the median value of the intensities of that pixel plus its eight nearest 
neighbours. An example of the output of a 3x3 filter can be appreciated in figure 2.2. 
 
 
Figure  2.2: Illustrating a median filter applied to MR image, a 3x3 filter was used (A). An example of 
the output of a 3x3 filter (B). 
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2.2.1.2.2 Image analysis  
 
After image filtering, the MR image was analysed to give the measures of bone 
parameters.   
 
Calculate Apparent Trabecular Bone Volume Fraction (appBV/TV) 
Regions of Interest (ROIs) were drawn within the trabecular bone region, in the area which 
is to be analysed, and within the cortical bone. The regions of Interest (ROIs) were defined 
manually using the cortical bone boundary as reference point to ensure that the analysed 
ROI consisted only of the trabecular bone and bone marrow (Figure 2.4). To extend the 
standard stereological techniques and quantify the trabecular bone microarchitecture, the 
images were thresholded and segmented into a trabecular bone and a bone marrow phase. 
The mean signal intensity within the trabecular bone region, IROI, was calculated, and a 
histogram of the distribution of signal intensities in the ROI was plotted. The ROI within 
the trabecular bone region contained both bone and marrow.  If the pixel dimensions were 
less than the trabecular width, then a histogram of the intensities within the ROI would 
show two distinct peaks one for bone and one for marrow.  However, since the pixel 
dimensions were similar to or greater than the trabecular width, a single pixel might 
contain signals from bone and from marrow, and this mixture results in a histogram with a 
single peak (Figure 2.4). By using the cortical bone as standard, the bone intensity Ibone was 
calculated as the mean value within the cortical bone ROI. Estimatation of the marrow-
equivalent intensity was made by finding the maximum value, Nmax, in the histogram, and 
setting a threshold value, Nthresh = 0.5*Nmax.  The marrow-equivalent intensity Imarrow is 
calculated from the upper intensity value at which Nthresh was reached (Figure 2.3). 
 
Figure  2.3: Illustrate estimation of the marrow-equivalent intensity 
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The apparent trabecular bone volume fraction was then calculated to satisfy the following 
equation: 
 
    marrowboneROI ITVappBVITVappBVI /1/   
 
marrowbone
marrowROI
II
II
TVappBV


 /  
 
Equation  2-1 
 
 
 
Binary image   
 
The apparent trabecular bone volume fraction is also defined as “number of bone 
pixels/total number of pixels”.  The total number of pixels in the ROI is known, and so the 
number of bone pixels and marrow pixels corresponding to the calculated value of 
appBV/TV can be calculated: 
totalbone NTVappBVN */  
bonetotalmarrow NNN   
 
Equation  2-2 
 
Bone has a lower intensity than marrow, and hence the pixels which appear in the left hand 
side of the intensity histogram are more likely to contain pure bone, or a large percentage 
of bone.  The intensity value at which the fractional trabecular bone content in the ROI 
corresponded to the calculated app BV/TV was selected as the threshold, and the images 
were binarized into a bone and a marrow phase. Finally, the region of interest (ROI) was 
binarised to produce an image of a pure bone phase and a pure marrow phase (Figure 2.4).  
 
Calculation Mean Intercept Length (MIL) 
 
The MIL at a given angle  was calculated by counting the number of trabeculae-marrow 
boundaries that cross a set of parallel rays oriented at a given angle  through the binarized 
image.  
A grid of parallel lines, each one pixel thick and separated by 10 pixels, is used as a mask, 
so that only the sections of the image which lie along the lines are considered and the rest 
of the image was set to zero.  For each line in turn, a starting value corresponding to the 
value of the first pixel in the line was established.  Each pixel along the line was then 
examined in turn, and the number of times that a change from bone to marrow (1 to 0) or 
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marrow to bone (0 to 1) occurs was counted, and defined as PL ().  The number of pixels 
which correspond to bone, PP was also counted, and the MIL was calculated using:  
 
 

L
P
P
P
MIL  2  
 
Equation  2-3 
 
 
Calculation of Apparent Trabecular Thickness (appTbTh) 
 
The MIL is calculated for all angles between 0
o
 and 360
o
 in steps of 10
o
.  The apparent 
trabecular thickness (in mm) was then calculated using: 
 
      mmsolutionPixelMILmeanmmappTbTh Re**50 360,0   
 
Equation  2-4 
 
Calculation of Apparent Trabecular Number (appTbN) 
 
Apparent trabecular number (in mm
-1
) was calculated using the following equation: 
 
 
appTbTh
TVappBV
mmappTbN
/1   
 
Equation  2-5 
 
Calculation of Apparent Trabecular Spacing (appTbSp) 
 
Apparent trabecular spacing (in mm) was calculated using the following equation: 
 
  appTbTh
appTbN
mmappTbSp 
1
 
 
Equation  2-6 
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Figure  2.4: Representative MR Image through an axial section in the proximal tibia using MRI.  
(A) Micro-MR images. (B) The trabecular bone compartment (ROI), the intensity mean (Ir) over this 
ROI was measured. The histogram for this ROI is also shown. (C) The region of interest (ROI) is 
binarised to produce an image of a pure bone phase and a pure marrow phase. (D) Higher 
magnification view of section within the ROI. 
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2.2.2 MRS  
2.2.2.1 Acquisition 
MRS was performed using an 8-element spine coil, using the method described by 
McComb et al (434).  Images of scan localisation are shown in (Figure 2.5). Spectra were 
obtained using a 20mm x 20mm x 20mm voxel positioned in the lumbar spine within the 
vertebral body of L3. A Point-REsolved Spectroscopy (PRESS) sequence with no water 
suppression was used with a short echo time (TE) to allow detection of lipids. The actual 
parameters of PRESS are shown in (Table 2.2). 
 
 
Figure  2.5: Representative MR image of spine showing the scan localisation at L3 vertebrae.  
Measurements were performed in automatically placed square region of interest (shimming box), yellow 
marked in the sagittal image and green marked in the axial image. 
 
Table  2.2: Pulse sequence (PRESS) parameters for MRS 
Parameters Used value 
TR  2000ms 
TE  30ms  
no. of averages 80 
Scan time  2.48s 
Voxel size  20 mm x 20 mm x 20 mm 
Bandwidth  1200Hz 
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2.2.2.3 Analysis  
MRS analysis was performed using Siemens Spectroscopy analysis software. The resulting 
spectrum shows peaks corresponding to water and fat are shown in (Figure 2.6).  A best-fit 
Gaussian model was applied to the acquired spectrum, and the area under the resulting 
water peak (Iwater) and lipid peak (Ifat) were measured.  The percentage fat fraction (FF) 
was then calculated in the following way.  
 
100
1
% 







LWR
LWR
FF
 
Equation  2-7. LWR; lipid water ratio. 
 
 
 
Figure  2.6: The method of frequency domain fitting using Gaussian line shape. The white line 
illustrates the original spectrum; the red line illustrates the fitting model.  
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2.2.3 Abdominal Fat Imaging  
2.2.3.1 Acquisition 
MRI images for abdominal fat quantification were obtained using the method described by 
Leinhard et al (496). Four element body coils with an 8-element spine coil were used to 
obtain images covering the abdominal region from the diaphragm to the bottom of the 
pelvis. A breath-hold sequence (approximately 17.2 Seconds per acquisition) was used to 
minimize the effects of respiratory motion on the images. To measure the abdominal fat 
contents, a T1 weighted turbo-spin-echo sequence was used to acquire 5 axial slices at the 
level of L3, the pulse sequences parameters are shown in (Table 2.3).  
Table  2.3: Pulse sequence parameters for abdominal imaging 
Parameters  Used value  
Resolution 1.2 mm x 1.1mm 
Slice thickness 4 mm 
Repetition time (TR) 300 ms 
Echo time  (TE) 11ms 
Flip angle 140 
Bandwidth 260 Hz/pixel 
Matrix size 205 x 320 
Field of view  243 x 360 mm 
Scan time 17.2 s 
 
2.2.3.2 Analysis  
The images were analysed with Slice-O-matic™ (version 4.3, Tomovision, Canada) for 
semi-automatic measurement of cross-sectional area (CSA), subcutaneous adipose tissue, 
(SAT), visceral adipose tissue (VAT) and total adipose tissue (TAT). The Morpho 
Mathematical TAG mode (Mosaic tagging) (Figure 2.7) has been used to create the TAG 
data. The main advantage of this technique is useful for segmenting tissue images that have 
a big enough surfaces and a well-defined image intensity gradient (e.g., abdominal adipose 
tissue). Five MR images at the level of L3 were opened in the software, the third central 
one was selected to be analysed for all participant.  
94 
 
 
Figure  2.7:  Representative MR Image through axial slice of abdomen at L3 vertebrae showing 
example of Slice-O-matic segmentation to delineate the subcutaneous (Green) and visceral (Blue) 
adipose tissue depots. 
(A) Illustrating mosaic segmentation coarse scale setting for SCAT ;(B) mosaic segmentation fine scale 
setting for VAT; (C,D) coloured tagged image with morpho lines (C) and without morpho lines (D). 
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2.4 Dual-Energy X-ray Absorptiometry (DXA) 
2.4.1 Principal of DXA  
DXA scanning (Lunar Prodigy, GE Medical Systems, Waukesha, Wisconsin, USA) was 
performed to evaluate the bone and body composition parameters. DXA scanners comprise 
of mobile X-ray source, a couch for the patient, and a detection system that detects 
radiation emerging from the bones being examined. On a DXA device, the X-ray source is 
under the couch and moves together with the detection system, which is located opposite 
the X-ray source and over the patient’s body (379). Principally, DXA is based on the 
difference in the attenuation properties of dual x-ray beams (high energy and low energy 
beam) when they pass through soft tissue and bone. As the dual beam passes through the 
body, the low-energy beam is attenuated more than the high-energy beam in both soft 
tissue and bone, but the difference is much greater in bone. With the use of a particular 
computing algorithm, the attenuation values of soft tissues are subtracted, leaving only the 
attenuation values of bone. By internal phantom calibration the bone attenuation can then 
be converted to gives the measures of bone mineral density(498). The resulting 
measurements provide estimates of bone mineral content (BMC, measured in grams), bone 
mineral density (BMD, measured in g/cm
2
), and bone area (BA, measured in cm
2
). Bone 
area is the projected area in the coronal plane of the region scanned. The computer 
software calculates the bone mineral density(BMD, gm
2
) by dividing BMC by the bone 
area, since BMD is determined using an area rather than a volume, it is referred to as areal 
BMD (aBMD) to emphasize that it is not a true volumetric density. Additionally, the dual 
beam allows for the delineation of soft tissue versus bone, thus in addition to measurement 
of BMD, DXA can assess body composition (fat mass, lean body mass, and percent body 
fat), on both total body (TB) and regional basis(379). The DXA also provide two standard 
deviations (SD) of BMD, which are described as T score and Z score. The T-score is a 
universally acceptable measure for diagnosis of osteoporosis; it compares the patients 
BMD to the optimal peak bone density for the same gender. It is restricted in adult age 
over 50 and not applicable for children and young people. On other hand, the Z score is 
applicable for children, premenopausal women and men younger than 50 yrs. A z score is 
also SD score of BMD based on same age and sex, height and weight. Its measurement of -
2.0 or lower is indicative of significantly decreased bone density for chronological 
age(499). 
DXA can measure effectively any skeletal site, but its clinical use has been commonly 
concentrated on the lumbar spine, hip (femoral neck and total hip), forearm, and total body. 
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Mistakes in BMD measurement by DXA have been reported, and most of these pitfalls 
related to the scanner and its software, the positioning of patient and analysis of scans, and 
various patient-related artefacts (498, 500). A well-trained and experienced DXA 
technologist is required to avoid most of the errors in acquisition and analysis. Importantly, 
it is crucial to evaluate precisely patient position and region of interest (ROI) in each 
measurement before the scanning(501). 
2.4.2 Outcomes of DXA 
After proper positioning of the participants, DXA of the whole body, femoral neck and 
lumbar spine (L1-L4) was performed to determine the main study outcomes. The DXA 
scan took approximately 10-15 min to complete, and all of these scans were acquired by Dr 
Sheila Shepherd at RHC, Glasgow. The bone area (cm
2
), BMC (g), mean areal BMD 
(g/cm
2
 ) and BMD-z score of whole body, femoral neck (FN) and lumbar spine were 
measured. To minimise the size-related effects of DXA a BMD measurements, BMAD at 
lumbar spine was calculated by estimating the vertebral depth as the square root of the area 
measured by DXA (Bone area). Then, the vertebral volume is calculated by simply 
multiplying the height x width(BA) x depth (502). Body composition, including whole 
body- fat mass WB-FM (kg), WB-FM Z score and android/gynoid (kg) were obtained from 
the whole body DXA scan.   
2.5 Blood analysis 
Non-fasting blood samples were collected, centrifuged, and the supernatant stored at 
 -80°C. Sample collection was standardized with collection performed in the afternoon to 
coincide with the clinic visit. Plasma total osteocalcin (OC) and serum bone-specific 
alkaline phosphatase (BAP) were analyzed by ELISA to assess bone formation 
(Immunodiagnostic Systems, Boldon, UK). Plasma undercarboxylated osteocalcin (uOC) 
was used to assess the inactive form of osteocalcin (Cusabio Life Science, Wuhan, PR 
China) and plasma C terminal telopeptide of type I collagen (CTX) was measured by 
ELISA to assess bone resorption (Immunodiagnostic Systems). The intra-assay variation 
for OC, uOC, BAP, and CTX was 5.3%, 13.2%, 0.8%, and 3.8%, respectively. Plasma 
leptin, preadipocyte factor-1, pentosidine, IGF-I and its binding proteins, IGFBP3, and the 
acid labile subunit (ALS) were also determined using ELISA (Mediagnost GmbH, 
Reutlingen, Germany). Intra-assay variabilities were 6.1%, 0.6%, 4.1%, 0.6%, 4.1%, and 
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3.4%, respectively. 25-Hydroxy vitamin D (25OHD) concentration was measured by a 
radioimmunoassay (Immunodiagnostic Systems). 
 
2.6 Statistical Analysis 
Statistical analyses were performed using Minitab 17 (Minitab Inc, PA, and USA) and 
SPSS 19 (IBM, New York, USA). Before performing any analysis, the data were checked 
for normality using an Anderson- Darling test. More information about the statistical tests 
used for data analysis is discussed in the relevant chapters. 
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Chapter 3 
 
 
 
 
 Deficits in Trabecular Bone Microarchitecture in 
Young Women With Type 1 Diabetes Mellitus 
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3.1 Abstract 
Background: The pathophysiological mechanism of increased fractures in young adults 
with type 1 diabetes mellitus (T1DM) is unclear.  
Aim:  We conducted a case-control study of trabecular bone microarchitecture and 
vertebral marrow adiposity in young women with T1DM.  
Subjects and methods: Thirty women with T1DM with a median age (range) age of 22.0 
years (16.9, 36.1) attending one outpatient clinic with a median age at diagnosis of 9.7 
years (0.46, 14.8) were compared with 28 age-matched healthy women who acted as 
controls. Measurements included MRI-based assessment of proximal tibial bone 
volume/total volume (appBV/TV), trabecular separation (appTb.Sp), vertebral bone 
marrow adiposity (BMA), and abdominal adipose tissue and biochemical markers of 
GH/IGF-1 axis (IGF-1, IGFBP3, ALS) and bone turnover.  
Results: Median appBV/TV in cases and controls was 0.3 (0.22, 0.37) and 0.33 (0.26, 0.4), 
respectively (p= 0.018) and median appTb.Sp in T1DM was 2.59 (2.24, 3.38) and 2.32 
(2.03, 2.97), respectively (p= 0.012). The median appBV/TV was 0.28 (0.22, 0.33) in those 
cases with retinopathy (n=15) compared with 0.33 (0.25, 0.37) in those without retinopathy 
(p=0.02). Although median visceral adipose tissue in cases was higher than in controls at 
5733 mm3 (2030, 11,144) and 3460 mm3 (1808, 6832), respectively (p= 0.012), there was 
no difference in median BMA, which was 31.1% (9.9, 59.9) and 26.3% (8.5, 49.8) in cases 
and controls, respectively (p=0.2). Serum IGF-1 and ALS were also lower in cases, and the 
latter showed an inverse association to appTbSp (r =–0.30, p = 0.04). 
Conclusion: Detailed MRI studies in young women with childhood-onset T1DM have 
shown clear deficits in trabecular microarchitecture of the tibia. Underlying 
pathophysiological mechanisms may include a microvasculopathy. 
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3.2 Introduction 
The risk of hip fractures in those with type 1 diabetes mellitus (T1DM) is reported to be 7 
to 12 times greater (336, 340) and this increased risk is also evident in young adults (221). 
The process of differentiation of mesenchymal stem cells into either adipocytes or 
osteoblasts is regulated by a number of growth factors including insulin, oxygen tension, 
and blood flow within the bone marrow (503, 504). T1DM is also associated with 
abnormalities of the growth hormone (GH)/insulin-like growth factor type 1 (IGF-1) axis 
with biochemical evidence of GH resistance (505). Growth hormone (GH) and IGF-1 also 
are important regulators of bone homeostasis and important for the maintenance of bone 
mass (506)and may also influence body composition and bone marrow adiposity(491). 
Mouse models of T1DM exhibit increased bone marrow adiposity (BMA), increased 
adipocyte markers, and increased numbers of lipid-dense adipocytes in the bone marrow 
(507).Childhood and adolescence are critical periods for skeletal development(508), and it 
is possible that those affected by T1DM at these ages may be especially susceptible. On 
dual-energy X-ray absorptiometry (DXA), adults with T1DM do show a reduction in bone 
mineral density (BMD) Z-score, reported in a meta-analysis at –0.22 at the lumbar spine 
and –0.37 at the hip,(11) but their fracture risk is much higher(161, 221, 336, 340) than 
expected for this modest reduction in BMD. Recent advances in magnetic resonance (MR) 
imaging have led to the generation of high-resolution 3D images of bone structure that 
correlate with other techniques such as computed tomography (440, 509).In addition, MR 
can quantify the amount of intra-abdominal fat, and MR spectroscopy can also estimate the 
fat that is present within the bone marrow (457).There is, therefore, the potential to 
combine these MR-based techniques to obtain objective data on bone microarchitecture 
and fat content and study these in a condition such as T1DM.  
With the increased reports of an association between marrow adiposity and bone 
health(510), the current study was designed to improve the understanding of the bone 
pathology in adults with childhood-onset T1DM by using high-resolution MRI and 
biochemical markers of GH action and bone turnover. To reduce the confounding effect of 
sex hormones, this study targeted young women with T1DM and compared them with a 
group of age-matched healthy women. 
 
 
101 
 
3.3 Material and method  
3.3.1 Subjects  
Figure 3.1 shows the pathway outlining participant recruitment and enrolment in this study. 
Between July 2012 and July 2013, 61 eligible women between the ages of 20 and 30 years 
and who were diagnosed before the age of 16 years were approached at one hospital clinic. 
From this group, 30 volunteered to participate. In addition, 28 age matched healthy control 
women working at the local university and hospital were also recruited. Exclusion criteria 
included the presence of metallic implants and pacemakers, active or planned pregnancy or 
lactation, kidney disease, chronic use of drugs that are known to affect bone health, and 
other chronic diseases that are known to be associated with an increased risk of fractures. 
Information on personal health and lifestyle habits, including cigarette smoking, alcohol 
consumption, current medication, use of vitamins or calcium, age at menarche, use of oral 
contraceptives, hours of weight-bearing physical activity per week, history of fractures, 
and a family history of early osteoporosis was also collected. Information on age at 
diagnosis, disease duration, insulin therapy, and presence of microvascular complications 
was obtained from the case records. A glycosylated hemoglobin (HbA1c) measurement 
within a 2-week period of the scan visit was used as current HbA1c. The study protocol 
was approved by the national research ethics service, and all participants provided written 
informed consent. 
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Figure  3.1: Pathway outlining participant recruitment and enrolment in the study. 
 
3.3.2  Biochemical markers of bone metabolism, adiposity, and GH/IGF-
1 axis  
In 25 cases and 24 control participants, non-fasting blood samples were collected and 
analysed as described in chapter 2. We measured bone formation markers (plasma total 
osteocalcin (OC), serum bone-specific alkaline phosphatase (BAP), plasma 
undercarboxylated osteocalcin (uOC)), bone resorption marker (plasma C terminal 
telopeptide of type I collagen (CTX)), adiposity markers (Plasma leptin, Preadipocyte 
factor-1 ), growth hormone axis (IGF-I, IGF-BP3, the acid labile subunit (ALS)), 
pentosidine, and other regulator markers of bone turnover (PTH, 25-Hydroxy vitamin D 
(25OHD).  
 
3.3.3 Micro-MRI  
30 slice images were acquired and analysed as described in Chapter 2. In 29 of 30 cases 
and in 27 of 28 control participants, the images were of a sufficiently good quality to be 
analysed. The analysis for each subject was repeated four times and averaged. Phantom 
validation of the used software has been performed previously by our diabetic endocrine 
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research group (DERG) (434).  In addition, an assessment of repeatability was performed 
by two operators who independently analysed ten volunteer datasets four times each. Intra-
operator repeatability was evaluated using coefficients of variation (CoV), and inter-
operator repeatability was evaluated using Levene’s test to compare the equality of 
variance between the results obtained by the two operators, and a Mann-Whitney test to 
compare the obtained values for each parameter. Five of the volunteers were scanned on 
two separate occasions, and the results were compared using a paired t-test.   
 
3.3.4  MRS 
MRS data were available in all 30 cases and 28 controls.   Image acquisition and analysed 
are as described in chapter 2. Analysis was performed following fitting of the spectrum in 
the time domain using a nonlinear least-squares algorithm, AMARES (511),in the Java-
based magnetic resonance user interface (jMRUI) software package (512). As for the 
micro-MRI data, an assessment of intra and inter- operator repeatability was performed by 
two operators who independently analysed ten datasets four times each. Five volunteers 
were also scanned on two separate occasions to assess the inter-scan repeatability. 
 
3.3.5 MRI of abdominal fat  
Of the participants who had MRS scans, in 24 cases and 19 controls, approval was also 
obtained to assess abdominal fat during the same scanning session. Five axial images at L3 
level were acquired and analysed as described in chapter 2.  
 
3.3.6  Calculation of sample size and statistical analysis 
The primary hypothesis in the study was that cases with T1DM would have a lower 
appBV/TV and appTbN and a higher appTbSp compared with controls. Based on recent 
studies from our group (434) the estimated coefficient of variation (CV) of the microMRI 
measurements was less than 5%. To show a 10% difference between cases and controls 
with a significant difference at p < 0.05 with a power of 0.8, at least 16 cases and 16 
controls were required for the above micro-MRI parameters. Data analysis was performed 
using Minitab 17 (Minitab Inc, PA, and USA). All data were described as medians and 
ranges; comparison between the cases and controls was performed, initially by the Mann-
Whitney U test for continuous variables and by the chi-square test for categorical variables 
and then subsequently adjusted for multiple comparisons using false discovery rates (FDR) 
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(513). Univariate analysis between continuous variables was performed using the Pearson 
correlation coefficient. 
 
3.4 Results  
3.4.1 Clinical characteristics 
 There were no significant demographic or anthropometric differences between the cases 
and controls (Table 3.1). Notably, the median body mass index (BMI) in the cases and 
controls was 24.8 kg/m2 (18.2, 31.2) and 22.9 kg/m2 (18.3, 33.9), respectively (p=0.1) 
with similar amounts of physical activity reported in the cases and controls. Of the 30 cases 
and 28 controls, 9 (30%) and 3 (11%) reported a history of traumatic fractures (p= 0.07). In 
2 cases, the fractures had occurred before the onset of diabetes, and in the other 7 cases, the 
duration of diabetes at the time of the fracture ranged between 2.5 years and 16 years. The 
median duration of T1DM was 12.8 years (7.9, 34.2) with a median age at diagnosis of 9.9 
years (0.5, 15.0). Of the 30 cases, 7 were on twice daily insulin injections, 6 were on three-
daily injections, and 17 were on four-daily injections. The median total daily insulin dose 
for body weight was 0.94 IU/kg/d (0.43, 1.52) and the median current HbA1C was 9.8% 
(5, 16), equivalent to 84 mmol/mol (31, 151). Of the 30 cases, 15 (50%) had retinopathy of 
which 12 had background retinopathy alone, 2 (7%) were being treated for hypertension, 1 
(3%) had neuropathy and gastroparesis, and none had microalbuminuria. One of the cases 
had stable Crohn’s disease requiring sulfasalazine therapy only for 2 years before the study 
and 2 cases were on a stable dose of thyroxine for acquired hypothyroidism, one of 3 
years’ duration and another of 5 years’ duration. 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
 
Table  3.1: Clinical and biochemical details of study participants. 
 T1DM Controls   
N 30 28 p 
Age (yrs)                                                                                                                       
BMI                                                                 
Cigarette smoker (n) 
Regular alcohol consumption (n) 
Ca,VitD,Multivit supplements (n) 
Age at menarche (yrs) 
Previous pregnancy (n) 
Oral contraceptive use (n) 
Physical activity (hrs/wk) 
22.0 (16.9, 36.1)
24.8 (18.2, 31.2) 
4 
25 
4 
12 (10, 17.5) 
3 
21 
4 (0, 10) 
21.8 (18.6, 37.5) 
22.9 (18.3, 33.9) 
0 
27 
                6 
13 (11, 15) 
1 
22 
4 (0, 10) 
0.7 
0.1 
0.05 
 
0.9 
 
0.8 
 
0.6 
 
0.3 
 
0.9 
 
0.9 
PTH (pmol/l) 3.4 (1.1,9) 4.2 (1.4,12.5) 0.3 
25OH D (nmol/l) 33 (19, 65) 45.5 (25, 84) 0.02 
Osteocalcin (µg/l) 
uOC (ng/mL)  
13.4 (3.6, 20.8) 
1.8 (0.5, 13.9) 
14.3 (6.6, 40.5) 
3.3 (0.5, 25.3)  
0.2 
0.18 
Bone ALP (U/l) 16.2 (10.5, 44.3) 17.2 (4.6, 28.8) 0.9 
CTX (µg/l) 0.15 (0.03, 0.39) 0.20 (0.05, 0.49) 0.04 
IGF-1 (µg/l) 135.2  (66.5, 83.1) 182.4 (83.1, 293.4) 0.002 
IGFBP-3 (µg/l)  2208 (1794, 3677) 2347 (1991, 3538) 0.17 
ALS (mU/ml) 2064 (1005, 3009) 2549 (1929, 3682) <0.0001 
Leptin (µg/l) 12.4 (1.3, 105) 14.3 (2.6, 43.3) 0.96 
Pref-1 (ng/ml) 0.19655(0.1105,0.3459) 0.22091(0.1128,0.3517) 0.3 
Pentosidine (pmol/ml) 1007 (177, 2998) 829 (108,5923) 0.5 
All continuous variables are described as median and range. PTH, Parathyroid hormone; OC, osteocalcin; 
25OHD, 25-hydroxyvitamin D; ALP, Alkaline phosphatase; CTX, crosslinked C-terminal telopeptides of 
type I collagen; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3; 
ALS, acid labile subunit; Pref-1, preadipocyte factor 1. Significance is assigned at p<0.05. 
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3.4.2 Biochemical markers of bone metabolism, adiposity, and GH/IGF-1 
axis  
Amongst the markers of bone metabolism, plasma 25OHD and CTX were significantly 
lower in cases compared with controls (Table 3.1). However, serum parathyroid hormone 
(PTH) and markers of bone formation were similar in both groups (Table 3.1). Amongst 
the markers of the GH/IGF-1 axis, plasma IGF-1 and ALS were significantly lower in the 
cases compared with controls, whereas IGFBP3 was similar in both groups (Table 3.1) 
(Figure 3.2). Serum pentosidine (1007 pmol/ml vs. 829 pmol/ml) was not different 
between both groups. Plasma leptin and Pref-1 were similar in the two groups and, as 
expected, Leptin showed a positive association with BMI (r=0.33; p= 0.02). There was no 
association between age of diagnosis disease duration, HbA1c and the presence of 
retinopathy with the markers of bone metabolism, GH/IGF-1 axis, adiposity markers, or 
pentosidine.  
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Figure  3.2:  Box plot of serum CTX, IGF-1 and ALS in women with T1DM (Green box) and controls 
(Blue box).  
CTX, crosslinked C-terminal telopeptides of type I collagen; IGF-1, insulin-like growth factor 1; ALS, acid 
labile subunit. The figure depicts the median and range for each plot, and p-value has been added.  
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3.4.3 MRI of abdominal fat  
Despite no significant differences in the BMI and plasma leptin between cases and 
controls, abdominal adiposity including CSA, VAT, and TAT was significantly higher in 
cases compared with controls (Table 3.2) (Figure 3.3). However, SCAT was less markedly 
higher in cases, and the difference did not reach statistical significance. Serum leptin and 
pref-1 did not show an association with any of the MRI based markers of abdominal 
obesity. In addition, there was no association between adiposity with markers of control, 
markers of bone metabolism, GH/IGF-1 axis, leptin or pentosidine. 
Table  3.2: MRI-based measures of abdominal adiposity, bone microarchitecture and vertebral bone 
marrow adiposity at L3 
All data are described as median and range. CSA- cross-sectional area of adipose tissue; SCAT – 
subcutaneous adipose tissue; VAT- visceral adipose tissue; TAT – total adipose tissue; AppBV/TV – 
apparent bone volume/total volume; AppTb.N – apparent trabecular number; AppTbSp – apparent trabecular 
separation; AppTbTh – apparent trabecular thickness. P-values have been adjusted for multiple comparisons 
using False Discovery Rates; significance has been assigned at adjusted p<0.05. 
 
 
 
 
 T1DM Controls P* 
 
N 30 
 
28  
CSA (mm
2
)  47,878 
(30,134, 78,651) 
 
39,918 
(30,232, 69,789) 
0.03 
SCAT (mm
3
) 21,583 
(3,719, 42877) 
 
15,582 
(7,454, 40,807) 
0.068 
VAT (mm
3
) 5,733 
(2,030, 11,144) 
 
3,460 
(1,808, 6,832) 
0.012 
TAT (mm
3
) 27,230 
(6,584, 54,021) 
 
19,130 
(10,046, 47,639) 
0.03 
AppBV/TV 0.3 
(0.22, 0.37) 
0.33 
(0.26, 0.4) 
0.018 
    
AppTb.N(mm-1)  0.26 
(0.2, 0.3) 
 
0.29 
(0.23, 0.3) 
0.012 
AppTb.Sp(mm)  2.59 
(2.24, 3.38) 
 
2.32 
(2.03, 2.97) 
0.012 
AppTbTh(mm)  1.14 
(0.86, 1.49) 
1.15 
(0.96, 1.39) 
 
0.3 
L3 fat fraction (%)  25.4 
(9.9, 72.8) 
 
19.7 
(8.5, 41.9) 
0.2 
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Figure  3.3:  Box plot of MRI-measured abdominal adiposity parameters in women with T1DM (Green 
box) and controls (Blue box). 
CSA- cross-sectional area of adipose tissue; SCAT,  subcutaneous adipose tissue; VAT, visceral adipose 
tissue; TAT, total adipose tissue.  
 
3.4.4 Bone microarchitecture by micro-MRI 
Intra-operator repeatability was high, with an average CoV of 2.79 % for appBV/TV, 2.81 
% for appTbTh, 1.36% for appTbN and 1.76% for appTbSp. Inter-operator repeatability 
was also high, with no statistically significant differences observed in the variance of the 
results obtained by the two operators, with the average CoV of 3.32 %  for appBV/TV, 
3.75 % for appTbTh, 2.02 % for appTbN and 2.58 % for appTbSp . Inter-scan repeatability 
for the same patient was also high with an average CoV of 3.4% for appBV/TV, 2.3% for 
appTbTh, 1.5% for appTbN and 2.8% for appTbSp. Comparison of bone microarchitecture 
variables revealed that appBV/TV and appTbN were significantly lower and appTbSp 
significantly higher in cases compared with controls (Table 3.2) (Figure 3.4). AppBV/TV 
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and appTbN did not show any association with any biochemical markers or MRI-based 
markers of abdominal obesity. However, appTbSp showed a significant inverse association 
to serum ALS (r= –0.30, p= 0.04) and OC (r =0.38, p=0.009) (Figure 3.5). This inverse 
association was not observed between appTbSp and uOC. An inverse association was also 
suggested between appTbSp and serum IGF-1, but this did not reach statistical significance 
(r= –0.27, p=0.06).  In the T1DM cases, there was no association of appBV/TV, appTbN, 
or app TbSp with HbA1cor daily insulin dose corrected for weight.  However, there was a 
clear difference in median appBV/TV between those cases who had retinopathy and those 
who did not have retinopathy. The median appBV/TV was 0.285 (0.22, 0.33) in those 
cases with retinopathy compared with 0.33 (0.25, 0.37) in those cases without retinopathy 
(p= 0.02) (Figure 3.6). The HbA1c was 9.5% (5, 16) and 9.2% (5.5, 13) in the cases with 
and without retinopathy (NS). Additionally, appBV/TV and appTbSp showed significant 
correlation with age of the patients and disease duration (p<0.05) (Figure 3.7).  
Furthermore, when we stratified the cases into groups based on age of diagnosis <5yrs. of 
age, 5-10 yrs. of age and >10 yrs. of age, T1DM women diagnosed ≤ 5 yrs (n=5) of age 
have trend toward lower appBV/TV than those with later age of diagnosis (0.29, 0.33, 
0.30), respectively (p=0.08) (Figure 3.8).  When appBV/TV and appTbSp were entered as 
a dependent variable and age, disease duration, age of diagnosis, HBA1c, BMI and related 
microvascular complications (retinopathy) as independent variables in regression model, 
these  correlations became insignificant. However, retinopathy was the only significant 
predictor of reduced bone volume (r
2
=44.77%, p=0.04).  
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Figure  3.4:  Boxplot of MRI-measured trabecular bone parameters in women with T1DM (Green box) 
and controls (Blue box).  
AppBV/TV, apparent bone volume/total volume; AppTb.N, apparent trabecular number; AppTbSp, apparent 
trabecular separation; AppTbTh, apparent trabecular thickness 
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Figure   3.5: The relationship between apparent trabecular separation (appTbSp) as assessed by MRI 
and serum acid labile subunit (ALS) (A) and serum osteocalcin (OC) (B) in women with T1DM (filled 
circles) and controls (open circles).  
A Gaussian ellipse of the data has been added to each plot, together with the correlation (r) and its p value 
(p). An inverse association between appTbSp and ALS and OC was observed. 
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Figure  3.6:  Apparent bone volume/total volume (appBV/TV) in women with T1DM with and without 
retinopathy and compared with control women  
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Figure  3.7: Unadjusted correlation of apparent trabecular separation (appTbSp) and appBV/TV with 
disease duration (A, B, respectively) and age of the patients (C, D, respectively) in women with T1DM.  
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Figure  3.8: App BV/TV in relation to age of diagnosis. T1DM women with earlier age of diagnosis 
showed trend towered lower bone volume compared with women with later age of diagnosis (p=0.08). 
 
3.4.5 Bone marrow adiposity  
Intra-operator repeatability was high, with an average CoV of 2.5%. Inter-operator 
repeatability was also found to be high, with no statistically significant differences 
observed in the variance of the results obtained by the two operators. Additionally, No 
statistically significant inter-scan differences were observed. Median vertebral BMA, 
expressed as percentage fat fraction (%FF), was higher in cases than controls, but this did 
not reach statistical significant difference (Table 3.2).Vertebral BMA did not show 
association with biochemical markers of bone turnover, leptin, pref-1 or pentosidine. 
However, there was trend toward an inverse association of FF% with (OC) (r=-0.20, 
p=0.2) and ALS (r=-0.25, p=0.08) (Figure 3.9). Vertebral BMA showed significant a 
positive independent association with VAT (r =0.34, p =0.03) (Figure 3.10), which, as 
stated earlier, was higher in cases compared with controls. There was no association 
between vertebral BMA and MRI measured trabecular bone parameters. Median BMA was 
30.5% (9.9, 59.9) in those cases with retinopathy compared with 31.6% (11.3, 50.1) in 
those cases without retinopathy (p = 0.97). In T1DM, vertebral BMA showed significant 
positive association with mean current HBA1c (r=0.45, P=0.02) (Figure 3.11). 
Additionally, in the T1DM group, with HbA1c of >7% (n=20) showed significantly higher 
median vertebral BMA than diabetic subjects with HbA1c levels ≤ 7% (n=7) (p=0.02) 
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(Figure 3.12). On the other hand, in T1DM, vertebral BMA did not show association with 
age of diagnosis or disease duration. 
 
 
 
 
 
 
Figure  3.9 The relationship between vertebral bone marrow adiposity  (FF%) as assessed by MRS and 
cross sectional area (CSA) (A),  subcutaneous adipose tissue  (SCAT) (B), visceral adipose tissue  
(VAT) (C) and total adipose tissue (TAT) (D) in women with T1DM (filled circles) and controls (open 
circles).  
Positive significant association between FF% and VAT was observed. 
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Figure  3.10: The relationship between vertebral bone marrow adiposiy (FF%) as assessed by MRS and 
serum acid labile subunit (ALS) (A) and  serum osteocalcin (OC) (B) in women with T1DM (filled 
circles) and controls (open circles).  
A Gaussian ellipse of the data has been added to each plot, together with the correlation (r) and its p value 
(p). Trend toward an inverse association between FF% and ALS and OC was observed. 
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Figure  3.11: The relationship between vertebral BMA (FF %) and current HBA1c. Positive significant 
association was observed.  
 
 
 
Figure  3.12 VBMA in relation to current HBA1c of >7% or ≤7%  
Diabetic subjects with HbA1c levels >7% (n= 20) showed significantly (P < 0.02) higher mean vertebral 
bone marrow fat content than diabetic subjects with HbA1c levels≤7% (n =7). The boxplot represents median 
of the vertebral bone marrow adiposity. 
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3.5 Discussion  
The current study was primarily aimed at using MRI to compare the trabecular 
microarchitecture in young women with childhood-onset T1DM with that in healthy age-
matched women. This is the first published clinical study to clearly show that this is altered 
in the former with reduced bone volume and trabecular number and increased trabecular 
separation. In addition, the study has also provided some insights into the underlying 
mechanisms that may lead to abnormality of skeletal development in adults with T1DM. 
In keeping with other reports of a higher prevalence of vitamin D deficiency in young 
people with T1DM, the women who participated in this study had lower vitamin D levels 
than the control group (514, 515). However, these levels were not particularly low and 
were not associated with a raised PTH or any other marker of bone formation or bone 
microarchitecture, and it is, therefore, unclear whether the lower vitamin D levels had a 
particularly marked contributory role. It is also unlikely that the women with T1DM had 
any other underlying genetic bone disorder because none had been revealed on history and 
examination. The reported rate of fractures in these cases seemed higher but not 
significantly different from controls and within the expected frequency for self-reported 
fractures in healthy women(516). 
The findings in the current study suggest that the deficits in bone microarchitecture that 
were encountered in T1DM may have a multifactorial etiology. First, the negative 
association between total osteocalcin, a marker of bone formation, and trabecular 
separation in the study participants suggests that the osteopathy in T1DM may be linked to 
reduced bone formation rather than increased bone resorption. This was further reinforced 
by the lower levels of CTX, a marker of bone resorption, in the T1DM cases. This state of 
low bone turnover with reduced bone formation in T1DM has been reported previously 
(369, 517) and has been known to be associated with GH deficiency (518). To facilitate 
recruitment, the current study did not stipulate fasting blood samples. Markers of bone 
turnover and especially markers of bone resorption, such as CTX, show a diurnal variation 
and may be affected by fasting status (519) and future studies would benefit from 
standardization of sample collection.  
The women with T1DM also had lower levels of circulating IGF-1 and ALS and the 
negative association of trabecular separation with ALS raises the possibility that the 
GH/IGF-1 axis and, in particular, reduced GH activity may contribute to the altered bone 
microarchitecture. GH and IGF-1 are important regulators of bone homeostasis and 
important for the maintenance of bone mass (506). GH stimulates osteoblastic proliferation 
through stimulation of circulating and local IGF-1 and it inhibits adipogenesis (520). In 
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humans, systemic availability of active IGF-1is modulated through its binding to proteins 
such as IGFBP-3 and ALS(521), which, along with IGF-1, are primarily synthesized in the 
liver under the stimulation of GH(522) .Insulin deficiency is reported to be associated with 
a state of GH resistance (523), an abnormality of posttranslational synthesis of ALS and 
ALS deficiency(524, 525), and with lower levels of ALS, circulating IGF-1 falls as a result 
of increased renal clearance. Because the insulin deficiency in the portal circulation exists 
despite insulin replacement in T1DM (526), it is likely that this state of GH resistance is 
not alleviated during treatment in T1DM, and the abnormal bone findings in this study may 
be a consequence of a persistent state of IGF-1 and ALS deficiency. The finding in the 
current study of an inverse association between trabecular separation and serum 
osteocalcin and ALS reinforces this view.  
The other possible reason for the abnormality in bone microarchitecture in T1DM may be 
related to microvasculopathy. In our study, retinopathy was independent negative predictor 
of bone deficit irrespective of other diseases related factors. The clear association of 
reduced bone volume in those cases of T1DM who had retinopathy, albeit background 
retinopathy in most cases, suggests that it is possible that the underlying pathophysiology 
of retinopathy may also influence trabecular development. The pathology of diabetic 
retinopathy evolves in an environment of increased formation of reactive oxygen species, 
leukostasis, and breakdown of the blood-retinal barrier that is followed by formation of 
acellular capillaries and development of micro aneurysms (527). The superoxide-
generating family of NADPH oxidase enzymes has not only been strongly implicated in 
the vascular complications of diabetes but also superoxide radicals may be associated with 
abnormalities of bone turnover (528, 529).The possibility of a microvasculopathy that 
affects bone in T1DM has not been studied widely and requires further exploration.  
The women with T1DM in this study did not have a significantly higher BMI compared 
with controls, but they had markedly higher visceral adiposity and it is possible that this 
abnormality is also associated with functional GH deficiency (530). Although bone 
marrow adiposity was similar in the cases and controls, the cases did have increased 
trabecular spacing, which showed an inverse relationship to circulating ALS and 
osteocalcin. Increased trabecular spacing is not universally associated with increased bone 
marrow adiposity (510). Although this association may be encountered in GH deficiency 
(434, 531), in other conditions such as osteogenesis imperfecta, the two parameters do not 
show an association (434). It is also possible that in states of GH resistance such as T1DM, 
bone marrow adiposity may be increased. This hypothesis reinforced by the observed 
significant positive association of BMA with VAT in our study participants. Additionally, 
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the observed positive association between BMA and HBA1C level supporting the role of 
IGF-1 as regulator of adipogenic differentiation under hypoinsulinemic conditions 
(204).The current study was not powered to detect significant differences in bone marrow 
adiposity between the cases and controls, and it is possible that with a larger sample size 
this would also have been detected. The finding of an abnormality of bone 
microarchitecture and bone marrow adiposity would be consistent with a defect in bone 
marrow mesenchymal stem cell differentiation, which leads to a net reduction in bone 
formation in favour of adipogenesis(206) and, as previously described in streptozocin-
induced T1DM mice(249) , conditions that are associated with relative IGF-1 deficiency 
(491, 532)  
The women with T1DM in this current group had a relatively high HbA1c and as expected 
for a population sample from an inner-city area in the west of Scotland (533). A 
relationship between HbA1c, pentosidine (AGEs markers) and trabecular bone parameters 
was not observed in the current study, and perhaps this investigation would have been 
facilitated if there was a wider range of HbA1c with large sample size. On the other hand, 
we observed positive significant correlation between BMA and HBA1c level (r =0.437; P 
< 0.02) suggesting an effect of T1DM on the vertebral BMA. This became also apparent 
when the diabetic subjects were classified based on HbA1c levels and significantly higher 
vertebral BMA was found in subjects with HbA1c levels >7% (p=0.02). More details about 
the association of glycaemic control and BMA will be discussed in Chapter 4.  
Younger age of T1DM onset and long standing disease duration are other clinical factors 
which may have effect on bone health in people withT1DM. So far, there was no general 
agreement on the relative importance of these factors. In consistent with other studies (351, 377, 
534-536), we did not observe significant association between bone parameters and disease 
duration. Younger age of onset of diabetes has been associated with bone deficits which continues 
to persist over years as noted in few studies (346), in our study, there was trend toward negative 
association between younger age of T1DM onset and bone deficit, with larger sample size this may 
be confirmed. 
Finally, the current study highlights the objective versatility of MRI-based techniques in 
identifying differences in relatively small cohorts. Although there is now sufficient 
supporting evidence for the use of MRI for assessing bone microarchitecture (445), with 
the greater availability of 3T MRI scanners, there is a need to standardize the analytical 
techniques so that the clinical utility of MRI in metabolic conditions that are associated 
with abnormalities of bone health can be realized. With technological advances in 
hardware as well as analytical tools, an improvement in the current limited resolution of 
MRI as well as its ability to study cortical structure is highly likely. We chose to study 
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young women only, primarily because they are more likely to develop osteoporosis in the 
long term and to avoid the confounding effects of sex hormones, but given that the 
increased fracture incidence has been encountered in both sexes and bone marrow 
adiposity increases with old age (119, 537), there is a need to study older as well as 
younger people with diabetes in both sexes. We did not perform DXA in this group, but 
there is a need in future studies to assess the relationship of micro-MRI findings to DXA 
BMD as well as DXA-based methods of assessing trabecular architecture (223). Given that 
hip fractures are reported to be more common in people with T1DM (161, 336, 340), there 
is a place to examine the microarchitecture at this site, too. The lack of a sufficient number 
of cases with other complications associated with microvasculopathy limited the 
investigation of this association in the current study. The relationship between bone 
pathology and type 2 DM is less clear with a lower risk of fractures(221).However, a 
recent study that examined bone marrow adiposity in women with type 2 DM did report a 
higher level of vertebral bone marrow adiposity in those who had a history of a fracture 
(464). 
3.6 Conclusion  
In summary, detailed MRI studies in young women with T1DM have shown clear 
abnormalities of bone health that are characterized by reduced trabecular bone volume and 
reduced trabecular numbers. Possible underlying mechanisms that require further 
exploration include a microvasculopathy and GH resistance. 
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Chapter 4 
 
 
 
 
 Longitudinal Changes In Bone Marrow Adiposity 
And Its Relationship To Diabetes Control In Young 
Women With Type 1 Diabetes Mellitus 
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4.1 Abstract 
Context: The pathophysiological mechanism of increased fractures in young women with 
Type 1 Diabetes Mellitus (T1DM) is unclear.  
Objective: Prospective, longitudinal study of trabecular bone microarchitecture and 
vertebral marrow adiposity in young women with T1DM and a control group of healthy 
women.  
Patients & Settings: 17 women with T1DM with a median (range) age of 22.2yrs (16.6, 
32.4) attending one outpatient clinic with a median age at diagnosis of 10.1 yrs (4.8, 14.8) 
were compared to 11 age-matched healthy women who acted as controls. 
 Methods & Main Outcome Measures: Measurements included MRI-based assessment 
of abdominal adipose tissue, proximal tibial bone volume/total volume (appBV/TV), 
trabecular separation (appTb.Sp), vertebral bone marrow adiposity (BMA) at baseline and 
12 months.  
Results: Median appBV/TV in cases and controls was 0.31 (0.22, 0.37) and 0.33 (0.28, 
0.4), respectively (p=0.05) and median appTb.Sp in T1DM was 2.57 (2.24, 3.15) and 2.32 
(2.03, 2.73), respectively (p=0.02). There was no difference in median BMA which was 
26.2% (12.1, 62.1) and 22.4% (9.6, 41.9) in cases and controls, respectively (p=0.57). Over 
the 12 month period, there was no significant change in these parameters. Although, there 
was no association between change in bone microarchitecture parameters and HbA1c in 
the cases, there was a strong correlation between change in HbA1c and change in BMA (r, 
0.8, p=0.002).  
Conclusion: Longitudinal MRI studies of trabecular bone show that over a period of one 
year, improvement in diabetes control is associated with a reduction in bone marrow 
adiposity but persistence of bone microarchitecture deficits  
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4.2 Introduction 
The risk of hip fractures in those with Type 1 diabetes mellitus (T1DM) is reported to be 
7–12 times greater (336, 340, 538). Although the underlying pathogenesis for this 
increased fracture risk may be multifactorial (539), bone marrow adiposity (BMA) may 
play an important role (463, 540). The process of differentiation of mesenchymal stem 
cells into either adipocytes or osteoblasts is regulated by a number of growth factors 
including insulin, oxygen tension and blood flow within the bone marrow (503, 504) and 
mouse models of T1DM exhibit increased BMA and increased adipocyte markers in the 
bone marrow (249). 
On dual energy X-Ray absorptiometry (DXA), adults with T1DM show a reduction in 
bone mineral density (BMD) Z-score, reported in a meta-analysis at -0.22 at the lumbar 
spine and -0.37 at the hip (161), but the fracture risk in affected adults is much higher (161, 
336, 340, 538) than expected for this modest reduction in BMD. Not only does MRI 
provide high resolution 3D images of bone structure that correlates with techniques such as 
computed tomography (440, 509) but it also allows MR spectroscopy for estimating BMA 
(541). Given the novelty of MRI-based assessment of bone microarchitecture and BMA, 
there is a need to assess the extent of longitudinal variation that may occur in healthy and 
disease states. Recent studies that use MRI and HR-CT have shown that people with 
T1DM may have a bone microarchitectural deficit (163, 542). However, an abnormality of 
BMA has not been observed to date in people with T1DM (542) and although the findings 
in those with T2DM are currently inconclusive, they suggest that there may be an 
association between chronic hyperglycemia and BMA (464, 466). Furthermore, there is 
scarce information on the extent of change when these measurements are repeated.  
The current study was, therefore, performed to assess longitudinal changes in MRI-based 
markers of bone health and their relationship to diabetes control in T1DM. This 
information will be vital for understanding the bone pathology in diabetes and for 
designing future intervention studies aimed at improving bone health.  
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4.3 Research Design & Methods 
4.3.1 Subjects 
Of the 29 women between the ages of 20 and 30 years and who were diagnosed with 
T1DM before the age of 16 years and who participated between July 2012 and July 2013 in 
a case: control study of bone health (542), 17 volunteered for another visit at 12-months. In 
addition, of the 28 healthy women who comprised the control group and were approached, 
11 volunteered for a repeat visit at 12 months (Figure 4.1). Exclusion criteria included the 
presence of metallic implants and pacemakers, active or planned pregnancy or lactation, 
kidney disease, chronic use of drugs that are known to affect bone health and other chronic 
diseases that are known to be associated with an increased risk of fractures. Information on 
personal health  and lifestyle habits, including cigarette smoking, alcohol consumption, 
current medication, use of vitamins or calcium, age at menarche, use of oral 
contraceptives, hours of weight bearing physical activity per week, history of fractures and 
a family history of early  osteoporosis was also collected. Information on age of diagnosis, 
disease duration, insulin therapy and presence of microvascular complications was 
obtained from the case records. A glycosylated hemoglobin (HbA1c) measurement within 
the four-week period prior to the visit was used as current HbA1c. The study protocol was 
approved by the national research ethics service and all participants provided written 
informed consent. 
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Figure  4.1: Path outlining study participant recruitment, enrollment and followup from baseline to 
follow-up assessment. 
 
 
4.3.2 MRI acquisition and analysis   
Micro MRI data were available in all 17 cases and 11controls.  MRS data were available in 
16 case and all controls, MRI of abdominal fat are available in 17 case and 10 controls.  
All magnetic resonance images acquisitions and analysis were described previously in 
Chapter 2.  
 
4.3.3 Statistical Analysis 
Data analysis was performed using Minitab 17, Minitab Inc, State College, PA. All data 
were described as medians and ranges; comparison between the cases and controls was 
performed by the Mann-Whitney U test for continuous variables and by the Chi Squared 
test for categorical variables. Spearman correlation analysis was used to assess the 
univariate relationship between continuous variables and statistical significance was set at 
p < 0.05. Multivariable linear regression was performed on models with weight, age and 
adiposity to determine the baseline difference of bone parameters between cases and 
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controls, and to examine associations of changes in bone parameters in relation to changes 
in visceral adiposity. SPSS mixed modelling was employed where appropriate to explore 
the confounding effects of independent variables on the percentage change in bone 
parameters over the one year period. 
 
4.4 Results 
4.4.1  Clinical Characteristics 
The median age at diagnosis of the cases was 10.1 yrs (4.8, 14.8) and the median duration 
of diabetes was 13.6 yrs (6.8, 26.5). There were no significant demographic or 
anthropometric differences between the cases and controls at baseline or at the 12-month 
follow-up visit   (Table 4.1). In addition, there were no intra-group differences at the two 
time points (Table 4.2). Notably, the median BMI in the cases and controls was 24.4 kg/m2 
(18.7, 31.6) and 22.6 kg/m2 184 (19.6, 28.0), respectively (p=0.2) at one year with similar 
amounts of physical activity reported in the cases and controls. Of the 17 cases, 5 (29%) 
reported a history of traumatic fractures and in 3, the fractures had occurred before the 
diagnosis of diabetes. No fractures were reported in the control group. None of the 
participants were on routine vitamin supplementation. Of the 17 cases, 9 (50%) had 
retinopathy of which 8 had background retinopathy alone, 2 (7%) were being treated for 
hypertension, and 3 (18%) had microalbuminuria. One of the cases had stable Crohn’s 
disease over the study period requiring only sulfasalazine therapy for three years prior to 
the baseline assessment. 
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Table  4.1:  Descriptive characteristic of study participants who were enrolled at baseline and follow-up. All continuous variables are described as median and range 
 Baseline  1 year 
           Diabetes (17)                     Controls (11)            p  Diabetes (17)        Controls (11)    p  
Age (Years)                                                                                                                                                                             22.2 
(16.6, 32.4) 
20.0 
(19.4, 23.1) 
0.08 23.7  
(17.4, 40.0) 
21.0 
(20.0, 23.9) 
0.07 
BMI  (kg/m
2
)
 
24.6 
(18.2, 31.2) 
22.6 
(19.7, 27.8) 
0.05 24.4 
(18.7, 31.6) 
22.6 
(19.6, 3) 
0.2 
Smoker (n) 
 
2 0 0.3 4 0 0.1 
Alcohol consumption  
 
13 10 0.8 13 9 0.9 
Menarcheal Age (Years) 12.5 
(10, 17.5) 
12 
(11, 15) 
0.8 13 
(10, 17.5) 
12 
(11, 15) 
0.8 
Pregnancy (n) 
 
2 0 0.3 3 0 0.2 
Oral Contraceptives (n) 
 
12 9 0.8 10 10 0.5 
Physical activity (hrs/wk) 4 
(0, 10) 
4 
(0, 7) 
0.7 3 
(0 , 10) 
3 
(1.5 ,10 ) 
0.7 
Total insulin dose (IU/kg/d) 2.5 
(1.2, 4.8) 
  2.5 
( 1.2, 3.7) 
  
Current HBA1c (mmol/mol) 77  
(36.6, 114.2) 
  75  
(51, 118) 
  
Ave HBA1C over 1yr (mmol/mol) 
 
74.4 
(41.3, 116.7) 
  75 
(60.2, 110.4) 
  
Hypertension (n) 
 
2   2   
Retinopathy (n) 
 
8, (Mild , 7)   9, (Mild , 8)   
Microalbuminuria (n) 0   3   
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Table  4.2: Differences in MRI baseline data for those who dropped out and those who completed the study. 
 Diabetes Controls 
 Dropout (n=13) Completed the study  (n=17) P Dropout (n=17) Completed the study (n=11) P 
CSA (mm
2
) 49186 
(31489, 77086 ) 
47878 
(30134, 78651) 
0.9766 47678 
(32966, 69789) 
36232 
(30232, 53888) 
0.1731 
SCAT (mm
3
) 25209 
(3,719, 37936) 
20458 
(7,347, 42877) 
0.660 17263 
(7454, 40807) 
11605 
(7,885, 28875) 
0.1731 
VAT (mm
3
) 5,065 
(2,402, 7,715) 
6,427 
(2,030, 11144) 
 
0.208 4042.5 
(2,592, 6,832) 
3,393 
(1,808, 6,083) 
0.3423 
TAT (mm
3
) 30788 
(6,584, 45651) 
26271 
(15433, 54021)  
0.660 22090 
(10046, 47639) 
15778 
(10312, 30869) 
0.2312 
AppBV/TV 0.30 
(0.23, 0.34) 
0.33 
(0.22, 0.37) 
0.6 0.31 
(0.22,0.37) 
0.33 
(0.28,0.40) 
0.047 
AppTb.N(mm-1) 0.26 
(0.20, 0.29) 
0.27 
(0.24, 0.30) 
0.5 0.27 
(0.24,0.30) 
0.29 
(0.24,0.30) 
0.031 
AppTb.Sp(mm) 2.66 
(2.25, 3.38) 
2.57 
(2.24, 3.15) 
0.4 2.57 
(2.24,3.15) 
2.32 
(2.03,2.73) 
0.019 
AppTbTh(mm) 1.18 
(0.86, 1.49) 
1.11 
(0.91, 1.46) 
0.5 1.11 
(0.91, 1.46) 
1.26 
(1.05, 1.39) 
0.144 
BMA (FF%) 22.92 
(9.86, 50.14) 
26.20 
(17.29, 59.60) 
0.6 26.20 
(12.05, 62.11) 
22.35 
(12.46,  49.82) 
0.572 
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4.4.2 MRI of abdominal fat 
While differences in BMI were not statistically different between cases and controls, the 
cases did have a higher BMI by 2kg/m2    (Table 4.1). However, abdominal adiposity 
including  CSA, SCAT, VAT and TAT, was clearly significantly higher in cases compared 
to controls at baseline and at 1 year and there was no significant change within these two 
groups for these respective parameters of adiposity (Table 4.3) (Figure 4.2, and 4.3). As 
expected, change in TAT showed a strong association to change in BMI (r, 0.7, p<0.001) 
and this association was similar in controls and those with T1DM (Figure 4.4). This 
relationship was also evident for weight and these two anthropometric measures were also 
strongly associated to CSA and SCAT (Figure 4.4). In the diabetes group, there was no 
association of abdominal adiposity parameters with current or annualized HbA1c, age at 
diagnosis and duration of T1DM at baseline or one-year. Furthermore, the percentage 
change in these markers of adiposity was not associated to a change in any of the markers 
of glycaemic control. 
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Table  4.3:  MRI-based measures of abdominal adiposity, bone microarchitecture and vertebral bone marrow adiposity at L3 for controls and participants with T1DM 
(diabetes) at baseline and one year. 
All data are described as median and range. CSA- cross-sectional area of adipose tissue; SCAT – subcutaneous adipose tissue; VAT- visceral adipose tissue; TAT – total adipose tissue; 
AppBV/TV – apparent bone volume/total volume; AppTb.N – apparent trabecular number; AppTbSp – apparent trabecular separation; AppTbTh – apparent trabecular thickness; 
BMA– bone marrow adiposity; FF% -fat fraction.
 Baseline One Year Change From Baseline (%) 
 Diabetes Controls p Diabetes Controls p Diabetes Controls p 
CSA  
(mm
2
) 
47878 
(30,134, 78,651 ) 
36124 
(30,232, 48,706) 
0.009 51,829 
(31,807, 73,485) 
39707 
(32,004, 55,860) 
0.02 3.7 
(-12.9, 18.2) 
0.7 
(-9.7, 32.4) 
1 
SCAT  
(mm
3
) 
20458 
(8,278, 42,877) 
10684 
(7,885, 20,790) 
0.009 22,662 
(8,747, 38,179) 
11881 
(8,078, 25,829) 
0.009 7.7 
(-12.6, 41.8) 
0.4 
(-36.6, 65.8) 
0.43 
VAT  
(mm
3
) 
6,427 
(2,030, 11,144) 
3,393 
(1,808, 6,083) 
0.003 60,85.0 
(2,112, 11,373) 
3,818 
(1,864, 7134) 
0.003 2.5 
(-27.6, 53.4) 
4.2 
(-4.1, 17.3) 
0.39 
TAT  
(mm
3
) 
26271 
(15,433, 54,021) 
15778 
(10,312, 24819) 
0.002 28,274 
(14,727, 49,161) 
15699 
(10,343, 32,963) 
0.003 5.6 
(-9.7, 44.5) 
1.8 
(-31.4, 52.1) 
0.58 
AppBV/T
V 
0.31 
(0.22, 0.37) 
0.33 
(0.28, 0.40) 
0.05 0.29 
(0.25, 0.38) 
0.32 
(0.27, 0.42) 
0.1 2.7 
(-21.6, 22.6) 
-3.6 
(-21.1, 36.7) 
0.59 
AppTb.N 
(mm
-1
)  
0.27 
(0.24, 0.30) 
0.29 
(0.24, 0.30) 
0.03 0.26 
(0.20, 0.32) 
0.28 
(0.24, 0.31) 
0.1 0 
(-25.0, 14.3) 
0 
-17.0, 8.0) 
0.85 
AppTb.Sp 
(mm)  
2.57 
(2.24, 3.15) 
2.32 
(2.03, 2.73) 
0.02 2.65 
(2.06, 3.38) 
2.47 
(1.94, 2.79) 
0.04 1.1 
(-15.5, 49.6) 
2.2 
(-18, 24) 
0.54 
AppTbTh 
(mm)  
1.11 
(0.91, 1.46) 
1.26 
(1.05, 1.39) 
0.14 1.17 
(0.95, 1.46) 
1.16 
(1, 1.52) 
1 6.9 
(-26.7, 35.2) 
-4.6 
(-21.6, 36.9) 
0.26 
BMA  
(FF%)  
26.20 
(12.05, 62.11) 
22.35 
(9.57, 41.85) 
0.57 26.91 
(17.24, 58.49) 
25.19 
(8.34, 35.10) 
0.44 17.9 
(-35.1, 92.6) 
5.9 
(-21, 43.1) 
0.41 
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Figure  4.2: The absolute changes in the abdominal adiposity parameters over the one year period in both women with T1DM and controls. 
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Figure  4.3: The median percentage changes in the abdominal adiposity parameters over the one year period in both T1DM (black circles) and controls (black squares).
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Figure  4.4: The relationship between % changes in CSA, SCAT and TAT as assessed by MRI and % change in BMI in women with T1DM (filled circles) and controls (open 
circles).  
A positive association between % changes in CSA, SCAT and TAT and % change of BMI was observed. 
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4.4.3 Bone Marrow Adiposity 
Absolute and median vertebral BMA, expressed as percentage fat fraction (%FF) did not 
change significantly during the study period in both cases and controls (Table 4.3) (Figure 
4.5). Although, there was no association between the change in BMA and any of the 
anthropometric variables or markers of abdominal adiposity, in the women with T1DM, 
percentage change in BMA showed a strong positive association to percentage change in 
HbA1C when comparing most recent HbA1c at the two study time points (r, 0.8, p=0.002) 
(Figure 4.5). This association was still present but weaker when the percentage change in 
BMA was compared to the change in average HbA1c for the year prior to the MRI study 
(r, 0.5, p=0.08) (Figure 4.6). Of the 7 participants in whom the most recent HbA1c 
increased over the study period, 5 had increased BMA and of the 8 participants in whom 
HbA1c decreased, 4 had decreased BMA (Figure 4.7).  Mixed model effect analysis 
showed that VAT was positively associated to a change in BMA (p=0.02). 
 
 
 
 
 
Figure  4.5:  Absolute and median % changes in fat fraction (%FF) over one year period in both 
women with T1DM and controls. (A) absolute changes in FF% in T1DM, (B) absolute changes in FF% 
in controls and (C) % changes in FF% in both T1DM (Black circles) and controls (Black squares) 
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Figure  4.6: The relationship between percentage (%) change in fat fraction as a measure of vertebral 
Bone Marrow Adiposity (BMA) and % change in HbA1c measured within the 4 weeks prior to MRI 
scan at baseline and follow-up visit at 1 yr (A) and average HbA1c for the year prior to MRI scan at 
baseline and follow-up visit at 1 yr (B). 
 
 
 
 
 
Figure  4.7:  Percentage change (%) in fat fraction as a measure of vertebral Bone Marrow Adiposity 
(BMA) for each participant in relation to the extent of change in HbA1c from baseline to 12 months.     
 
The open circle on the horizontal intersect denotes the actual HbA1c (mmol/mol) at baseline and the closed 
circle denotes the the actual HbA1c (mmol/mol) for the same subject at 12 months. 
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4.4.4 Bone Microarchitecture by Micro-MRI 
Compared to controls, the cases had a lower median appTbN and a higher median 
appTbSp at baseline and 12 months (Table 4.3) and this difference persisted after adjusting 
for age, VAT and TAT. A clear difference existed for median appBV/TV and appTbSp 
between those cases who had retinopathy and those who did not have retinopathy. The 
median appBV/TV and appTbSp was 0.28 (0.25, 0.34), and 2.78 (2.44, 3.22), respectively, 
in those cases with retinopathy compared to 0.34 (0.28, 0.38) and 2.54 (2.06, 3.38) in those 
cases without retinopathy (p=0.01, 0.03, respectively). There was no significant change in 
any of the bone microarchitecture parameters over the one year period in either group and 
the extent of change within each group was similar in the group of women with  and 
without T1DM (Table 4.3) (Figure 4.8)(Figure 4.9). In the T1DM cases, there was no 
association of percentage change in appBV/TV, appTbN or app TbSp with percentage 
change in HbA1c, age at diagnosis, duration of T1DM or daily insulin dose adjusted for 
weight. Mixed model effect analysis showed that the age was negatively associated with 
the percent changes of app BV/TV, appTbN and appTbSp in both cases and controls 
(p=0.02, p=0.02, p=0.002, respectively). The percentage change in trabecular bone 
microarchitecture parameters did not show any association to the MRI-based markers of 
abdominal obesity and BMA, even after controlling for BMI. 
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Figure  4.8:  The median percentage changes in the bone microarchitecture parameters over the one year period in both women with T1DM and control groups. 
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Figure  4.9:  The median % changes in the bone microarchitecture parameters over one year period in both women withT1DM (Black circles) and controls (Black sequares).
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4.5 Discussion 
The current study was primarily aimed at assessing the extent of change that may occur in 
MRI based parameters of bone health and adiposity in these women with T1DM, as well as 
in healthy young women. In addition, this study aimed to study the clinical factors that 
may be associated with longitudinal changes in MRI based measures of bone health.  
Although women with T1DM tended to be slightly overweight and their BMI was not 
significantly higher than the control group, abdominal adiposity as assessed by MRI was 
significantly raised in the women with T1DM. Although the overall change in the markers 
of abdominal adiposity did not show a significant difference between the cases and 
controls, the range of variation within the group of women with T1DM was greater. Raised 
abdominal adiposity in young people with T1DM is not a universal finding (543-545) and 
may perhaps be associated with overall control and lower socioeconomic status (546). A 
recent report of islet cell transplantation in a cohort of cases of T1DM of a similar 
socioeconomic status showed that improved control was also associated with a reduction in 
central obesity (546). However, in the current T1DM group, the changes in adiposity did 
not seem to be clearly related to any clinical variables. The average change in markers of 
abdominal adiposity was about 3% and this was similar to that published before in healthy 
young women and within the coefficient of variation for the technique which is about 5% 
(547).  
In the previous case control study from our group, we did not show any statistical 
difference in BMA between cases with T1DM and controls (542) and, consistent with that, 
we did not detect a significant difference in the current smaller cohort. The average change 
in BMA over the year was about 12% and tended to be higher in the cases than the 
controls. Whilst there are several reports of increased BMA in mouse models of 
uncontrolled T1DM (249, 292, 507) there are currently no published reports of increased 
BMA in humans with T1DM and, given the extent of variation, a larger sample size may 
assist in conclusively evaluating this association. However, our current study has shown a 
clear and unequivocal association between a change in HbA1c and a change in BMA. 
Given that there is increasing evidence of a direct link between BMA and bone strength 
(467) we believe that this is a very important finding as it sheds further light on the 
aetiology of the osteopathy that is associated with increased bone fragility in T1DM. There 
is increasing evidence that the developmental origins of VAT and SCAT are different 
(185). The preliminary finding of an association between BMA and VAT but not TAT or 
SCAT needs to be confirmed in a larger group of individuals but suggests that the 
developmental origin of BMA may be more similar to VAT than SCAT. 
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The bone microarchitecture findings in the current study were also very striking and 
confirm our previous findings that a bone deficit exists in young women with T1DM and 
that this deficit is particularly marked in those with microvascular disease (542). These 
findings are especially notable as the association with retinopathy was statistically 
significant despite the relatively smaller number of cases in the current study sample. The 
average change in the trabecular parameters of bone microarchitecture over a period of the 
year was 3% and well below the upper level of variation of 7% in trabecular parameters in 
healthy volunteers (411). Unlike BMA, the range of change was lower for the bone 
microarchitecture parameters.  
An association between change in BMA and markers of bone microarchitecture was not 
observed and although this may be due to the limited sample size, it is also possible that 
this could be explained by a lag phase between an effect of chronic hyperglycemia on 
BMA and its effect on bone microarchitecture and which may not have been adequately 
captured in  this study and may require a longer period of study. The clear association of 
reduced bone volume in those cases of T1DM who had retinopathy, albeit background 
retinopathy in most cases, suggests that it is possible that the underlying 
microvasculopathy may also influence trabecular development. 
Thus, the paradigm that these preliminary studies suggest is that BMA which might be 
associated to changes in HbA1c is the first marker of bone pathology and it is possible that 
this is followed over the longer term by abnormalities of bone microarchitecture which are 
less modifiable and mirror other microvascular conditions such as retinopathy. If this is 
true, then it would suggest that early identification of abnormalities of BMA may be a 
more effective approach for improving bone health in T1DM as well as other metabolic 
conditions that are associated with osteoporosis. Given that the increased risk of fractures 
in T1DM may also be present in older children and adolescents (219), there is a need to 
understand changes in BMA at an earlier stage of skeletal development than currently 
studied. The current study was limited to a relatively small group of cases and controls and 
there is a need to perform these studies in larger group of patients over a longer period to 
mitigate the effects of variability 
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4.7 Conclusion 
In summary, detailed, longitudinal MRI studies of trabecular bone show that over a period 
of one year, improvement in diabetes control is associated with a reduction in bone marrow 
adiposity but bone microarchitecture deficits may persist. The chronological link between 
bone marrow adiposity and bone microarchitecture in pathological states needs further 
study.  
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Chapter 5 
 
 
 
 
 
 An assessment of adiposity-based determinants of 
bone density and microarchitecture in healthy young 
women and women with T1DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
5.1 Abstract:  
Context: People with T1DM are at higher fracture risk yet the pathophysiological 
mechanism is unclear. Recent studies have demonstrated an important link between excess 
adiposity and bone deficits.   
Aim of the study: The aim of this pilot study was primarily for assessing adiposity-based 
determinants of bone density and bone microarchitecture in healthy young women and 
women with T1DM. Secondly, to compare the feasibility of DXA and MRI measured bone 
parameters to differentiate between women with and without T1DM. 
Methods: Measurements included MRI-based assessment of abdominal adipose tissue, 
proximal tibial bone volume/total volume (appBV/TV), trabecular separation (appTb.Sp), 
vertebral bone marrow adiposity (BMA). Additional measures included DXA based 
assessments of the whole body, femoral neck (FN) and lumbar spine bone area (cm2), 
BMC (g) and mean areal BMD (g/cm2). Body composition, including whole body fat mass 
(WB-FM (kg)), WM-FM Z- score and android/gynoid were also obtained from the whole 
body DXA scan.  
Results: Women with T1DM had higher MRI based abdominal adiposity (p<0.05) and 
greater WB-FM Z-score (p=0.03) versus matched controls; BMI did not differ. Although, 
there was no difference in vertebral bone marrow adiposity (VBMA) which was 26.9 
(17.2, 58.5) and 25.2 (8.3, 35.1) in cases and controls, respectively (p=0.51), there was an 
inverse association between VBMA and DXA-measured BMD, BMD Z-score and BMC at 
all measured sites (p<0.05).   These correlations remained significant after controlling for 
age, BMI, WB-FM (Kg), VAT, TAT, SCAT. On the other hand, visceral adipose tissue 
(VAT) showed positive correlations with VBMA (r=0.42, p=0.03), and negative 
correlation with TB-BMD Z score (r=-0.46, p=0.02).  After controlling for TB-BMD Z-
score and VAT, the correlation between VAT and vertebral bone marrow fat became 
insignificant (P = 0.28), but VBMA and BMD remained significant (P = 0.04). No 
significant difference in DXA and MRI measured bone parameters was evidenced between 
women with or without diabetes. In contrast, diabetic women with microvasculopathy 
demonstrated altered bone microarchitecture compared to healthy controls and those 
without microvasculopathy, but they did not show any significant differences in DXA 
measured bone parameters. AppTbSp showed a significant inverse association to TB BMD 
(r= –0.40, p= 0.04) and FN BMC (r =-0.41, p=0.04).  
Conclusions: In this young-aged population, a negative relationship existed between MRI-
measured VBMA and femoral neck, lumbar spine and total body BMD independent of 
demographics and body composition. These observations support the growing evidence 
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linking BMA with low bone density. Comparing to DXA scan, micro-MRI appears 
promising to assess bone microarchitecture in term of its feasibility to detect disease-
related changes in women with T1DM compared to healthy controls.  
 
5.2 Introduction 
T1DM is a chronic metabolic disorder that is characterized by a pathological quantity and 
distribution of adipose tissue (542). Looking at the literature, it is quite clear that patients 
with T1DM are at high risk of osteoporosis (548) and fracture (160, 161, 221). There is a 
growing body of evidence that suggests that the fat bone connection plays an important 
role in the pathophysiology of bone loss. Previous studies have reported an inverse 
association of BMA with BMD in patients with osteoporosis and other metabolic diseases 
(457, 466, 549). BMA is higher in mouse models with T1DM (249), however, the 
relationship of BMA and BMD in T1DM has scarcely been studied (369). Although, this is 
potentially related to altered mesenchymal stem cell differentiation into osteoblasts or 
adipocytes(199), the role of marrow adiposity and its relation to bone remains poorly 
understood. One important area of clinical investigation has considered the relationship 
between marrow adiposity and other body adiposity depots.  However, several clinical and 
experimental studies indicate that adipose tissue itself is not functionally uniform, and 
different adipose depots have distinctive characteristics in terms of adipocytokine 
production(550, 551), and consequently may have distinct relationships with bone. 
Evidence regarding the relationship between VAT, BMA and bone health is inconsistent. 
Recent evidence suggests that VAT may negatively impact bone health. Decreased BMD 
and altered bone microarchitecture was associated with marrow adiposity and visceral 
adiposity in other different populations (460, 469, 491, 552). However, these relationships 
have not been examined in women with T1DM.  
Our primary objective was to evaluate different measures of adiposity in healthy young 
women and women with T1DM, and to determine associations of these adiposity measures 
with BMD, BMC using DXA, and trabecular bone microarchitecture using high resolution 
MRI. The secondary objective was to compare the feasibility of DXA and MRI measured 
bone parameters to differentiate between women with and without T1DM. 
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5.3 Subjects and methods 
5.3.1 Subjects  
This was a cross-sectional, controlled study of 17 women between the ages of 17 and 34 
years who were diagnosed with T1DM before the age of 16 years and who returned for a 
follow up visit between January 2014 and July 2014 in the previous longitudinal study of 
bone health (Chapter 4), and had a DXA scan. Of the 11 healthy women who comprised 
the control group, 9 had DXA scan. Exclusion criteria included the presence of metallic 
implants and pacemakers, active or planned pregnancy or lactation, kidney disease, chronic 
use of drugs that are known to affect bone health and other chronic diseases that are known 
to be associated with an increased risk of fractures. Information on personal health and 
lifestyle habits, including cigarette smoking, alcohol consumption, current medication, use 
of vitamins or calcium, age at menarche, use of oral contraceptives, hours of weight-
bearing physical activity per week, history of fractures and a family history of early 
osteoporosis was also collected. Information on age of diagnosis, disease duration, insulin 
therapy and presence of microvascular complications was obtained from the case records. 
A glycosylated hemoglobin (HbA1c) measurement within a four-week period of the scan 
visit was used as current HbA1c. The study protocol was approved by the national research 
ethics service and all participants provided written informed consent. 
5.3.2 MRI acquisition and analysis  
Micro MRI data were available in all 17 cases and 11 controls.  MRS data were available 
in 16 case and all controls, MRI of abdominal fat were available in 17 case and 9 controls.  
All magnetic resonance images acquisitions and analysis were described previously in 
Chapter 2.  
5.3.3 DXA  
DXA data were available in 17 cases and 9 matched controls.  DXA of the whole body, 
femoral neck and lumbar spine (L1-L4) was performed to determine the main study 
outcomes. The bone area (cm
2
), BMC (g) and mean areal BMD (g/cm
2
) of whole body, 
femoral neck (FN) and lumbar spine were measured. In addition, bone mineral apparent 
density (BMAD) at lumbar spine was calculated. For the assessment of the bone mass in 
addition to the absolute values of bone mineral density presented in g/
cm2
 we used the so 
called Z-score (number of standard deviations the patient`s BMD differ from age- sex- 
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matched reference value). Because of the age characteristic (17-40 yrs.) of our study 
groups it was inappropriate to use T-score to determine BMD changes and WHO 
classification of osteopenia and osteoporosis could not be applied. Body composition, 
including WB-FM (kg), WB-FM Z -score and android/gynoid were obtained from the 
whole body DXA scan. 
5.3.4 Statistical analysis 
Statistical analyses were performed using Minitab 17, Minitab Inc, State College, PA. All 
data were described as medians and ranges; comparison between the cases and controls 
was performed by the Mann-Whitney U test for continuous variables and by the Chi 
Squared test for categorical variables. Spearman correlation analysis was used to assess the 
univariate relationship between continuous variables and statistical significance was set at 
p <0.05. Multivariable linear regression was performed to examine associations of VBMA, 
BMD and visceral adiposity. BMA, age, BMI, WB-FM, VAT, SCAT were selected for the 
regression model because of their relatively high correlations with BMD.  
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5.4 Result 
5.4.1 Clinical characteristics 
There were no significant demographic or anthropometric differences between the cases 
and controls (Table 5.1). The study included 17 patients with T1DM, their median age was 
23.7 yrs. (17.4, 34), the median age at diagnosis of the cases was 10.1 yrs. (4.8, 14.8) and 
the median duration of diabetes was 13.6 yrs (6.8, 26.5).  
Table  5.1: Clinical characteristic of study participants 
  Cases (n=17) Control (n=9) p 
Age (yrs)                                                                                                                                                                             23.7 (17.4, 34) 21.6 (20, 23.8) 0.1
Ht SDS -0.03 (-1.5, 1.9) 0.4 (-0.7, 3.2) 0.5 
Wt (kg) 68.8 (50.2,91.5) 63.8 (54.4,76.5) 0.5 
Wt SDS 1.2 (-1, 2.9) 0.7 (-0.4 , 2.9) 0.5 
BMI  24.4 (18.7, 31.6) 22.6 (19.6, 28.0) 0.1 
BMI SDS 0.82 (-1.4, 2.4) 0.2 (-0.9, 1.7) 0.1 
Smoker  4 0 0.2 
Regular alcohol 13 7 1 
Menarcheal Age (yrs) 13 (10, 17.50) 12 (11, 15) 0.9 
Pregnancy 3 0 0.2 
Hormonal use pills (n) 10 9 0.4 
Physical activity 3 (0, 10) 3 (1.5, 10 ) 0.8 
Fracture (n) 5 0  
Hypertension 2 0  
Retinopathy 9, (background,8) -  
Microalbuminuria 3 -  
Total insulin (IU/kg/d) 2.50( 1.23, 3.74) -  
Current HBA1c (mmol/mol) 75 (51,118) -  
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5.4.2 Body composition  
Body composition results are summarized in (Table 5.2). MRI –measured abdominal 
adiposity parameters including CSA, SCAT, VAT and TAT were significantly higher in 
cases compared to controls. Additionally, women with T1DM had significantly higher 
DXA-measured whole- body fat mass z-score (p=0.03), and a tendency toward higher 
whole-body fat mass (WB-FM, Kg) and A/G ratio compared to matched healthy controls 
(p=0.07; p=0.08, respectively). Median vertebral BM (FF %) was not significantly 
different between cases and controls. Different body composition measures were 
significantly correlated among each other (Table 5. 3). BMI was positively correlated with 
DXA measured adiposity parameters and MRI-measured abdominal adiposity parameters. 
Age positively correlated with A/G, CSA, SCAT, VAT and TAT. There was no effect of 
disease related parameters on different body composition measures.   
Table  5.2: Bone and body composition parameters in women with T1DM and matched controls 
 Cases (n=17 ) Controls (n=9) p 
Bone microarchitecture  
App BV/TV 
App TbN  (mm-1) 
App TbSp (mm) 
App ThTh (mm) 
 
 
0.29 (0.25, 0.38) 
0.26 (0.20, 0.32) 
2.65 (2.06, 3.38) 
1.17 (0.95, 1.46) 
 
0.32 (0.27, 0.42) 
0.27 (0.24, 0.31) 
2.52 (1.94, 2.79) 
1.19 (1.00, 1.52) 
 
0.1 
0.2 
0.08 
0.7 
BMA L3 fat fraction 
(FF %) 
 
26.9 (17.2, 58.5) 
 
25.2 (8.3, 35.1) 
 
0.5 
TB BMC (g)  
TBMD g/cm2 
TB-BMD z score 
 
2504 (1669, 2967) 
1.1 (1, 1.2) 
-0.2 (-1.1, 1.5) 
2636 (2147, 3) 
1.1 (1, 1.3) 
0.4 (-1.2, 2.0) 
0.3 
0.5 
0.3 
L2-L4 BMC (G) 
L2-L4 BMD (g/cm2)  
 L2-L4 BMD z score 
BMAD 
 
49.8 (26.6, 60.8) 
1.18 (0.82, 1.39) 
-0.1 (-3.1, 1.6) 
0.38 (0.29, 0.42) 
56.7 (38.2, 66.9) 
1.24 (0.99, 1.42) 
0.4 (-1.7, 1.8) 
0.37 (0.27, 0.46) 
0.2 
0.8 
0.8 
0.7 
Femoral BMC (G) 
FN-BMD (g/cm2)  
FN-BMD Z-score   
 
28.2 (21.3, 34.1) 
0.94 (0.84, 1.13) 
-0.6 (-1.2, 1) 
31.1 (24.2, 35.8) 
0.98 (0.88, 1.22) 
-0.2 (-1.2, 1.7) 
0.2 
0.6 
0.3 
MRI-measured  adiposity  
CSA (mm
3
)
 
SCAT (mm
3
)
 
VAT (mm
3
)
 
TAT (mm
3
) 
 
 
51829 (31807,73485) 
22662 (8747, 38179) 
6085 (2112, 11373) 
28274 (14727, 49161) 
 
39761 (32004, 55860) 
12529 (8078, 25829) 
3460 (1864, 7134) 
16251 (10343, 32963) 
 
0.04 
0.02 
0.004 
0.007 
DXA-measured body fat 
Android/Gynoid 
WB-FM (kg) 
WB-FM z score  
 
0.8 (0.5, 1.1) 
24.47(14.30,41.53) 
1.1 (0.5, 2.5) 
 
0.8 (0.6, 0.9) 
17.56(14.01,31.76) 
0.3 (-0.2,1.9) 
 
0.08 
0.07 
0.03 
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Table  5.3: Correlations among body fat measures in T1DM and Matched Controls 
  CSA SCAT VAT TAT WB-
FM(Kg) 
WB-FM 
Z-score 
A/G 
SCAT (mm
3
) 
 
0.98 
p=0.000 
 
      
VAT (mm
3
)
 
0.55 
p=0.003 
0.51 
p=0.006 
     
TAT (mm
3
) 
 
0.89 
p=0.000 
 
0.97 
p=0.000 
0.66 
p=0.000 
    
WB-FM(Kg) 
 
0.88 
p=0.000 
 
0.83, 
p=0.000 
0.51 
p=0.009 
0.82 
p=0.000 
   
WB-FM Z-score 
 
 
0.78 
p=0.000 
0.74, 
p=0.000 
0.69 
p=0.000 
0.75 
p=0.000 
0.96 
p=0.000 
  
A/G 
 
0.59 
p=0.002 
0.83, 
p=0.000 
0.54 
p=0.005 
0.79 
p=0.000 
0.51 
p=0.008 
0.60 
p=0.002 
 
BMA (FF %) 
 
0.09 
p=0.66 
0.03 
p=0.88 
0.42 
p=0.03 
0.12 
p=0.57 
0.08 
p = 0.68 
0.19 
P= 0.39 
-0.01 
p= 0.95 
 
5.4.3 Bone measured parameters 
Results of the measurement of bone mineral density and bone microarchitecture  in women 
with T1DM and that in age matched healthy controls are presented in Table 5.2. All results 
are presented as median and range. No significant difference in DXA and MRI measured 
bone parameters was evidenced between women with or without diabetes. In contrast, 
diabetic women with microvasculopathy demonstrated altered bone microarchitecture 
compared to healthy controls and those without microvasculopathy, but they did not show 
any significant differences in DXA measured bone parameters (data not shown). DXA-
measured BMD at different measured sites showed positive significant association with 
body weight, but this association was not observed between body weight and MRI-
measured bone microarchitecture parameters. AppTbN and appTbSp showed significant 
association with the age of the whole participants (r=-0.56, p=0.003; r=0.45, p=0.02, 
respectively) and disease duration (r=-0.49, p=0.04; r=0.54, p=0.03, respectively) in 
patients with T1DM. This association was not observed between age and disease duration 
with BMD at all measured sites. In women with T1DM, by using regression analysis the 
negative association of AppTbN and appTbSp with age and disease duration became 
insignificant (r
2
=33.54%). 
Correlation among different measured bone parameters are showed in Table 5.4. There was 
a significant correlation among DXA measured parameters at different skeletal sites 
(P<0.05). AppTbSp showed a significant inverse association to TB BMD (r= –0.40, p= 
0.04) and FN- BMC (r =-0.41, p=0.04) (Figure 5.1). Additionally, appTbSp showed a trend 
toward inverse association with TB BMC and FN-BMD(r=-0.37, p=0.07) (Figure 5. 1). 
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Table  5.4: Correlation among bone measures in T1DM and matched controls. 
 
AppBV/TV AppTb.N(m
m 
AppTb.Sp(m
m) 
AppTbTh(m
m) 
TB BMC 
(g) 
TB-BMD 
TB-Z 
score 
L2-L4 
BMC 
L2-L4 BMD 
L2-L4 
Z 
score 
L2-L4 
BMAD 
FN-
BMC 
(G) 
FN-
BMD 
TB BMC 
(g) 
0.24 
p=0.2 
0.25 
p=0.2 
-0.36 
p=0.07 
 
0.09 
p=0.6 
 
         
TB-BMD 0.34 
p=0.09 
0.23 
 p=0.2 
-0.40, 
p=0.04 
0.21 
p=0.3 
0.88 
 p=0.000 
 
        
TB-Z score 
 
 
0.23 
 p=0.3 
0.17 
p=0.4 
-0.25 
p=0.2 
0.11 
p=0.6 
0.71 
 p=0.000 
0.89 
p=0.000 
       
L2-L4 BMC 0.30 
p=0.1 
 
0.10 
p=0.6 
-0.33 
 p=0.1 
 
0.27 
 p=0.2 
0.78, 
p=0.000 
0.79 
p=0.000 
0.68 
p=0.000       
L2-L4 
BMD 
0.27, p=0.2 0.07 
p=0.7 
 
-0.27,p=0.2 0.28, p=0.2 
0.78 
 p=0.000 
0.89 
 p=0.000 
0.76 
 p=0.000 
0.89 
p=0.000      
L2-L4 Z 
score 
0.29,p=0.1 0.09 
 p=0.6 
 
-0.29, p=0.1 
0.28, p=0.2 
0.78 
 p=0.000 
0.87 
p=0.000 
0.76 
p=0.000 
0.90 
p=0.000 
0.99 
 p=0.000     
L2-L4 
BMAD 
0.13,p=0.5 
0.08 
 p=0.7 
 
0.14, p=0.5 0.10, p=0.6 
0.73 
 p=0.000 
0.81 
 p=0.000 
0.75 
 p=0.000 
0.71 
p=0.000 
0.91 
 p=0.000 
0.91, 
p=0.0
00 
   
FN-BMC 
(G) 
0.30, p=0.1 
0.28, 
p=0.1 
 
-0.41, 
p=0.04 
0.17, p=0.4 
0.83 
 p=0.000 
0.85 
 p=0.000 
0.72 
p=0.000 
0.87 
p=0.000 
0.84 
p=0.000 
0.83, 
p=0.0
00 
0.71, 
p=0.000 
  
FN-BMD 
0.35, 
p=0.08 
0.26 
p=0.2 
 
-0.37, 
p=0.07 
0.20, p=0.3 
0.61 
p=0.001 
0.72 
p=0.000 
0.68 
 p=0.000 
0.69 
 p=0.000 
0.75 
 p=0.000 
0.76, 
p=0.0
00 
0.72, 
p=0.000 
0.81, 
p=0.0
00 
 
FN-Z score 0.30, p=0.1 
0.26 
p=0.2 
 
0.29, p=0.1 0.15, p=0.4 
0.45 
p=0.02 
0.85 
p=0.000 
0.68 
 p=0.000 
0.57 
p=0.000 
0.65 
p=0.000 
0.67, 
p=0.0
00 
0.64, 
p=0.000 
0.68, 
p=0.0
00 
0.93, 
p=0.00
0 
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Figure  5.1: The relationship between apparent trabecular separation (appTbSp) as assessed by MRI and total body BMD (TB-BMD g/cm
2
), Total body BMC (TB-BMC (g)), 
Femoral neck BMD (FN-BMD (g/cm2)) and Femoral neck-BMC (FN-BMC (g)) in women with T1DM (filled circles) and controls (open circles). 
An inverse significant association between appTbSp and TB-BMD g/cm and FN-BMC (g) was observed 
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5.4.4 The relationship among different measures of body composition 
and bone measured parameters  
Table 5 showed the correlation among different measures of body composition and bone 
measured parameters. MRI measured bone parameters did not show any significant 
association with vertebral BMA.  However, VBMA showed significant negative 
correlation with TB-BMD, L2-L4 BMD and FN-BMD (r=-0.54, P =0.005; r= -0.40, 
p=0.04; r=-0.44, p=0.03; respectively) (Table 5.5) (Figure 5.2). This negative association 
was also observed with L2-L4 BMD Z score and FN- BMD Z score (r= -0.41, P= 0.04; r=-
0.40, P= 0.05; respectively) (Table 5.5) ( Figure 5.2). Femoral BMC (G) was also 
significantly associated with BMA (r= -0.425, P = 0.03) (Table 5.5) (Figure 5.2). When 
BMD, BMD Z score and BMC  were entered as a dependent variable and age, BMI, 
VBMA,SCAT,VAT and WB-FM as independent variables in regression model, vertebral 
bone marrow fat was a significant predictor of BMD (p<0.05) for all models (Table 5.6). 
On the other hand, Vertebral BMA showed positive correlations with VAT (r=0.42, 
p=0.03) (Table 5.5) (Figure 5.3). TB-BMD Z score negatively correlated with VAT (r=-
0.46, p=0.02) (Table 5.5) (Figure 5.3).  Because VAT is associated with TB-BMD Z score, 
we controlled for VAT and TB-BMD Z score using multivariate analysis. After controlling 
for TB-BMD Z-score, the correlation between vertebral bone marrow fat and VAT became 
insignificant (P = 0.28). After controlling for VAT, the correlation between vertebral bone 
marrow fat and TB- BMD Z score remained significant (P = 0.04). 
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Table  5.5:  Correlations among bone measures, BMA, and body composition in T1DM and Matched Controls 
 
 
 
 
 
 
 
 
 
 CSA SCAT VAT TAT Total tissue fat Z- score fat A/G  BMA 
TBMD g/cm2 
TB- BMD z score 
TB BMC (g)  
0.02, P= 0.9 
-0.21, P= 0.3 
0.11, P= 0.6 
-0.051,P= 0.8 
-0.259,p= 0.2 
-0.052,P= 0.8 
-0.179,P= 0.4 
-0.457,P= 0.022 
-0.182, P=0.385 
-0.143,P= 0.5 
-0.378,P = 0.06 
-0.117,P= 0.6 
0.060,P =0.8 
-0.176,P= 0.4 
0.212,P= 0.3 
0.012,p=0.6 
-0.199,p=0.4 
0.191,p=0.4 
0.062,P=0.8 
-0.128,P=0.5 
0.008,P=0.9 
-0.544,P=0.005 
-0.491,p=0.013 
-0.284,p= 0.2 
L2-L4 BMD (g/cm2)  
L2-l4 BMD  Z score 
L2-L4 BMC (G) 
BMAD 
0.14, P= 0.5 
0.11, p= 0.6 
-0.01, p= 1 
0.25, p= 0.2 
0.083,p= 0.7 
0.059,p= 0.8 
-0.108,p= 0.6 
0.193,p= 0.3 
0.042,p= 0.8 
0.023,p= 0.9 
-0.122,p = 0.5 
0.202,p= 0.3 
0.004,p= 0.9 
-0.022,p= 0.9 
-0.197,p= 0.3 
0.137,= 0.5 
0.129,P=0.5 
0.114,P=0.6 
-0.018,P=0.9 
0.283,P=0.2 
 
0.155,p=0.5 
0.146,p=0.5 
-0.013,p=0.9 
0.162,p=0.5 
0.226,P=0.3 
0.227,P=0.3 
0.061,P=0.8 
0.349,P=0.09 
-0.405,P= 0.04 
-0.410,P= 0.04 
-0.347,P= 0.08 
-0.382,P= 0.06 
Femoral N- BMD (g/cm2)  
FN- BMD Z-score   
FN- BMC (G) 
-0.050,P= 0.8 
-0.232,p= 0.2 
-0.009,p = 1 
-0.122,p= 0.5 
-0.274,p= 0.2 
-0.075,p= 0.7 
-0.105,p= 0.6 
-0.201,p= 0.3 
-0.169,p= 0.4 
-0.169,p= 0.4 
-0.304,p= 0.1 
-0.151,p= 0.5 
0.039,p=0.8 
-0.136 ,p=0.5 
0.045,p=0.8 
 
-0.021,p=0.9 
-0.211,p=0.3 
0.032,p=0.9 
0.067,P=0.7 
-0.027,P=0.9 
0.008,P=-0.9 
-0.444,P= 0.03 
-0.400,P= 0.05                  
-0.425,P = 0.03 
App BV/TV 
App TbN  (mm-1) 
App TbSp (mm) 
App ThTh (mm) 
-0.300,p=0.1 
-0.404,p=0.04 
0.369,p=0.06 
-0.001,p=0.9 
-0.279,p=0.2 
-0.262,p=0.2 
0.315,p=0.1 
-0.032,p=0.9 
-0.200,p=0.3 
-0.292,p=0.1 
0.312,p=0.1 
0.090,p=0.6 
-0.289,p=0.1 
-0.269,p=0.2 
0.348,p=0.07 
-0.021,p=0.9 
-0.139, p=0.5 
-0.033,p=0.9 
0.120,p=0.6 
-0.019,p=0.9 
-0.072,p=0.7 
0.072,p=0.7 
0.003,p=0.9 
-0.017,p=0.9 
-0.071,p=0.7 
-0.095,p=0.6 
0.130,p=0.5 
0.117,p=0.7 
-0.287,p=0.1 
-0.280,p=0.2 
0.358,p=0.08 
-0.028,p=0.9 
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Table  5.6:  Regression model with BMD and FN-BMC as the dependent variable  
Independent variable  
Dependent variable  1 2 3 
TBMD g/cm2 
TB- BMD z score 
-0.00348 (0.01) 
-0.0422 (0.01) 
 
-0.00374 (0.006) 
-0.0396 (0.02) 
-0.00361(0.02) 
-0.0396 (0.02) 
L2-L4 BMD (g/cm2)  
L2-l4 BMD  Z score 
-0.00680 (0.03) 
-0.05739 (0.03) 
-0.00743 (0.02) 
-0.0624 (0.02) 
 
-0.00864 (0.02) 
-0.0720 (0.02) 
Femoral N- BMD (g/cm2)  
FN- BMC (G) 
-0.00452 (0.02) 
-0.18919 (0.02) 
-0.00466 (0.02) 
-0.1951 (0.02) 
-0.00541(0.01) 
-0.1976 (0.03) 
  
Note: Values are regression coefficients and p-value are in between the bracket. Abbr.: TB BMD; total body bone mineral density: L2-L4 BMD; lumbar spine bone mineral density: 
FN-BMD; femoral neck bone mineral density: FN-BMC; femoral neck bone mineral content. 
 
Age is the covariate tested in each model: 
Model 1 = VBMA + age + BMI 
Model 2 = VBMA + age + WB-FM.  
Model 3 =VBMA+ age + SCAT+ VAT.   
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Figure  5.2:  The relationship between VBMA and BMD and BMC at different measured sites (Whole body, FN, L2-L4) in women with T1DM (filled circles) and controls 
(open circles). 
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Figure   5.3: The relationship between visceral adipose tissue (VAT) as assessed by MRI and vertebral bone marrow adiposity (FF %) and Total body BMD (TB-BMD 
(g/cm
2
)) in women with T1DM (filled circles) and controls (open circles).  
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5.5 Discussion  
To our knowledge, this is the first study to characterize relationships between detailed 
measures of body composition with DXA and MRI measured bone parameters in young 
healthy women and women with T1DM. Our study demonstrated that young women with 
T1DM had greater adiposity parameters compared to the healthy controls. Moreover, our 
data suggest that vertebral BMA is negative predictor of BMD despite normal BMD and 
trabecular bone microarchitecture.  
The key finding in this study was demonstration of a striking inverse relationship between 
DXA measured bone parameters at different measured skeletal sites and BMA. Several 
studies have shown that BMD and BMA are reciprocally related in diverse population, 
e.g., anorexia nervosa, glucocorticoid therapy, healthy children, young adults, elderly and 
other osteoporotic conditions (443, 452, 457-461, 463, 537, 553, 554). Rodent models of 
T1DM showed that higher BMA, which occur in diabetes, correlates with decreased bone 
biomechanical quality and increased fractures (249), However, the relationship of BMA 
and BMD in people with T1DM has scarcely been studied, our finding is consistent with a 
recent study in type one diabetic people reported that BMA was not altered by T1-diabetes, 
but was inversely related to BMD (369). The current findings provide additional support at 
the macroscopic level for an inverse relationship between BMA and BMD. Since 
osteoblasts and adipocytes share a common precursor (i.e., the MSCs in bone marrow) 
(119, 194, 555), it is hypothesized that an increase in adipogenesis may impair bone 
integrity through  reducing osteoblastogenesis (194). On the other hand, we did not 
observe this significant correlation with the measures of bone microarchitecture. There are 
few studies that have examined the association of bone microarchitecture with BMA (556, 
557). Although, the effect of BMA on bone is different depending on the bone parameter 
of interest, bone marrow is highly concentrated in trabecular bone and the correlation 
between BMA and trabecular bone might be stronger than that with BMD, therefore, the 
lack of this association in our study might be due to small sample size. More studies with 
larger sample sizes are needed on the association between BMA and skeletal health. In 
particular, no prospective study has related BMF to fracture, the most important clinical 
consequence of osteoporosis. 
In the present study, we observed an inverse relationship between BMA and BMD in an 
anatomically matched region (i.e., spine BMA and spine BMD), and non-anatomically 
matched region (i.e. spine BMA with femoral and total body BMD). Therefore, it is 
reasonable that both local level MSC differentiation and systemic level hormonal factors 
contribute to the observed inverse relationship between BMA and BMD. Our results add to 
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the body of literature that supports the competitive relationship between marrow fat and 
bone. Future studies may investigate potential targets to prevent and treat osteoporosis at 
both the MSC level and hormonal level.   
In addition to the detrimental effect of BMA on bone health, VAT was negatively 
correlated with TB-BMD Z score and positively correlated with BMA, but this association 
became insignificant after regression analysis. The role of VAT on bone has not been 
elucidated yet; previous studies in other population have shown inconsistent association 
between body composition and bone measures (360, 494, 558-564). These studies were 
limited by the use of dual-energy x-ray absorptiometry (DXA), which is unable to 
distinguish VAT from SAT. In our study, despite high correlation between the DXA and 
MRI measured parameters of body composition, we found differences in their relation with 
BMA and bone measured parameters. Our data are in consistent with some reports (360, 
564) that did not show any association between body composition assessed by DXA and 
BMD. In contrast, recent studies have reported that visceral fat has negative effects on 
bone health and correlates inversely with BMD and bone structure (486, 488-493). 
However, in our data we did not find this association with bone microarchitecture. In 
consistent with our findings, Bredella et al. (491) concluded that both BMA and VAT have 
detrimental effect on BMD whereas there was no difference in BMD, but these results 
remained significant even after adjustment for BMD. The effect of visceral adiposity is 
associated with dysregulation of the GH/IGF-I which is important regulators of bone 
homeostasis and importance for the maintenance of bone mass (506). Thus, further studies 
with larger sample size are needed to clarify this association in women with T1DM. 
Another interesting finding, in consistent with Shanbhogue, V.V., et al (163) we have 
demonstrated that 3T MRI can detect deficit in bone microarchitecture which was only 
apparent in T1DM with microvasculopathy compared with the healthy controls. In 
contrast, we did not observe any differences in DXA measured bone parameters between 
T1DM with or without microvsculopathy and healthy controls. The discrepancy between 
DXA and trabecular bone results is consistent with previous studies in other population 
(153, 159, 565). Because DXA could not detect lower BMD in women with T1DM 
compared with the controls; the results suggest that MRI assessment of microarchitecture 
may potentially be more sensitive than DXA assessment of areal BMD as a method to 
assess changes in bone quality related to diabetes mellitus. 
Although, there was discrepancy between DXA and MRI to determine bone deficit in 
severely affected diabetic women compared to healthy controls, we found minor positive 
correlation between the bone DXA-based measures and MRI-based measures. Previous 
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studies have reported this correlation (403, 431, 432, 566, 567). In our study the correlation 
was not observed with all MRI parameters, non-anatomically matched region was 
limitation of this study comparing to what previously described (567). The positive 
relationship between the MRI-based measures and the DXA-based measures provides 
some validation for the assessment of trabecular bone using MRI. Additionally, this minor 
correlation indicates that the MRI method of bone quantification is providing additional 
structural properties from trabecular bone that cannot be measured by DXA.  
5.6 Conclusion  
Our study group was relatively small and therefore conclusions must be drawn with some 
caution. However, in this population-based study group, with carefully matched control 
subjects, women with T1DM demonstrated greater pattern of adiposity compared to 
healthy controls. Additionally, we found that vertebral BMA was a significant predictor of 
BMD, whereas there was no difference in BMD, suggesting a distinct role of BMA in 
skeletal integrity 
More importantly, in T1DM our study has demonstrated the feasibility of 3-T MRI to 
differentiate between women with and without microvasculopathy. On the other hand, 3-T 
MRI-derived measures showed positive correlations with DXA-derived BMD, suggesting 
that the two methodologies assess similar and complementary characteristics of bone. 
However, this is a small pilot study, and further validation with a large cohort is necessary. 
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 Discussion, conclusion and future perspective 
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6.1 General discussion  
The studies presented in this thesis are the first clinical studies to investigate bone health 
by using high resolution micro-MRI (3T) in young women with childhood-onset T1DM 
compared with healthy women without T1DM. These studies add a number of novel 
findings to the knowledge base.  
Deficit in trabecular bone microarchitecture in young adult women with childhood-onset 
T1DM compared with women without T1DM was demonstrated in Chapter 3. This cross-
sectional study elucidated some possible underlying mechanisms that might contribute to 
deficits in trabecular bone microarchitecture, including: (1) patients with T1DM had a state 
of low bone turnover with reduced bone formation and resorption compared with healthy 
age matched controls; (2) deficit in the GH/IGF-1 axis; (3) associated diabetic 
microvascular complications. The deleterious effect of T1DM on trabecular bone 
microstructure is well established in rodent models of T1DM (568, 569). Currently, there is 
no published research about using MRI for studying trabecular bone microarchitecture in 
people with T1DM. However, as described in the introduction, two studies in humans have 
evaluated trabecular bone microarchitecture using HR-pQCT and histomorphometry and 
mCT techniques in adults with T1DM compared with healthy controls and the results were 
conflicting(163, 570). Since this study began, a single cross-sectional study has been 
published that evaluated bone structural parameters using HR-pQCT in adults with T1DM 
in comparison with healthy controls (163).  This study reported that trabecular bone deficit 
was not characteristic of all T1DM patients, but of a subgroup characterized by the 
presence of microvascular complications. This finding is confirmed by our study; although 
bone deficits were observed in all the participants with T1DM, it was remarkably 
noticeable in those with microvascular complication.  On the other hand, Armas et al. 
(570) reported no abnormalities in trabecular bone histomorphometric or mCT variables in 
a small cohort of adult with T1DM (n=18) in the absence of detectable microvascular 
complications. However, it was possible that the sample size in this study was not 
sufficient to detect between-group differences in multiple measures of trabecular bone 
microarchitecture. Previous ex vivo and in vivo studies have shown that trabecular bone 
microarchitecture parameters play an important role in the determination of bone strength 
and structural changes associated with bone pathology (403, 434, 571). Moreover, previous 
studies have shown that MRI-measured trabecular microarchitecture parameters are 
effective in differentiating subjects with and without fragility fractures (152). Therefore, 
our results suggest that the observed compromised trabecular bone microarchitecture may 
provide an explanation for increased fracture risk in women with T1DM. Further large 
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prospective studies will be required to determine whether MRI can potentially improve 
fracture prediction in this population. 
Our study identified the association of microvascular complications with compromised 
bone microarchitecture as possible underlying mechanisms of diabetic osteopathy. This has 
been demonstrated in T1DM (163) as well in T2DM (572), and similarly our longitudinal 
study (Chapter 5) has confirmed this association. Although our sample size of participants 
with microvascular complications was very small (n=8), trabecular bone deficit was more 
noticeable in this group compared with those without microvascular complications and 
healthy controls. Interestingly, by using regression model and adjusting for multiple 
variables (age, BMI, disease duration, age of diagnosis, glycaemic control), microvascular 
complication was negative significant predictors of reduced bone volume. Thus, our data 
are consistent with abundant evidence which suggests that patients with T1DM are at 
significant risk for greater bone loss from diabetic complications such as vascular disease, 
retinopathy, nephropathy, and neuropathy (161, 162). The independent association of 
microvascular complications with reduced BMD and higher fracture risk has been reported 
previously (342, 345, 573-575). Some studies  reported higher fracture risk in T1DM 
patients with microvascular complication, independent of BMD (161). This discrepancy 
could be explained by frequent falls that might result from associated microvascular 
complications (576). Therefore reduced BMD and compromised bone microarchitecture in 
combination with an increased susceptibility for falls likely explains the higher fracture 
risk in patients with T1DM.  
Moreover, this study confirms the findings from previous reports that suggest that bone 
deficit in T1DM patients is associated with low bone turnover with reduced bone 
resorption (163, 224, 369) as described in section 1.4.3, and is accompanied by an inactive 
GH/IGF-1 pathway compared with healthy controls as described in section 1.4.4 (164). In 
our study this mechanism is elucidated and confirmed through the negative association of 
trabecular separation with total osteocalcin and ALS in women with T1DM. This study 
was the first to find the association between the markers of bone metabolism and trabecular 
bone microarchitecture parameters in women with T1DM. Insulin-like growth factor-1 
(IGF-1) is an important local factor regulating bone turnover, promoting the proliferation 
and differentiation of osteoblasts, and its activity is modulated through its binding to 
proteins such as IGFBP-3 and ALS. Therefore, long-standing low bone turnover with an 
impaired IGF system which observed in T1DM may result in defective micro damage 
repair and increased bone micro crack accumulation that contributes to excess skeletal 
fragility and thus increased fracture risk. In non-diabetes subjects, bone turnover markers 
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are correlated with bone deficit and predicted fragility fractures (577) and accordingly 
bone turnover may be a marker of fracture risk in T1DM. However, this is not observed yet 
in T1DM. Additionally, IGF-1 is reported as a potential fracture predictor independent of 
BMD in postmenopausal women with T2DM (275). Therefore, it is possible that IGF-1 is 
also a predictor in T1DM. Further studies with larger sample sizes are needed to evaluate 
the association of fracture risk with trabecular bone deficit and bone metabolism to fully 
understand this mechanism.  
Other possible explanations for bone deficit in young women with childhood onset T1DM 
include longer disease duration and poor glycaemic control. As mentioned in section 1.4.4, 
the existing data regarding these factors are still conflicting. Despite our study participants 
having childhood onset T1DM at a young age, the median age at diagnosis was 9.7 years 
(0.46, 14.8) and the median duration of T1DM was 12.8 years (7.9, 34.2), we did not 
observe any significant association of the observed bone deficit with age of diagnosis or 
disease duration. This finding may provide support to the inherent concept which suggests 
that childhood onset T1DM results in impairment of attaining peak bone mass and results 
in predisposition to more fragile bones later in life.  
Additionally, the influence of glycaemic control on bone has not yet been well established 
as clinical studies exist to both support (346, 354) and rebut this idea (319, 564), but it has 
been well clarified in in vitro studies (226). The majority of the previous studies measured 
HBA1c at a single time point, which does not reflect long term hyperglycaemia. There are 
only a few studies that investigated repeated measures of HBA1c, and chronically poor 
glycaemic control has been found to correlate with low BMD (358, 370). Although our 
participants had poor glycaemic control and median HBA1c was 9.8% (5, 16), a 
relationship between HbA1c and MRI measured parameters was not demonstrated in the 
cross-sectional design. It has been shown that HbA1c levels above 9% compared with 
levels of 6-7% increase the risk of hip fracture (578). Our study was limited by the small 
sample size and limited range of HBA1c. Clearly, larger studies are required in the future 
to comprehensively establish how chronic hyperglycaemia influences trabecular bone 
parameters and other bone-related surrogate markers in particular fracture incidents. On the 
other hand, the adverse effects of chronic hyperglycaemia may be related to the 
accumulated AGEs (Pentosidine) which may impact bone quality (18). However, in the 
current study we did not observe any association of bone parameters with pentosidine. 
Larger sample size is needed to clarify this association.  
Increasing BMA is another underlying pathophysiological mechanism for bone deficit in 
T1DM (204, 249), but it has not yet been clarified in patients with T1DM. Although our 
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study participants had greater abdominal adiposity parameters compared with healthy 
controls, consistent with those reported by Slade et al. (369), our baseline data did not 
allow us to demonstrate an abnormality of BMA in patients with T1DM. Additionally, we 
did not observe any association of BMA with MRI-measured trabecular bone parameters 
and biochemical markers of bone turnover, adiposity or GH/IGF-1 axis. The cross-
sectional design and small sample size did not allow us to explore these associations; it is 
possible that a longitudinal design with larger sample size would allow these associations 
to be identified.   
Based on this hypothesis, the study described in Chapter 4 was designed to explore the 
longitudinal changes in MRI-based measurements of bone health and adiposity in young 
women with T1DM compared with healthy controls. Furthermore, this study examined the 
possible underling mechanism that might be associated with the expected changes. An 
advantage to using a prospective study design over a cross-sectional design is that insight 
can be gained into the time course of skeletal changes in T1DM compared with healthy 
controls, improve understanding of the bone pathology in diabetes and facilitate the design 
of future intervention studies aimed at preventing bone loss and thus reduce fracture risk.  
Although there were no differences between groups for bone marrow adiposity at the 
baseline, and no changes over time, this study has shown for the first time a clear positive 
association between changes in HBA1C and BMA in women with T1DM. This finding is 
reinforced by our baseline data which was showed positive association between current 
HBA1c and BMA. There is a wealth of knowledge about the process and factors involved 
in adipogenesis and its association with bone loss in relation to T1DM; however, the 
current understanding of adipogenesis has largely emerged from in vitro studies (204). 
Consistent with our findings, it has been suggested that poor glycaemic control is a 
potential factor for accelerating adipogenesis in diabetes (579). It is also possible that the 
states of GH resistance associated with persistent hypoinsulinemia and poor glycaemic 
control might underlie mechanisms of increased bone marrow adiposity in T1DM. 
Currently, there are no longitudinal studies evaluated BMA in humans with T1DM, and 
given the extent of variation in our data, a larger sample size may assist in conclusively 
evaluating this association. Similar to our finding, poor glycaemic control has been 
demonstrated to lead to increased bone marrow adiposity in T2DM (466). There is 
increasing evidence of a direct link between BMA with  bone strength (467) and fracture 
risk (464), so this is an important finding that may provide us not only with an 
understanding of diabetic adipogenesis but also with designing future intervention studies 
aimed at preventing bone loss. 
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Unlike BMA, the average changes were lower for the bone microarchitecture parameters 
and did not show any association with the changes of glycaemic control over a one year 
period. However, despite the wide variability of our data, the median of the percentage of 
these changes was still lower than that reported in healthy volunteers (411). With mixed 
modelling analysis, we observed that age was a negative predictor of these changes. This 
finding is consistent with recent a report which showed that alteration in trabecular 
microarchitecture occurs with aging (580).  Interestingly despite the relatively smaller 
number of the cases, the study showed that bone deficit still exists in diabetic women 
compared with controls and this deficit is particularly marked in those with microvascular 
disease. These differences remained even after correction for age, BMI and abdominal 
adiposity parameters. The association of trabecular bone deficits with microvascular 
disease but not with glycaemic control suggested that both of these factors work 
independently. Theoretically, the lack of association between the changes in trabecular 
bone parameters and short-term changes in glycaemic control might indicate that poor 
glycaemic control at the onset and the initial years in the development of microvascular 
complications could dictate the long-term consequences to skeletal integrity. Currently, 
there are no longitudinal studies evaluating the changes of trabecular bone 
microarchitecture in T1DM, but because BMD measurements are related to trabecular 
bone microarchitecture measurements (431), prospective studies on BMD changes in 
patient with T1DM (345, 346, 535, 581-583) are informative and might help in 
understanding our findings. Consistent with our findings, one study has shown that young 
women with T1DM have lower bone mineral density that persists over time (346). 
However, some studies suggest that greater longitudinal decline in BMD occurs over time 
which was particularly observed in males with T1DM and those who develop 
microvascular complications over the follow-up period (345, 534, 581, 583). The 
inconsistency between existing studies may be due to the variability of included 
populations, as some data were not analysed by gender (583), and some studies observed 
that an increase in BMI and the improvement of glycaemic control may have a protective 
effect and contribute to the stabilization of BMD (345). Small sample sizes (583) and 
relatively short period of follow up (582) were other confounding factors. Overall, the lack 
of changes in the measures of trabecular bone microarchitecture in this study support the 
evidence that greater loss in BMD occurs within the years of achieving peak bone mass at 
the time of T1DM onset, which may explain why women with type 1 diabetes have 
skeletal fragility and an increased risk of fractures later in life. However, the small sample 
size, short period of follow up and wide variability of the data limited us in making a 
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definitive conclusion.  Further longitudinal studies with a longer follow up interval 
including men and women and children at the time of T1DM onset are clearly warranted. 
 
There is a growing body of evidence to indicate the association between fat and bone 
health. However, the way in which fat at different locations directly or indirectly 
influences bone strength has not been clarified to date. In addition to the systemic adverse 
effect (584), the location of fat deposition is implicated in adverse bone outcomes. 
Essentially, increased BMA and greater visceral adipose tissue (VAT) are risk factors of 
reduced BMD, altered trabecular microarchitecture and increased fracture risk in a variety 
of populations (460, 469, 482, 491, 492, 552, 556, 557, 585). Given that T1DM is 
associated with greater body fat composition and abdominal adiposity which was reported 
previously and observed in our study as well, this study was designed to assess the detailed 
adiposity determinants of bone health in healthy young women and women with T1DM. In 
addition to MRI, we used DXA scans to measure the total body composition and BMD in 
both T1DM and healthy controls. Furthermore, our secondary aim was to compare the 
feasibility of MRI compared with DXA scans in detecting bone abnormality in those with 
T1DM compared with healthy controls. To our knowledge, this is the first study to 
characterize the relationship between detailed measures of body composition with DXA 
and MRI measured bone parameters in young healthy women and women with T1DM. A 
number of interesting findings emerged from this study.  
Firstly, though the sample size was small, our study demonstrated that young women with 
T1DM still had greater adiposity parameters compared with the healthy controls.  
Additionally, our data suggested that vertebral BMA is an independent negative predictor 
of BMD at both anatomically and non-anatomically matched regions, but we did not 
observe this association with trabecular microarchitecture parameters in the current study 
or in our previous studies (Chapter 3 and 4). This finding is consistent with previous 
studies that reported an association of BMA with decreased BMD and increased fracture 
risk in a diverse range of clinical conditions (Section 1.5.2.4.2). Consistent with our 
finding, one study on T1DM reported this inverse association between BMA and BMD 
(369). The reciprocal association of BMA and bone parameters is potentially related to 
altered mesenchymal stem cell differentiation into osteoblasts or adipocytes (199).  The 
normal aging process and a variety of metabolic diseases are suggested to affect this 
process and favour adipogenesis versus osteoblastogenesis. This suggests that increased 
BMA will adversely affect bone metabolism and thus the bone strength surrogate markers, 
including BMD and trabecular microarchitecture parameters. The lack of association 
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between BMA and trabecular microarchitecture in our study might be due to the small 
sample size, and therefore more studies with larger sample sizes are needed to clarify this 
association.   
The second result to be considered from our analysis was the significant positive 
association of VAT with BMA (r = 0.42, p = 0.03) and TB-BMD Z score (r = -0.457, p = 
0.02), but only the association of BMA and TB-BMD Z score remained significant (p = 
0.04) in the adjusted model. The positive association of VAT and BMA was also observed 
in our baseline data, but the lack of DXA results at the baseline unable us to correct it for 
BMD. This is important finding and support the emerging hypothesis that suggests that the 
developmental origin of BMA may be more similar to VAT. Lack of the association 
between abdominal adiposity measures and bone parameters in our study may be due to 
small sample size. 
Another interesting finding was the discrepancy between DXA and MRI measured bone 
parameters in detecting bone deficits in T1DM patients with microvascular complications 
compared with those without microvascular complications and healthy controls. This 
discrepancy is consistent with previous studies in other populations (153, 159, 565).  This 
finding suggested that MRI of trabecular bone microarchitecture may therefore serve as a 
novel tool for assessing BMD-independent skeletal fragility in T1DM patients. 
Additionally, the lack of good correlation between MRI- measured trabecular parameters 
and DXA-measured BMD support the concept that MRI provides different information 
about bone quality beyond that provided by DXA. Thus, assessment of BMD and 
trabecular bone microarchitecture gives a more complete picture of bone health in people 
with T1DM. 
 
6.2 Final conclusion 
The initial hypotheses were evaluated and conclusions based on these hypotheses were: 
1. Patients with T1DM had altered trabecular bone microarchitecture, low bone 
turnover state and a deficit in the GH/IGF-1 axis compared with women without 
T1DM. A difference in BMA was not discovered between cases and controls as the 
study was not powered to detect this difference.  
2. The deficit in bone microarchitecture in patients with T1DM was associated with 
abnormal levels of biochemical markers of bone metabolism and the presence of 
microvascular complications.  However, there was no association between this 
bone deficit and adiposity measures. 
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3. Although, there were no significant changes over a one year period in the measures 
of bone microarchitecture and adiposity in women with T1DM compared with 
women without T1DM, deficits in bone microarchitecture persisted. 
4. Different body adiposity measures have different effects on DXA and MRI-
measured bone parameters. 
5. Vertebral BMA is negatively correlated with BMD and positively with VAT, but 
we did not demonstrate any association between VAT and DXA and MRI -
measured bone parameters. 
6. MRI-measured bone parameters were able to differentiate between T1DM patients 
with microvascular complications and those without microvascular complications, 
which was not detected by DXA.  
7. Although we did not observe an association of markers of diabetic control and 
other possible clinical factors with bone microarchitecture and biochemical markers 
of bone metabolism and adiposity, BMA was positively correlated with current 
HBA1c, moreover, improvement in diabetes control was associated with a 
reduction in bone marrow adiposity. 
 
Overall, this collection of work provides preliminary evidence that compromised bone 
microarchitecture, not deficits in BMD, is the underlying basis for excess skeletal fragility 
in young women with childhood onset T1DM. Moreover, our studies provide additional 
clues supporting this hypothesis including the association of altered trabecular 
microarchitecture with low bone turnover accompanied with reduced bone formation and 
resorption, deficit in the GH/IGF-1 axis and associated microvascular complications. 
Furthermore, although we did not demonstrate abnormality in vertebral BMA, the 
observed inverse association between changes in glycaemic control and changes in 
vertebral BMA may further our understanding of diabetic adipogenesis which may explain 
excess skeletal fragility in T1DM and point at possible beneficial effects of glycaemic 
control on bone health in patients with diabetes. This was further reinforced by an 
independent significant association of BMA with DXA-measured BMD at both 
anatomically matched and unmatched regions. Moreover, our preliminary finding of a 
positive association of BMA with VAT but not with BMI and the other body fat depots 
suggests distinct metabolic roles for visceral fat and other body fat depots, and further 
suggests that the developmental origin of BMA may be more similar to VAT than SCAT. 
More importantly, our observed positive correlation between VAT and BMA irrespective 
of BMD may provide clues to the underlying mechanism of the detrimental effects of 
  174 
 
visceral fat on BMD and suggests a distinct role of BMA in skeletal integrity. The 
discrepancy between DXA and MRI-measured bone parameters in detecting bone deficits 
in T1DM with microvascular complications compared with those without microvascular 
complications and healthy controls highlights the sensitivity of MRI-measured bone 
parameters in identifying structural differences in relatively small cohorts and suggests that 
trabecular micro architectural parameters might be used as an additional tool to detect 
patients with poor bone quality who cannot be detected by DXA. 
Collectively, these data have improved our understanding of how T1DM adversely impacts 
bone health, and clearly explain that T1DM is associated with structural bone abnormality 
that could not be captured with DXA. Therefore, the clinicians should be aware of the 
association between diabetes and osteoporosis, which is not reflected by the BMD. Thus, if 
osteoporosis is suspected more investigations should be done to rule out any suspected 
fracture. The suggestion that bone loss may be another manifestation of diabetes-related 
microvascular disease raises the possibility that assessment of bone health may become a 
routine component of screening for health complications in diabetes. Given the advances in 
routine clinical MRI imaging, our studies clearly show that MRI and MRS are both 
sensitive techniques for measuring bone quantity and bone quality, and can be readily 
translated into clinical practice and are likely to lead to improved targeted prevention of 
fractures in T1DM. Because T1DM is most commonly diagnosed in childhood and 
adolescence, the early assessment of bone health and skeletal risk factors in children with 
T1DM will be important, in an effort to maximise the acquisition of peak bone mass in 
these patients, and to minimise the impact of T1DM on the skeleton going forward.   
6.3 Strengths and Limitations 
The studies presented in this thesis have important strengths that should be highlighted.  To 
our knowledge, this is the first study that has examined trabecular bone microarchitecture, 
BMA and the associations among fat distribution and bone outcomes in young women 
with childhood-onset T1DM using both high resolution MRI and DXA at the same time. 
Moreover, the well-characterised study population represents a significant strength. 
However, we acknowledge certain limitations in our studies. First, the sample size was 
relatively small. The initial power analysis was performed to detect differences in 
trabecular bone parameters (434). There was no option to calculate the power for a study of 
BMA to discriminate individuals with T1DM because data were lacking. Additionally, this 
relatively small sample size might be responsible for the lack of statistical significance in 
the relationship between BMA with trabecular bone parameters and biochemical markers 
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of bone metabolism, GH/IGF-1 axis and adiposity. Moreover, it is possible that additional 
underlying mechanisms would be discovered if a larger number of patients were evaluated; 
however, the significant findings that were noted suggest that there was adequate power to 
identify several important differences. Second, the cross sectional study design of Chapters 
3 and 5 limits our ability to prove causality concerning the observed significant 
associations. To facilitate recruitment, we collected non-fasting blood samples; however, 
markers of bone turnover and especially markers of bone resorption, such as CTX, show a 
diurnal variation and may be affected by fasting status. Moreover, we did not collect blood 
samples at the second visit, and this limited our ability to study the longitudinal changes of 
biochemical markers of bone turnover, adiposity and GH axis, and to find their association 
with the changes in MRI-based measurements. In addition, studying only one skeletal site 
limits the ability to generalise our findings to the other skeletal sites.  The lack of a 
sufficient number of cases with other microvascular complications limited the investigation 
of this association in the current study. Furthermore, many missing HBA1c measurements 
over a longer time period of 5 to 10 years in most of the cases did not allow us to study the 
long term effect of glycaemic controls on MRI-measured parameters. Despite the 
promising results of using micro MRI and MRS to better understand diabetic bone disease, 
there are still technical challenges to be overcome. In particular, the scan time was 
relatively long at 10 minutes, which could be restrictive in certain patient groups, and may 
increase the chance for motion artefact. Though we did not notice motion artefact on our 
images, in order to increase the applicability of the technique as part of routine clinical 
investigations, it will be necessary to reduce the scan time.  Additionally, MRI has certain 
disadvantages in measuring trabecular bone microarchitecture as mentioned in the 
introduction section 1.6.3.4, e.g. partial volume effects, produced when imaging trabeculae 
that are smaller than the spatial resolution, may confound and overestimate measures of 
bone microarchitecture such as BV/TV and Tb.Th. Furthermore, MRI is technically 
demanding, and does not provide the option of measuring BMD and therefore we cannot 
compare or adjust for bone density at the measured site, and there are fewer reference data. 
Finally, measuring trabecular structures in the tibia and BMA in the lumbar spine is 
somewhat of a limitation, as it limited our ability to find the relationship between both 
parameters in the same location. This was not possible due to technical reasons – MRS was 
unsuccessful in the tibia, and the small FOV used in micro MRI was not compatible with 
spine imaging. 
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6.4 Future Perspectives   
The studies presented in this thesis provide novel promising results on structural bone 
quality in young women with childhood onset T1DM that should be explored in future 
research studies. Firstly, future investigations should evaluate the association between MRI 
measured parameters and DXA data in cases of incident fractures which are the most 
important clinical consequence of osteoporosis. Given that hip fractures are reported to be 
more common in people with T1DM, examining the trabecular microarchitecture and 
BMA at this site would be more informative. 
Moreover, a numbers of underlying pathophysiological mechanisms have emerged from 
the studies included in this thesis. More studies with larger sample sizes are needed to 
confirm these mechanisms and their relationship to the increased fracture risk observed in 
T1DM. Given the wide range of T1DM-related microvascular complications, there is a 
need to investigate the association of different microvascular abnormities with MRI 
measured parameters. The data from our study could be used for future sample size 
calculations for a larger prospective study involving a wide spectrum of diabetic related 
microvascular complications. To draw definitive conclusions about the association of bone 
turnover markers with MRI-measured parameters, future large longitudinal studies are 
needed to study the changes of bone turnover marker and their association with changes in 
MRI parameters and fracture.  
The study presented in Chapter 4 provides feasibility data but obviously larger longitudinal 
studies with longer time intervals are required to study the evolution of T1DM-related 
trabecular bone microarchitecture and marrow adiposity changes. In addition, more studies 
are also needed to confirm our findings regarding the potential mechanisms responsible for 
decreasing BMA in young women with T1DM. Good glycaemic control may decrease 
BMA; a future study looking at the effect of intensive insulin therapy may confirm this 
association. 
The cumulative evidence suggests that changes in bone architecture are beginning early in 
childhood, particularly in those diagnosed at very young ages. Additionally, the increased 
fracture risk in T1DM has been encountered in both sexes and even in young children. 
Therefore, a definitive prospective study with adequate power comparing trabecular bone 
microarchitecture and BMA in children and adults of both sexes with T1DM and fragility 
fractures versus non-fracture T1DM controls is clearly warranted. 
Altered bone marrow fat composition expressed as saturated, unsaturated and residual fat 
was  related to T2DM and fragility fractures in postmenopausal women and women with 
T2DM (464). Consequently, there is a need to examine bone marrow composition in 
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patients with T1DM as well, and it will be more informative in those with fractures. The 
MRS acquisition in the current studies was not optimised to allow detection of saturated, 
unsaturated and residual fat. For future studies, the MRS pulse sequence should be 
optimised to allow these measurements to be made. 
HR-pQCT based cortical abnormalities have been shown to play a key important role in 
increased skeletal fragility fracture in T2DM (157, 158, 586), and identified in those with 
T1DM as well (163). Further investigation of cortical bone parameters by using MRI 
would shed more insight into the pathophysiological mechanism of diabetic bone disease. 
In the current studies, because of some technical changes we were not able to do this. 
Firstly, we scanned the proximal tibia which is not the best place to assess cortical bone. 
Furthermore, the micro MRI images were designed to image trabecular bone, and the 
image contrast is such that it can be difficult to differentiate between cortical bone and 
muscle/tendons. For future studies, acquiring images from the distal femur where the 
cortical bone is thicker is needed. Additionally, ultra-short TE (UTE) pulse sequences are 
needed to assess cortical porosity. However, this type of pulse sequence was not available 
on the current scanner. Future studies could involve collaboration with other research 
groups to access this. 
Finally, although there is now sufficient supporting evidence for the use of MRI for 
assessing bone microarchitecture, future research to expand upon the methodology 
employed in our studies will improve the clinical utility of 3 Tesla MRI and make it an 
acceptable option for widespread non-invasive assessment of bone health. 
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7.2 Appendix A: Study protocol  
1. Title 
Pilot Study Of Bone Health In Young People With Type 1 Diabetes Mellitus 
 
2. Introduction 
Although the association between diabetes and increased fracture risk is well 
recognised (Schwartz, 2003), the underlying mechanisms for this increased fracture 
predisposition are unclear. Adults with Type 1 diabetes mellitus (T1DM) tend to 
have mild osteopenia as adults, with bone mineral density (BMD) values which are 
about 10% lower than normal (Bouillon, 1991, Hofbauer, 2007). This modestly low 
BMD should lead to an increase in hip fracture risk of about 2-fold, yet prospective 
studies indicate that postmenopausal women with type 1 diabetes have 7–12 times 
greater risk of hip fracture compared with age-matched non-diabetics (Forsen, 
1999, Nicodemus, 2001). People with type 2 diabetes (T2DM) tend to have normal 
or modestly increased BMD, which should be associated with reduced fracture risk. 
However, these patients’ fracture risk is increased at the hip, proximal humerus, 
and lower extremity by about 2-fold compared with normal (Forsen, 2008, 
Schwartz, 2001). Thus, clinical evidence indicates that fracture risk in 
diabetic patients is disproportionately high relative to BMD as assessed by 
DXA. 
 
Abnormalities of bone microarchitecture as well as geometry that may lead to a 
reduction in material properties of bone cannot be assessed by DXA and the use of 
other techniques such as quantitative CT (QCT) have revealed alterations in bone 
geometry in adults and adolescents with DM (Saha, 2009, Melton III, 2008). In a 
large study of children and young adults with T1DM, markers of bone formation 
were lower than normal (Bouillon,1995). Studies in animal models of diabetes as 
well as studies of biochemical markers of bone turnover in humans with diabetes 
suggest that the defect may be related to poor osteoblastic function (Mccabe, 2007) 
and may also be related to disease duration and metabolic control (Brandao, 2007). 
Lastly, pentosidine is a non-enzymatic collagen cross-link which rises with age 
(Saito and Marumo, 2010) and a rise in this advanced glycation end product has 
been reported to be associated with a reduction in the maximal load of bone 
without a notable reduction in BMD in a rodent model of diabetes (Saito M, 2006) 
as well as patients with T2DM (Schwartz, 2009). 
 
TIDM mice exhibit increased bone marrow adiposity, increased adipocyte markers 
and increased numbers of lipid-dense adipocytes in the bone marrow (Martin and 
McCabe, 2007). Whereas osteoclasts belong to the macrophage family, osteoblasts 
and adipocytes share a common precursor and are derived from mesenchymal stem 
cells. The process of differentiation into either adipocytes or osteoblasts is regulated 
by a number of growth factors including insulin (Chamberlain, 2007), oxygen 
tension and blood flow within the bone marrow (Wang, 2007). It is possible that the 
increased marrow adiposity in the T1DM rats is due to a combination of these 
factors as well as hyperglycaemia, hyperlipidaemia and reduced insulin action. The 
increased adiposity may itself have a lipotoxic effect on osteoblasts and may even 
stimulate local osteoclast activity (Duque, 2008). It is also possible that in older 
people with T1DM, other factors such as peripheral neuropathy and susceptibility to 
falls may also play a part in the increased fracture risk (Patel, 2008). Recently, 
insulin itself, acting through its cognate insulin receptor has been shown to have a 
direct role on osteoblast signalling and postnatal bone acquisition (Fulzele, 2010). 
 
As bone, itself, may influence insulin sensitivity, the relationship between 
osteopenia and DM may be difficult to tease out in T2DM (Lee, 2007). The 
underlying aetiology of T2DM, itself, is complex and these factors may themselves 
have an effect on bone health which is independent of the effect of DM. The bone 
pathology which is associated with T1DM may serve as a more straightforward 
system to understand the effect of suppressed insulin signalling, hyperglycaemia, 
223 
 
and metabolic abnormalities on the regulation of bone formation. Given that 
childhood and adolescence is a period of net bone acquisition and T1DM is relatively 
common in this age group, a detailed study of the bone and fat link in this group of 
subjects would be particularly useful and provide valuable insight into the 
development of the osteopathy. However, there is a need to explore suitable non-
invasive methods that can reliably investigate these features longitudinally.  
 
Recent advances in MR imaging have allowed the generation of 3D images of bone 
structure (Wehrli, 2006) where bone structure can be assessed indirectly by 
microMRI via measurements of the surrounding marrow and other soft tissues. The 
‘apparent’ trabecular properties that are derived from these images correlate with 
trabecular architecture obtained with higher-resolution techniques (Majumdar, 
1996, Link, 1999). Until recently, evaluation of trabecular bone morphology was 
limited to appendicular sites. However, innovative surface coils and pulse 
sequences show potential for MR-based assessments of trabecular structure in the 
proximal femur and MR-derived trabecular microarchitecture measurements can 
reflect age- and disease-specific differences(Benito, 2003, Wehrli, 2007). Recent 
studies show good correlation between MRI & CT derived measures of bone health 
(Issever, 2010). There are, however, limited data on treatment related changes 
(Cheshunt, 2005, Zhang, 2008). Recently, MR spectroscopy has also raised the 
potential to quantify the amount of fat that is present within the marrow in the 
lumbar spine (Griffith, 2006, Shen, 2007, Liu, 2010, Li, 2011). There is, therefore, 
the potential to combine the two MR based techniques to obtain objective 
longitudinal data on bone microarchitecture and fat content and abdominal adipose 
tissue and study its relationship to T1DM and its metabolic control in a group of 
children and young people. 
 
There is a need to explore whether microMRI can discriminate between groups of 
patients in a way that other measures of bone health cannot and, thus, act as a 
diagnostic biomarker of alterations in bone health. 
 
 
It was also observed that visceral adipose tissue positively correlated with vertebral 
bone marrow fat content in obese women and in postmenopausal women with 
T2DM, (Bredella MA, et al 2011,Baum et al 2012).However, this relationship has not 
been examined in women with T1DM. Therefore, we aimed to determine whether 
vertebral bone marrow fat content correlates with the volume of abdominal adipose 
tissue in young women withT1DM by using MRI.  
 
However, before using microMRI in a larger group of children and adolescents of 
varying ages, there is a need to perform these studies in a small group of young 
adults with T1DM. These preliminary studies will provide data that can then 
facilitate the development of a more comprehensive study of bone health in 
children and adolescents with T1DM. 
 
3. Translational Aspects Of The Research 
A. MicroMRI promises to be a clinically useful technique for assessing bone health. 
Suitable MRI scanners are increasingly available across the health service as 
well as research institutes and there is a need to explore the utility of these 
scanners in assessing bone health. 
B. In the field of osteoporosis and fragility fractures, there are at least three 
groups of patients who pose a major clinical challenge - those who have a 
fragility fracture but have a normal DXA BMD, those with osteoporosis who do 
not show an increase in DXA BMD despite receiving bone-protective therapy 
and, finally, those with osteoporosis who have a fracture on bone-protective 
therapy. Another method of assessing bone health may improve the 
management of these patients. 
C. A practical, non-invasive method of assessment of bone health that provides 
details of microarchitecture and bone quality will be of value in the management 
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of challenging cases of metabolic bone disease. Its non-invasive nature may 
obviate the need for bone biopsies. 
D. Improved methods of assessing and understanding diabetes-related osteopathy 
will pave the way for interventional studies that are aimed at improving bone 
health. 
E. Alterations in insulin sensitivity and bone health are commonly encountered in 
people with chronic inflammation and the lessons learnt from these studies can 
be applied to children and adults with chronic inflammation. 
F. Lessons learnt from these studies can also be applied to investigating the 
concerns about bone health in patients with T2DM. 
G. Targeting bone marrow adipogenesis is an attractive option for improving bone 
health and treating possible osteoporosis. However, before this is considered as 
a novel therapy, there will be a need to develop innovative methods of imaging 
bones.  
 
4. Results of any pilot studies 
The MRI Department in Glasgow and the Developmental Endocrinology Research 
Group (DERG) have successfully performed some pilot studies exploring the utility 
of 1.5T and 3.0T MRI in assessing the microarchitecture of 
bone in healthy volunteers and some young adults with 
concerns about bone health. We were successful in 
developing a program that allowed quantification of four 
key bone parameters; apparent bone volume to total 
volume ratio (appBV/TV), apparent trabecular thickness 
(appTb.Th), apparent trabecular number (appTb.N) and 
apparent trabecular separation (appTb.Sp).  Validation of 
the software has been performed with a purpose-built 
phantom with known trabecular thickness and separation, 
and a good correlation was found between the actual and 
measured values.  Repeat scanning of four healthy individuals allowed the CoV to 
be assessed for appBV/TV, appTb.Th, appTb.N and appTb.Sp, and all values were 
found to be 7% or less. Figure above shows a binarised image of a slice from the 
proximal tibia of a control subject versus that of a person with osteogenesis 
imperfecta (OI). As expected, patients with OI had a significantly lower appBV/TV 
and appTb.N and a significantly higher appTb.Sp. AppTb.Th was also lower in the 
OI group but this did not reach statistical significance.  A further pilot study was 
performed in  volunteers with growth hormone deficiency (GHD), who are expected 
to have less severe bone abnormalities than in OI.  In this study, there was a 
statistically significant decrease in appBV/TV, increase in appTb.Sp and decrease in 
appTbN in the GHD group, and again appTbTh was reduced but this did not reach 
statistical significance. 
 
Pilot data have also been obtained for MRS the lumbar vertebral site, and also in 
the tibia, showing that the methodology can be applied to obtain reliable data for 
fat and water content. The figure below shows a sample of the spectra that has 
been obtained from the proximal tibia and L2. 
 
 
 
 
 
 
 
 
 
In addition to the above pilot study, DERG has an active interest in assessing bone 
health in children with chronic disease with active research studies in children with 
inflammatory bowel disease, leukaemia and extreme prematurity. The group uses a 
range of densitometry techniques including DXA, peripheral quantitative CT and 
quantitative ultrasound. It has collected DXA data on school-children in Glasgow 
 
  
Tibia Vertebra 
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and contributed these data towards the creation of UK reference range. The MRI 
physics team has extensive experience of performing MR spectroscopy in various 
organs in the body, for example the brain, liver and heart, using both 1.5T and 3T 
MRI scanners. 
 
5. Aims 
The primary aim of this study is to perform a cross-sectional study of bone health 
and markers of metabolic control in a group of young adults with T1DM. The 
innovative methods that we propose to use will provide us with novel data that can 
inform the development of a case-control study of bone health in children and 
adolescents with T1DM. 
 
6. Research questions & Hypotheses 
In young adults:- 
A. Is T1DM associated with a normal bone health as assessed by microMRI? 
B. What is the variation in microMRI parameters over a period of one year? 
C. Is T1DM associated with increased bone marrow adiposity as assessed by bone 
marrow MRS? 
D. Is T1DM associated with an abnormality indual x-ray absorptiometry (DXA)-
based total body (TB), Femoral Neck (FN) and lumbar spine (LS) bone mineral 
content (BMC)? 
E. Is there a relationship between microMRI bone parameters, DXA BMCand 
adiposity parameters? 
F. Is there an association between abdominal fat and bone marrow fat as assessed 
by MRI? 
G. What is the relationship between these parameters and markers of diabetes 
control? 
H. Is T1DM associated with abnormal biochemical markers of bone health and 
adiposity?   
 
Primary Null Hypotheses  
A. There is no difference in the measurements of key bone parameters obtained 
from   micro-MRI images of people with T1DM compared to healthy controls 
B. There is no difference in bone adiposity measurements obtained using MRS in 
patients with T1DM compared to healthy controls 
 
 
 
 
 
7. Plan, methods, expertise available, statistical power 
7.A. Recruitment 
Ethics approval is already available to perform MRI scans for assessment of bone 
health in individuals over the age of 16 years but a revised application will be 
submitted. The subjects shall be recruited from the diabetes clinics that are linked 
with the clinical diabetes service network in the West of Scotland. All patients with 
childhood-onset T1DM, ie diagnosis of T1DM before the age of 16 yrs and their 
sisters and female friends within the same age band shall be invited to participate 
in the study. For this pilot study, 30 cases and 30 controls between the ages of 16 
and 40yrs shall be recruited.  Any adult with T1DM shall be invited to participate in 
the study. For this study, 20 cases shall be recruited.   
 
Eligible participants who cannot sit or lie still for 15 minutes, are pregnant, have a 
known bone disease or cannot have a MRI scan for routine technical reasons shall 
be excluded from the study. Height and weight will be measured using standard 
validated techniques.  Age at menarche and a menstrual history shall be recorded. 
Information about T1DM including age at diagnosis, current HBA1C, total insulin 
dose shall be obtained. 
 
 7.B. Scan Procedure 
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Participants will be required to come for an MRI scan at the BHF Glasgow 
Cardiovascular Research Centre on two occasions. 
Visit one: 
MRI scan and a blood sample– this has been completed already. 
 
 Visit 2: 
 This visit shall be undertaken one year after the first one. It involves two scans: a 
MRI  
 Scan which will be performed by the same team at BHF and a DXA scan which shall 
be  
 Performed at Yorkhill hospital. The patients shall be invited by a letter to discuss 
the 
 information about the study.  
 
 
Prior to taking part in the research, participants will be taken through the MR safety 
checklist by a member of the research team. Any subject who fails to satisfy any of 
the safety criteria e.g. has metal inside their body will not be allowed to take part in 
the research. 
 
Participants shall have a scan of the right knee, L2 and the abdomen. The 
participant will initially be positioned on the MR scanner bed with their right knee 
inside a receiver coil, which is effectively a cylinder which surrounds the knee.  
Padding will be placed between the knee and the coil to reduce the potential for 
movement and help the volunteer to remain as still as possible during the scan.  
The volunteer will be moved into the scanner feet first, and their head and 
shoulders will remain outside of the scanner for the duration of the scan. 
 
The scan protocol will consist of 3 short localiser scans which allow the area of 
interest to be identified, followed by a 10 minute micro MRI scan.  The knee coil will 
then be removed, and a further 3 short localiser scans followed by approximately 
10 minutes of MRS will be performed in the lumbar spine (L2).  The spine coil is 
built into the scanner bed, and it will not be necessary for the volunteer to move.  A 
surface body coil will then be positioned over the abdomen, and a further 3 short 
localiser scans followed by approximately 10 minutes of image acquisition to allow 
quantification of abdominal fat will be performed.  Again, it will not be necessary for 
the volunteer to move.  The total time in the MRI scanner will be a maximum of 1 
hour. 
 
The MRI scanner generates acoustic noise whilst it is operating. For this reason all 
research participants will be provided with adequate ear protection before entering 
the scanner e.g. earphones. This is a standard procedure used in clinical practice. 
Volunteers may also find the scanning process unpleasant, particularly if they suffer 
from claustrophobia. The research team will be able to communicate with the 
volunteer during the scanning process and reassure them if necessary. The 
volunteer will have an alarm that they can press to stop the scan at any time. 
Should the volunteer become distressed at any point, the scan will be stopped. 
Each volunteer will have the opportunity to listen to some music during the scan to 
help them feel relaxed.  
 
  
 7.C. Primary Outcome 
MicroMRI parameters of bone health – High resolution MRI images of the 
proximal tibia at the 8% site will be acquired using a 3T MRI scanner (Siemens 
Verio) with the use of a transmit/receive extremity coil. Following immobilisation, 
localiser scans shall be performed in the sagittal, axial and coronal planes to 
identify the region of interest. A TrueFISP sequence shall be used at a resolution of 
0.2 x 0.2 x 0.4mm. Acquisition of the high resolution images shall be achieved with 
a scan time of 10 minutes. Images shall be coded and analysed blindly. 
Quantitative analysis will be performed using software developed in-house (based 
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on the method described by Majumdar et al and Issever et al) to obtain measures 
of cortical thickness, apparent bone volume to total volume ratio (appBV/TV), 
apparent trabecular thickness (appTb.Th), apparent trabecular number (appTb.N) 
and apparent trabecular separation (appTb.Sp). 
 
7.D. Secondary Outcomes 
Bone Marrow Adiposity – MR spectroscopy will be performed in the lumbar spine 
using a 3T MRI scanner during the same scanning session as the microMRI image 
acquisition, using the method described by Tang et al.  Spectra will be obtained 
from a volume of interest of approximately 2 x 2 x 2mm within the vertebral body 
using a Point-REsolved Spectroscopy (PRESS) sequence with a short echo time (TE) 
to allow detection of lipids.  Analysis of the spectra will be performed using software 
provided by the MRI scanner manufacturer for this purpose.  The peak amplitudes 
of the resulting water peak (Iwater) and lipid peak (Ifat) will be measured, and the 
percentage fat fraction (FF) will be calculated in the following way: 
 
  100% 


waterfat
fat
II
I
FF  
 
Abdominal Adiposity – MRI images will be acquired using a 3T MRI scanner 
during the same scanning session as the microMRI and MRS acquisitions, using the 
method described by Leinhard et al. A four element body coil will be used to obtain 
images covering the abdominal region from the diaphragm to the bottom of the 
pelvis. A dual echo, multi slice, spoiled, fast gradient echo pulse sequence will be 
used. To measure the fat, Dixon method will be used, it is performed by acquiring 
two separate images: one where the signals from fat and water are 180° out of 
phase (I1 = w − f) and one where they are in phase (I2 = w + f). Ideally, water 
and fat can then be obtained as the sum and difference of these images, 
respectively, and the total fat content in any region of interest can then easily be 
calculated. 
 
Bone Densitometry  
Measurement by DXA (total body, lumbar spine vertebrae 2-4 and femoral neck) using 
the Lunar Prodigy DXAScanner.  Instrument precision has been determined onsite to 
be <1% forTB, LS and femoral neck. 
 
Blood sample - A blood sample (10mls) shall be collected when patients attend for 
the MRI scan. This sample shall be used for measuring markers of bone turnover as 
well as adiposity. 
 
8. Expertise Available 
Prof SF Ahmed is a clinical investigator who leads the Developmental Endocrinology 
Research Group (DERG) at Yorkhill. He has a particular interest in the assessment 
and management of bone health of children and adolescents with chronic disease. 
His research group is currently engaged in a range of projects on bone health and 
skeletal development. Dr J Foster is Academic Supervisor and Consultant MR 
Physicist with 20 years of MRI experience and a team of MR Physicist, including 
Christie McComb who has been involved in the pilot work and is funded through the 
Academic Health Sciences Collaboration to support such studies. Christie McComb 
will continue to remain closely involved in the work. Dr Naiemh Abdalrahaman who 
is a research fellow studying for a PhD at Glasgow University and is funded by Govt 
of Libya and the Medical Fund of the University of Glasgow. Dr G Shaikh and Dr K 
Robertson are closely involved in the Children’s and Adolescent Diabetes Service in 
the West of Scotland which is the largest children’s diabetes service in the UK. Dr C 
Perry, Dr A McLennan and Dr R Lindsay manage young people with T1DM. Dr J 
McClure at the Glasgow Cardiovascular Research centre has provided statistical 
input into the calculation of the sample size. DXA scans shall be performed by 
Sheila Khanna in bone densitometry. 
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9. Sample Size and Statistical Analyses 
Based on our current studies of healthy controls and the cases of osteogenesis 
imperfecta, we estimate the CV to be about 7-10%. If a greater than 10% 
difference between case and controls is aimed to show a significant difference at 
p<0.05 with a power of 0.8, at least 16 cases and 16 controls will be required for 
assessing apparent trabecular separation (appTb.Sp) and at least 14 cases and 14 
controls will be required to assess apparent trabecular number (appTb.N). Group 
differences will be analysed by Students t-tests using, where necessary, normalised 
data and Chi square for categorical variables. Measurements of bone health, 
adiposity and metabolic status will be tested using ANOVA. 
 
10. Timetable 
Months -6 to -2: Obtain ethics approval. Design study database.  
Months -3 to 0: Identify suitable patients and send paperwork 
Months 1 to 12: Recruit subjects, begin assessments and follow-up 
Months 12 to 15: Perform preliminary analysis 
Month 15:   Consider the feasibility of a study in children with T1DM 
 
11. Existing Facilities 
All the expertise, equipment and techniques required for the study are available in 
Glasgow within the Royal Hospital for Sick Children, Yorkhill and the BHF 
Cardiovascular Research Centre, Glasgow, and have previously been used in 
adolescents and adults to ensure the techniques are acceptable and reproducible.  
 
12. Justification of Requirements 
We are requesting support for:- 
 
12.A. Scans  
- MRI scans – Each 3 hour session will accommodate 3 scans and preliminary 
analysis. These scans will be supervised by Ms C McComb. Based on a scan cost of 
£320, total MRI scan cost shall be £12,800. 
 
12.B. Patient Visits 
Visits – Each participant will receive £20 to cover travel expenses for the MRI. 
Total costs £800. 
 
The funding for this pilot work has been secured from the Medical Fund at the 
University of Glasgow as well as the bench fees of a PhD studentship. 
 
13. Future exploitation plan, including potential funding sources, to 
achieve NHS benefit 
 The data and skills that are collected and developed from the proposed study can 
help develop research in and clinical practice in a number of ways:- 
A. We propose to use resources and skills that are readily available in the current 
research and NHS settings in Glasgow and adapt them for our needs, thus allowing 
us to perform research that could in the future be performed at multiple sites. 
B. T1DM has an approximate prevalence of 1 in a 1000 children in Scotland. The 
lessons we learn can be used to initially design cross-sectional case-control study in 
children and then design a longitudinal study that has an intervention arm which 
compares the effect of two forms of treatment (in T1DM) on the bone health. 
Funding could be sought from a number of diabetes-related charities. 
C. Using MRI to assess bone health may provide a better insight into those cases of 
osteoporosis who do not respond to bisphosphonates and those who fracture 
despite relatively normal DXA results.  Using a technology that is readily available 
in the NHS already may facilitate implementation. Identification of this group would 
allow better targeting of anti-osteoporosis drugs. 
D. There is increasing realisation that abnormalities of bone health, glucose 
homeostasis, and cardiovascular health may be a common manifestation of a 
chronic inflammatory process that is linked to ageing. Novel methods of assessing 
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bone health will become an integrated part of assessing the chronic effects of 
inflammation and fit within the theme of current research in Glasgow and many 
funding institutions. 
E. The results that will be generated from these studies have the potential to 
influence clinical practice within the next 5 years. 
 
 14. Public Engagement In Science 
The study is currently being discussed with older patients who attend the Diabetes 
Service at Yorkhill which will also include details and progress of the study on its 
website http://www.diabetes-scotland.org/ggc/. The study will also be personally 
discussed within the diabetes team and in patient discussion groups. Although 
physical activity is stressed regularly, there is little awareness of maintaining good 
bone health in children and adults with diabetes. Engaging the CYP and their 
families in this project will fit within the general strategy of diabetes management 
of promoting physical activity.   
 
15. Dissemination  
The initial data shall be presented at an international MRI meeting in 2011 in 
Montreal and are currently being prepared for submission for publication. The 
findings from this study will be presented at national and international scientific 
meetings and submitted to scientific peer-reviewed journals for publication. Bodies 
such as Diabetes UK and the National Osteoporosis Society will also be informed on 
the outcomes of the study. The data shall be used to design further studies of a 
larger cohort. 
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7.3 Appendix B: Pilot Study Of Bone Health In Young People With 
Type 1 Diabetes Mellitus, Case Report Form. 
 
 
Hospital number: 
 
Study number: 
 
Date of visit: 
 
        Demographic and anthropometric data: 
 
 
Patient ID: 
 
Patient initials 
   
 
Tel number:  
 
Sex: 
Female 
  
Male 
 
Date of birth  
   
 
Age in year 
 
 
 
Height=  
 
Weight=  
 
 
 
Details of diabetes: 
 
Age at diagnosis: 
 
Disease duration: 
 
Current HbA1c:   
 
Total insulin dose: 
 
Pump or injection: 
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Health behaviour and diet  
 
Smoker:                           current.                       Past.                                  Never. 
 
Drinker (unites).                      /Day                    /Week                                   /Month  
 
Calcium (mg/day):  
 
Vitamin D (IU/day): 
 
Multivitamin use:  
 
Physical activity: 
 
 
 
 
Reproductive history 
 
Onset of puberty (years):  
 
Menarche (years):  
 
Average menstrual cycle length:  
 
Amenorrhea for ≥3 months:  
 
Ever pregnant: 
 
Number of pregnancies:  
 
Current hormone use:  
Estrogen + progesterone   
Progesterone only  
 
 
 
Medical History 
 
  
Patient History 
 
High blood pressure:      
Last BP=          /   
 
Thyroid disorder:                  
Last TFT at    …………/ ……/………… 
Result 
 
Orthopaedic: 
Joint problems 
Fracture    
 
   
Family History 
 
Family history of osteoporosis:     
  
Family history of fracture:          
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Heart disease: 
 
Peripheral vascular disease (varicose veins): 
 
Renal complication (Microalbuminuria): 
Date ……/……/………… 
Result 
 
Retionopathy: 
Last follow up at ……/……/………… 
Result  
 
Neuropathy: 
…………………………… 
………………………….. 
Statin use or any other drug  
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood Investigation: 
 
Biochemistry Leptin Adiponectine IGF-I 
Date of blood taken    
Result     
Reference Range    
Measurement unit     
 
 
Biochemistry OC CTX 25VitD PTH B-ALP 
Date of blood taken      
Result      
Reference Range      
Measurement unit      
  
Radiological Investigation: 
 
Radiography site Yes No 
Micro MRI Proximal tibia   
 
 
 
MRI  
 
Abdominal fat  
 
 
 
MRS Lumbar spine   
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HBA1c Results Of The Last 5 To 10 Years:   
 
Date. Result. 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Patient Logo-  
 
Date of first meeting   
Patient information sheet given   
Patient’s telephone number  
Date of patient visit at BHF  
Patient’s consent taken  
MRI scan done  
Blood sample taken   
 
 
 
 
 
